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CAMP cyclic adenosine monophosphate
CEP cyan fluorescent protein
cGMP guanosine monophosphate
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KOP K opioid receptor
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MAPK mitogen activated protein kinase
MOP p opioid receptor
PBS phosphate buffered saline
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Abstract
Chemokine receptors CXCRl and CXCR2 are expressed on several immune cell types 
including granulocytes and monocytes. The two receptors share 78% sequence identity and
XIV
primarily function to mediate chemotaxis. Homo- and hetero-oligomerisation of CXCRl 
and CXCR2 was investigated in this study.
CXCRl and CXCR2 were modified with either N- or C-terminal epitope tags in order to 
facilitate the detection of receptor oligomers. The modified receptors were predominantly 
cell surface expressed and underwent prominent internalisation following exposure to 
Interleukin- 8 (IL-8). The modifications were found to have no effect on affinity for IL-8 
determined by competition radioligand binding assays. The modified receptors retained the 
ability to couple to G proteins assessed by agonist-induced reduction in forskolin- 
stimulated cAMP levels. Co-immunoprecipitation experiments demonstrated the existence 
of constitutive CXCRl and CXCR2 homo-oligomers and CXCRl/CXCR2 hetero­
oligomers following expression in HEK293T cells. Single cell FRET imaging experiments 
also confirmed constitutive CXCRl and CXCR2 homo- and hetero-oligomerisation. A 
lower level of energy transfer was observed between both CXCRl and CXCR2 and the 
less homologous aia-adrenoceptor. Saturation BRET experiments indicated that 
CXCRl/CXCR2 homo- and hetero-oligomers formed with equal propensity. This approach 
also indicated that the interaction between CXCRl and the aiA-adrenoceptor detected in 
FRET studies was non-specific as a linear relationship between donor and acceptor was 
shown to exist. Tr-FRET experiments indicated that constitutive CXCRl and CXCR2 
homo- and hetero-oligomers exist pre-foimed at the cell surface. The effect of agonist on 
oligomerisation was investigated. Experiments using BRET and Tr-FRET did not 
demonstrate any modulation of energy transfer following exposure to IL-8 .
A novel endoplasmic reticulum (ER) trapping strategy was developed in order to 
investigate the location and selectivity of oligomer formation. CXCRl was modified by the
XV
addition of an ER retention sequence to the C terminal tail that prevented expression of the 
receptor at the cell surface. Upon co-expression with wild type CXCRl and CXCR2, 
CXCRl-ER reduced their cell surface expression. This suggested that oligomerisation 
between the wild type receptors and CXCRl-ER was initiated during protein synthesis and 
maturation and prior to cell surface delivery. Cell surface expression of the aiA- 
adrenoceptor was unaffected by co-expression of CXCRl-ER indicating a lack of 
interaction. Despite cell surface constitutive CXCRl/CXCR2 hetero-oligomers being 
indicated by Tr-FRET, no co-internalisation of CXCRl and CXCR2 was observed in 
response to GRO-a, a ligand specific for CXCR2.
Expression of opioid receptors on immune cells has been demonstrated and opioid agonists 
have been demonstrated to modulate chemotaxis. CXCR2 is also expressed in the brain. 
Co-immunoprecipitation experiments indicated oligomerisation between CXCR2 and 
DOP, MOP and KOP receptors. Single cell FRET also indicated oligomerisation between 
CXCR2 and the opioid receptors. This highlights the potential existence of chemokine and 
opioid hetero-oligomers in physiologically relevant settings that could be of great potential 
interest in dmg development for the treatment of inflammatory conditions.
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1.0 Introduction
1.1 G protein coupled receptors (GPCRs)
GPCRs are a superfamily of receptors that play an important role in signal transduction. 
Analysis of GPCR sequences reveals that >800 GPCRs are encoded in the human genome 
(Fredriksson et ah, 2003). The majority of GPCRs identified are oiphan receptors for 
which no endogenous ligand has been found and the receptor function has not been defined 
(Kamik et al.^  2003). GPCR dysfunction has been shown to be associated with human 
disease and many GPCRs are tai’gets for pharmaceuticals and drugs of abuse. A report 
from 2002 indicated that >50% of all drugs available in the clinic target GPCRs and 20% 
of those drugs present in the top 50 prescribed drugs worldwide target GPCRs (Ma and 
Zemmel, 2002). Members of the GPCR superfamily can represent up to 30% of the 
portfolio of many pharmaceutical companies, demonstrating the importance of these 
receptors as drug targets (Klabunde and Hessler, 2002).
GPCRs function to transduce a signal received via an extracellular mechanism into the cell. 
The majority of this intracellular signalling involves the activation of hetero-trimeric G 
proteins that serve to trigger multiple signal transduction pathways within the cell.
1.1.1 Structure of GPCRs
Despite low sequence homology obseiwed across the GPCR superfamily, a similar basic 
structure has been identified. Recently the crystal structure of the GPCR bovine rhodopsin 
at 2 .8Â was reported revealing a highly organised heptahelical an-angement of
transmembrane (TM) domains (Palczewski et al, 2000). This was in agreement with data 
generated from earlier studies utilising electron microscopy (Unger et al., 1997). 
Rhodopsin was shown to consist of a central core domain of seven TM helices connected 
via three extracellular loops (ECLs) and three intracellular loops (ICLs).
The N-terminal region of GPCRs varies considerably in length between individual 
receptors and can be important in ligand binding. All GPCRs possess one or more N-linked 
glycosylation sites (Asn-X-Ser/Thr) where X is any amino acid except proline or 
asparagine (Kristiansen, 2004). This region has been implicated in determining the coiTect 
trafficking of the receptor to the plasma membrane (Petaja-Repo et ah, 2000). For several 
GPCRs prevention of receptor N-terminal glycosylation resulted in reduced cell surface 
expression but had no effect on ligand binding or function of those receptors that were 
plasma membrane expressed (George et al, 1986; Ji et al, 1990; Liu et al., 1993; 
Davidson et al., 1995; Ray et al., 1998). Some GPCRs also possess cysteine residues 
within this region thought to be important in correct protein folding (Kristiansen, 2004).
The seven transmembrane domains vary in length and form a  helices. The crystal structure 
of bovine rhodopsin has revealed that the transmembrane domains are kinked or tilted. 
This is due to the presence of certain amino acids capable of distorting the helical domains. 
The helices are an*anged in a counter-clockwise order. The helices of TM I and II in bovine 
rhodopsin were found to be tilted from the plane of the membrane by 25° while TM III 
demonstrated a 33° tilt. The C-terminal end of TM III contains a highly conserved DRY 
(Asp-Arg-Tyr) motif, commonly identified in rhodopsin-like receptors, that has been 
implicated in the regulation of receptor interaction with its G protein (Franke et al., 1990). 
TM IV and VI were found to be almost peipendicular to the membrane while TM V tilts at
26° (Teller et al., 2001). TM VII possesses a highly conserved NPXXXY motif. This motif 
is thought to be involved in forming a structural domain that facilitates an interaction with 
TM VI, important in conferring the conformation relating to the inactive state. The crystal 
structure also highlighted the presence of an amphipathic cytoplasmic helix termed helix 
VIII located at the extension of TM VII. This helix is tilted at 90° to the membrane and 
plays a role in G protein coupling in rhodopsin (Teller et al., 2001).
The crystal structurée of rhodopsin yielded little data concerning the cytoplasmic regions of 
the receptors. However, these regions have been demonstrated to play an important role in 
G protein coupling with the second and third intracellular loop and C-terminal tail all 
implicated (Wess et al, 1998; Cotecchia et al, 1992; O’Dowd et al, 1988). The third 
intracellular loop of GPCRs also demonstrate several serine and threonine residues that 
provide sites for receptor regulation. Phosphorylation of these sites by receptor kinases can 
trigger receptor desensitisation and internalisation.
The extracellular loops of rhodopsin possess two highly conserved cysteine residues in 
ECL II and the N-terminal end of TM III (Cys^ ^  ^ and Cys^ ®^  respectively) that form a 
disulphide bond (Teller et al, 2001), This interaction has been demonstrated to provide 
stabilisation of receptor structure (Dohlman et al, 1990). Site-directed mutagenesis of 
cysteine residues (Cys^ ^  ^ and Cys^ '^^ ) within the P2-adrenoceptor demonstrated a reduced 
ability to bind ligand and destabilisation of receptor tertiary stmcture (Dixon et a l, 1988; 
Dohlman g/a/., 1990).
A further cysteine residue is located in the membrane proximal C-terminal region of 
several GPCRs that has been identified as a potential site for palmitoylation (O’Dowd et
al., 1989). Palmitoylation is a post-translational modification in which the fatty carbon 
chain palmitic acid is attached to a cysteine residue via a thioester bond. This modification 
serves as an anchor into the membrane, creating a fourth intracellular loop termed helix 
VIII, discussed previously. This helix has been shown to affect the coupling of the receptor 
to the G protein (Ganter et al, 1992; Milligan et al, 1995a). The C-teiminal tail also 
possesses several sites that enable receptor phosphorylation by receptor kinases, inducing 
receptor desensitisation (Carman et al, 1998).
1.1.2 GPCR family classification
GPCRs are capable of transducing signals initiated by ligand binding to the receptor. A 
diverse range of ligands can activate GPCRs including biogenic amines, amino acids, 
lipids and peptides. Ligand binding can trigger heterotrimeric G protein dependent and 
independent signalling cascades as shown in Figure 1.1. The GPCR superfamily is 
subdivided into five subclasses based on both sequence similarity and pharmacological 
nature of the ligand. Family 1 or rhodopsin-like receptors represent the largest class in the 
GPCR superfamily. Members of this family have short N-terminal domains and possess 
several highly conserved amino acid residues within each transmembrane domain. This 
class can be further broken down into three subgroups based upon the ligand-binding site. 
Class la includes the rhodopsin and adrenergic receptors for which the ligand-binding site 
is located within the seven transmembrane domains. The second subclass, family lb, 
includes receptors for which the binding site includes the N-terminal, extracellular loops 
and parts of the TM domains. This includes peptide receptors such as the chemokine, 
opioid and somatostatin receptors. Family Ic incorporates receptors that bind their ligands 
via a large extracellular domain although some contact between the ligands and ECL 1 and
3 also occurs. Members of this family include receptors for glycoprotein hormones such as 
luteinising hormone.
Family 2 or secretin-like receptors are a smaller class of receptors. Members of this family 
commonly possess a larger N-terminal than observed for family 1 GPCRs and contains 
several cysteine residues that form a network of disulphide bridges. This subtype includes 
receptors for ligands such as secretin and vasoactive intestinal polypeptide (Davletov et al, 
1998).
Family 3 or metabotropic-glutamate-receptor-like receptors includes the calcium sensing 
and GABAb receptors (Kaupmann et al, 1997; Pin and Bockaert, 1995). This family also 
contains putative pheromone receptors termed VRs and Gq-VN (Bargmann, 1997). This 
family is characterised by a long amino terminus, often between 500-600 residues, which 
folds producing a sepaiate ligand-binding domain. The crystal structure of the extracellular 
domain of the metabotropic glutamate receptor mglui has been resolved and this 
demonstrated that the ligand-binding domain, present in the amino terminal, forms a 
disulphide-linked dimer (Kunishima et aL, 2000). This structure is thought to open and 
close in response to agonist binding and has been likened to the mechanism of the Venus 
flytrap.
The fourth class of receptors include the pheromone receptors (VNs) that bind to the G, 
class of G protein (Dulac and Axel, 1995). Family 5 includes the frizzled/smoothened 
receptors involved in embryonic development. In mammals there are 10 frizzled and 1 
smoothened receptors that are structurally similar to family 2 GPCRs (Foord et al., 2002).
Variations on the structure and conserved residues of GPCRs can be observed throughout 
the classification system illustrated in Figure 1.2. The majority of family 1 GPCRs are 
thought to possess a structure homologous to that elucidated for rhodopsin. For family 2 a 
similar overall morphology to family 1 receptor structure has been hypothesised, however, 
the palmitoylation site is missing and conserved residues and motifs vary from family 1 . 
The structui'al organisation of the TM regions has not been determined but are thought to 
vary significantly from that obseiwed for family 1 receptors due to the variation in amino 
acid sequence, particularly concerning the consei-ved prolines that confer the tilting of the 
TM domains identified in rhodopsin. Family 3 are extremely distinct from family 1 GPCRs 
sharing only two conserved cysteines in extracellular loop 2 and TM domain III, forming a 
putative disulphide bridge. The third intracellular loop of this family is short and highly 
conserved. As with the family 2 GPCRs, little can be determined at this time regarding the 
orientation of the TM domains (George et al., 2002).
1.1.3 Ligand induced activation of GPCRs
The molecular basis of GPCR activation has been best studied for rhodopsin. Rhodopsin is 
involved in the detection of light energy and upon binding of a photon transduces a 
neuronal signal directed to the secondary neurons of the retina. In rhodopsin the inverse 
agonist, lI-cA-retinal, is covalently bound to the receptor (Teller et al., 2001; Meng et al., 
2001). Generally, binding of inverse agonists can initiate the transition of a GPCR from the 
native partially active state to an inactive state (Gether et al., 2000). This is also the case 
for rhodopsin, which exists in two fomis. The rhodopsin form is the inactive form of the 
receptor while the opsin form exists in a partially active state (Meng et al., 2001). Upon
photon absorption the Î 1-cw-retinal ligand isomerises to all-/raw5-retinal and induces 
several conformational changes in the receptor (Teller et al, 2001; Subramaniam et al, 
1999; Meng et al, 2001). This is an extremely rapid process completed in less than 200fs 
(Schoelein et al, 1991). These conformational changes trigger disruption of a salt bridge 
formed between TM III and TM VII. Analogous mechanisms of activation have been 
demonstrated for amine receptors (Porter et al, 1996) and also peptide receptors however 
in this family salt bridge disruption was uncommon although residue displacement of TM 
III was observed (Miura et al, 1999; Ji et al, 1998).
It is evident that the ligand induced conformational changes in GPCRs are essential for 
correct function (Kenakin, 2002). Studies have been performed investigating the homology 
of the rhodopsin mechanism of activation thi’oughout the GPCR family. These reports have 
demonstrated that separation of TM III and VI is a common mechanism in GPCR 
activation (Sheikh et al, 1996; Miura et al, 2003; Gether et al, 1997; Ballesteros et al, 
2001; Sheikh et al, 1999; Shapiro et al, 2002). Studies in which the movement of TM III 
and VI was hindered artificially prevented G protein activation (Meng et al, 2001). The 
degree of movement of TM VI was greater than that observed for TM III and TM VII, 
resulting in a structural change in which the inner faces of TM II, III, VI and VII become 
more exposed and the cytoplasmic ends of TM IV and V become less exposed, facilitating 
G protein activation. The movement of the TM helices also acts to initiate changes in the 
cytoplasmic domains, ensuring G protein binding and activation.
1.1.4 G proteins
Upon ligand activation, GPCRs associate with guanine nucleotide binding proteins (G 
proteins). G proteins act as mediators of the receptor-activation signal and are 
heterotrimeric consisting of a, p and y subunits. In the inactive state GDP is bound to the a  
subunit which associates with p and y subunits, forming an inactive heterotrimer. Upon 
activation by ligand binding, the receptor undergoes a conformational change resulting in 
increased affinity for G protein. This permits the exchange of GDP for GTP, which reduces 
the affinity of the interaction between a  and Py complex and the heterotrimer dissociates. 
Both a  and the py subunits can then interact with several effectors transducing the signal. 
The activated state lasts until GTP is hydrolysed to GDP by the intrinsic GTPase activity 
of the Ga subunits. The rate of this hydrolysis is under the regulation of GTP-ase 
activating proteins (GAPs) termed regulators of G protein signalling (RGS proteins) 
(Siderovski et ah, 1996; Koelle and Hoiwitz, 1996). Each RGS protein demonstrates a 120 
amino acid sequence termed the RGS domain. This region forms a nine alpha helix bundle 
that contacts the Ga switch regions (Tesmer et ah, 1997). Many RGS proteins stimulate 
rapid GTP hydolysis and attenuate GPCR signalling (Neubig and Siderovski, 2002). This 
intervention can be at the level of the receptor via interaction with PDZ domains or the G 
protein level,
1.1.5 G protein a  subunit
The heterotrimeric G proteins are composed of a  subunits (39-45kDa), p subunits (35-39 
kDa) and y subunits (6 -8kDa). At least 28 distinct a  subunits have been identified that are 
the products of 16 different genes. G proteins are classified into four subfamilies with
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respect to the Ga amino acid sequence similarity; Q, Gs, Gq and G12. The Gai family 
includes Gan.3 which act to inhibit adenylyl cyclase (Cabrerawera et al., 2003). Gan is 
widely expressed, preferentially in neuronal systems, however Gais is preferentially 
expressed in non-neuronal systems. Ga z^ is ubiquitously expressed (Ellis et al, 2004). 
Gatr-c stimulates cGMP phosphodiesterases (Mochizuki et al, 1999; Pierce et al, 2002) 
and are expressed in retinal rods and cones respectively. Gaoi-2 are also members of this 
family and are expressed in neuronal and neuroendocrine cells and have been shown to 
inhibit adenylyl cyclase and voltage-dependent calcium channels and stimulate GIRK and 
phospholipase C (Hsu et al, 1990). Gagust is a further member of this family expressed in 
taste and neuronal cells while Ga% is found in endocrine cells and platelets. Gagust 
stimulates cGMP phosphodiesterase while Ga% inhibits adenylyl cyclase (Taussig and 
Gilman, 1995).
The Gq family includes Gaq, Gan, Ga#, Ga^ and Gaie (Pierce et al, 2002; Cabrera-vera 
et al, 2003; Willets et al, 2003) and all act to stimulate phospholipase activity. Gq family 
members are broadly expressed with Gan, Gan and Gan expressed in haematopoietic 
cells and tissues and Gaq ubiquitously expressed. Gan is also broadly expressed but is not 
found in haematopoietic cells. Gg family members include several long and short splice 
variants. They act to stimulate adenylyl cyclase activity and are widely expressed (Pierce et 
al, 2 0 0 2 ). Gi2 consists of two family members termed Gan and Gan that are ubiquitously 
expressed. This family has been implicated in the regulation of Ras homology (Rho) 
guanine nucleotide exchange factors (RhoGEFs) and GTP-ase activating protein of Ras. 
This can lead to stimulation of Rho and stress fiber formation and activation of Ras (Jiang 
et al, 1998; Pierce et al, 2002).
Ga subunits are essentially enzymes that possess inherent GTPase activity and are 
composed of two domains. The first domain is responsible for binding and hydrolyzing 
GTP to GDP while the second confers a unique helical domain that buries the GTP in the 
core of the protein (Noel et al, 1993; Coleman et al, 1994). Structurally it is composed of 
5 a  helices surrounding a 6-stranded p sheet, binding the phosphate and the guanine 
moiety of GTP (Sprang, 1997). Most Ga proteins can act as a substrate for mono-ADP 
ribosylation which is catalysed by either cholera toxin for Gag and Gat or pertussis toxin 
for Ga, and Gao and Gat. Pertussis toxin catalyses the covalent binding of ADP ribose to a 
cysteine residue that is located four amino acids fi:om the C-terminal tail. This results in the 
uncoupling of the Ga subunit from the receptor as the activation of the subunit is inhibited. 
Cholera toxin specifically targets an arginine residue in the Ga subunit that inhibits the 
inherent GTPase function resulting in constitutive activation of these subunits (Hepler and 
Gilman, 1992).
The Ga subunits are subject to several modifications. Ga, undergoes N-myristoylation that 
occurs following removal of the initiating methionine residue (Gordon et al., 2001). All 
other G proteins except Gat are subject to palmitoylation. These modifications are thought 
to permit the membrane attachment of the a  subunits. This has been demonstrated as 
palmitoylation deficient mutants of Gag demonstrate a reduced capacity to associate with 
the membrane (Wedegaertner et al., 1994). These N-terminal modifications also increase 
the affinity for py subunits (Linder et al., 1991; Milligan et al., 1995b). The C-terminal 
region of Ga contains a region thought to be involved in the specificity of receptor G- 
protein interaction (Hamm et al., 1996).
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1.1.6 G protein Py subunits
Five different Gp and twelve different Gy subunits have been identified. The expression 
pattern of the p subunits varies considerably. Gpi and GPi are ubiquitously expressed 
while GPs is expressed in cone cells and taste cells. Gp4 is found in the brain, lung and 
placenta while Gps is found in neuronal, lung, lymph and ovarian cells (Ellis et ah, 2004). 
The Y subunits aie widely expressed throughout the body. Gyi is expressed in retinal rods 
and neuronal cells while Gyi-y and Gyio-i3 have been identified throughout the body 
especially in neuronal cells. Gyg is expressed in retinal cones. The large number of P and y 
subunits give rise to numerous possible combinations. Most combinations are functional 
however some are unable to form complexes, for example GPi is unable to form a 
functional dimer with Gyi (Ellis et al., 2004).
The structure of the Gp subunit is a 7-membered propeller structure based on its seven 
WD-40 repeats (Sondek et ah, 1996; Lambright et al., 1994; Wall et al, 1995). The y 
subunit interacts with Gp via an N-terminal coiled-coil interaction and also at numerous 
contact points along the base of p, forming a strong functional complex that can be 
considered as one unit. This association is so strong that dissociation can only be achieved 
by protein dénaturation. The y subunits are either famesylated or geranylgeranylated and 
this serves to anchor the unit to the membrane (Wedegaertner et al., 1995).
The interaction of GPy subunit with Ga occurs via an interaction of the N-terminal helical 
domain of Ga with the propeller structure of the p subunit (Lambright et al., 1996). As
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mentioned previously, G protein activation by ligand binding to the GPCR triggers the 
exchange of GDP for GTP on Ga, causing a conformational change within Ga leading to 
reduced affinity for the py subunits and the heterotrimer to dissociate into Ga and Gpy 
subunits.
Several effectors of Gpy exist. The GPy subunits act to inhibit adenylyl cyclase I while 
stimulating the function of adenylyl cyclase II, IV and VII. They also act to stimulate G- 
protein regulated inward rectifier K+ (GIRK) channels, phospholipase Cp isoforms 
(PLCp), and G-protein coupled receptor kinases (GRK) 2 and 3 (Ellis et al, 2004).
1.1.6 GPCR desensitisation and internalisation
As mentioned previously, ligand binding to GPCRs can trigger the activation or 
attenuation of several signalling pathways. However, following stimulus GPCRs become 
desensitised and lose cellular sensitivity (Ferguson, 2001; Claing et al, 2002). Short-term 
desensitisation is mediated, in part, by the phosphorylation of residues within the C- 
terminal tail by G protein receptor kinases (GRKs). Long-term loss of cellular sensitivity 
can involve the down regulation of receptors by protein degradation and decreased receptor 
synthesis. The C-terminal tail of GPCRs contains several serine and threonine residues that 
can determine the intracellular trafficking and fate by providing phosphorylation sites for 
several protein kinases (Smith and Scott, 2002; Tobin, 2002).
Desensitisation can be either heterologous or homologous. Heterologous desensitisation is 
a process that does not require agonist activation of the target GPCR. In this situation the 
activation of a distinct GPCR can result in the activation of intracellular kinases that can
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phosphorylate other non-activated GPCRs, specifically at sites involved in G protein 
coupling interfering with G protein function. There are several kinases involved including 
protein kinase A (PKA) and protein kinase C (PKC) (Ferguson, 2001). Homologous 
desensitisation is a process for which agonist occupation is required for desensitisation of 
that GPCR (Claing et al, 2002).
The binding of ligand to the GPCR triggers phosphorylation by GRKs. There are currently 
seven GRKs identified that share considerable sequence homology. The structure of the 
GRK family members consists of a central catalytic domain, an amino terminal domain 
important in substrate recognition and a carboxyl teiminal domain that contributes to the 
plasma membrane targeting of the kinase (Ferguson, 2001). GRKs also possess an RGS- 
like domain in the amino terminal which suggests that they may play a role in regulating 
the G protein as well as regulating signalling at the level of the receptor (Carman et al, 
1999; Sallese et a l, 2000). GRKl and GRK7 are primarily involved in the regulation of 
rhodopsin (Shichi and Somers, 1978; Weiss et al, 1998). GRK2 and 3 were initially 
identified as pARKl and PARK2 responsible for the phosphorylation of the p 
adrenoceptor but have subsequently been shown to have widespread expression (Benovic 
et al, 1986; Benovic et al, 1991). GRK4-6 are widely expressed in many cell types 
(Premont et al, 1994; Sallese et al, 1994; Kunapuli and Benovic, 1993; Benovic and 
Gomez, 1993). Several serine and threonine residues are located within the C-terminal tail 
of many GPCRs, providing phosphorylation sites for the GRKs. However, GRKs have also 
been shown to phosphorylate residues within intracellular loop 3 for the human M2 
muscarinic and a%A adrenoceptors (Ferguson, 2001). Although no consensus site for GRK 
activity has been determined, the presence of acidic amino acids proximal to the 
phosphorylation site favours GRK2 mediated phosphorylation (Onorato et al, 1991; Chen
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et al, 1993). GRKs preferentially phosphorylate receptors that are in the agonist-occupied 
conformation (Luttrell and Leftkowitz, 2002).
Phosphorylation of receptors by GRKs alone has little effect on receptor-G protein 
coupling but instead serves to increase the affinity of the receptor for cytosolic cofactors 
termed arrestins. Airestin binding sterically hinders G protein coupling, seizing to 
uncouple the receptor fiom the G protein and target the receptor for endocytosis (Benovic 
et al, 1987; Lohse et al, 1990; Pippig et al, 1993). To date fbui' members of the arrestin 
family have been identified. These are visual arrestin and cone arrestin that are localised 
primarily in the retina (Shinohara et al, 1987; Yamaki et al, 1987). Two p-arrestins have 
been isolated; P-arrestinl and p-arrestin2 (Lohse et al, 1990; Attramadal et al, 1992). P- 
arrestins are ubiquitously expressed but are predominantly located in neuronal tissues and 
the spleen (Attramadal et al., 1992). All members of the arrestin family are capable of 
binding to ligand-activated GPCRs that have been phosphorylated by GRKs.
p-arrestins serve as endocytic adaptor proteins which can target GPCRs for internalisation 
via clathrin-coated vesicles (Ferguson et al, 1996; Zhang et al, 1996). GPCR 
internalisation is an important process in signal attenuation, receptor resensitisation and 
down-regulation. p-arrestins are capable of binding to the p2 -adaptin subunit of the 
heterotetromeric AP-2 adaptor complex (Goodman et al, 1997; Laporte et al, 1999). The 
AP-2 adaptor complex then targets the receptors to the clathrin endocytic pathway by 
binding clathrin and dynamin and initiates clathrin pit formation (Kirchhausen, 1999). 
Dynamin is a large GTP-ase molecule that is required for the budding of clathrin-coated 
pits from the receptor (Zhang et al, 1996).
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Receptor endocytosis is followed by the targeting of the receptor to either recycling 
pathways or to lysosomes for degradation (Kristiansen et al., 2004). Receptor 
resensitisation involves receptor dephosphorylation and dissociation horn its ligand.
The time frame over which these events occur is seconds for GPCR phosphorylation, 
minutes for receptor internalisation and horns for receptor downregulation.
Recently p-arrestins have been implicated as being GPCR signal transducers. P-arrestins 
have been demonstrated to interact with a number of other signalling proteins including c- 
Src (Luttrell et al., 1999), Hck (Baiiic et al., 2000), c-Fgr (Barlic et al., 2000), MAPKs and 
Raf (DeFea et al., 2000). The formation of a complex between the GPCR and p-arrestin 
can act as a scaffold permitting the interaction of these signalling molecules, thereby 
allowing p-arrestin to terminate receptor-G protein coupling while initiating alternative 
signal transduction cascades potentially important in the regulation of cellular processes.
1.2 GPCR Oligomerisation
Traditional models of GPCR ligand binding and signal transduction have always portrayed 
GPCRs as monomeric signalling units. However, oligomerisation had been suggested from 
data generated over twenty years ago. Complex radioligand binding techniques using both 
agonists and antagonists generated data suggesting positive or negative cooperativity 
between ligands. This result was thought to be due to interactions between receptor 
monomers (Hazum et ah, 1982; Limbird and Leftkowitz, 1976; Limbird et ah, 1975; 
Mattera et al., 1985; Potter et al., 1988). Indirect evidence of GPCR oligomerisation was 
provided by experiments performed on the gonadotropin releasing hormone receptor 
(GnRH). This study demonstrated that a bivalent antibody directed at a GnRH receptor
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antagonist could trigger receptor aggregation and signalling (Conn et al., 1982), Functional 
evidence of GPCR oligomerisation was suggested from radiation inactivation experiments 
that demonstrated that GPCRs fimction as complexes larger than predicted by their 
monomeric structure (Conn et al., 1985; Lilly et al., 1983; Venter et al., 1983). Receptor 
affinity labelling studies also identified higher molecular weight species that could 
correspond to receptor oligomers (Herberg et al., 1984; Avissar et al., 1983).
The initial stimulus fuelling investigation into GPCR oligomerisation was the discovery 
that the GABAb receptor was in fact an obligate heterodimer of two distinct subunits, 
GABAbRl and GABAbR2 (Jones et al., 1998; Kaupmann et al., 1998; White et al., 1998; 
Sullivan et al., 2000). The GABAbRl subunit was initially identified and although it 
possessed a seven transmembrane structure, it could not account for the pharmacology 
observed for the native GABAb receptor. The GABAbRl subunit was unable to traffic to 
the cell smTace when expressed in heterologous systems. Subsequent identification of the 
GABAbR2 subunit revealed the heterodimer pair involved in conferring the observed 
pharmacology of the GABAb receptor. An endoplasmic reticulum (ER) retention motif 
was identified within the C-terminal tail of the GABAbRl. Interaction with the C-terminal 
tail of the GABAbR2 subunit masks the retention signal, pemiitting export from the ER 
and trafficking of the heterodimer complex to the cell surface (Margeta-Mitrovic et al., 
2000; Pagano et al., 2001).
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1.2.1 Techniques for detection of oligomerisation
1.2.1.1 Functional reconstitution
Functional reconstitution experiments have been used to demonstrate GPCR 
oligomerisation. This technique utilises non-functional mutants or chimeric receptors that 
are unable to signal when singly expressed, but upon co-expression with a receptor 
possessing a different mutation or chimera functionality is restored. A study performed by 
Monnot et al. (1996) investigating oligomerisation of the angiotensin ATi receptor used 
this approach. Two point mutant forms of the ATi receptor were generated that were 
incapable of binding ligand when expressed alone. However, when co-expressed ligand 
binding was restored. The trans-complementation obseiwed upon co-expression of the 
mutant constructs is strongly suggestive of protein: protein interactions occurring.
1.2.1.2 Co-immunoprecipitation
Co-immunoprecipitation is a biochemical technique that utilises two differentially tagged 
receptor forms and immunoprécipitation and subsequent protein detection with antibodies 
directed against the epitope tags. In 1996 Hebert et al., utilised differentially tagged p2- 
adrenoceptors in this approach to detect homo-oligomerisation. Using c-Myc and HA 
epitope tagged receptors, the forms were co-expressed. In samples immunoprecipitated 
with anti-Myc antibody, anti-HA immunoreactivity was observed following western 
blotting consistent with the formation of an oligomer. This interaction was shown to be 
specific as the co-expression of c-Myc tagged muscarinic receptors with the HA tagged 132- 
adrenoceptors resulted in no co-immunoprecipitation obseiwed. This teclmique has raised 
concerns as the high levels of receptors expressed and also the hydrophobic nature of the
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GPCRs may cause artefactual aggregation resulting in a false positive result. This can be 
addressed by including controls which represent samples singly expressing the 
differentially epitope tagged forms of the receptors and mixing prior to 
immunoprécipitation (Jordan and Devi, 1999).
1.2.1.3 Resonance Energy Transfer (RET) teehniques
RET techniques have been extensively used to demonstrate the existence of GPCR 
oligomers in living cells. These techniques utilise the non-radiative transfer of energy 
between an energy donor and acceptor pair and are based on the Forster mechanism. 
Forster theory states that energy transfer efficiency is inversely proportional to the distance 
between donor and acceptor molecules by the sixth power calculated by;
£=l/(l+[r/(J?„)«]
(Forster et al., 1948), This demonstrates that energy transfer is highly dependent on the 
proximity of the donor and acceptor moieties with the permissive distance being <100Â 
apart to observe significant energy transfer (Wu and Brand, 1994). Receptors under 
investigation are N- or C-terminally fused with luminescent or fluorescent proteins 
possessing suitable spectra for use as energy donors or acceptors. Co-expression of both 
donor and acceptor receptor conjugates and subsequent donor excitation either directly or 
via bioluminescence, results in energy transfer if donor and acceptor are within RET 
permissive distance. Energy is re-emitted at a wavelength that is characteristic to the 
acceptor moiety.
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Energy transfer is dependent on the extent of overlap between the donor emission and 
acceptor excitation spectra. The quantum yield of the donor and the acceptor excitation 
spectra are also factors effecting energy transfer. The orientation of the donor and acceptor 
moieties is also crucial and it is possible that an interaction could be occurring that results 
in the donor and acceptor molecules being organised into an orientation unfavourable to 
energy transfer (Pfleger and Eidne, 2004; Kroeger and Eidne, 2004).
1.2.1.3.1 Bioluminescence energy transfer (BRET)
BRET is an energy transfer technique based on a bioluminescent donor Renilla luciferase 
(Rluc) and a fluorescent acceptor. This technique was developed from the natural 
phenomenon of bioluminescence in marine organisms such as the sea pansy Renilla 
reniformis and the jellyfish Aequora victoria. Energy transfer is generated by the transfer 
of energy to a fluorescent acceptor green fluorescent protein (GFP) resulting from the 
oxidation of the Renilla luciferase substrate coelenterazine (Xu et ah, 1999). 
Coelenterazine is a naturally occurring imidazolopyrazine luciferin that can participate in 
the bioluminescent process. This substrate is cell permeable and several analogs of 
coelenterazine exist each demonstrating distinct luminescent properties.
The original BRET system utilised Rluc as a donor and a red shifted version of GFP 
termed enhanced yellow fluorescent protein (eYFP) as the acceptor. The substrate in this 
technique is the h derivative of coelenterazine. Rluc emits light between 475-480nm while 
eYFP emits between 525-530nm, resulting in poor spectral resolution. The Rluc produces a 
broad emission spectrum that overlaps with that of eYFP, creating high ‘bleedthrough’ of
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the Rluc signal into the eYFP window. Therefore the signal: noise ratio of this technique is 
relatively poor. This methodology was first utilised to detect protein dimérisation for the 
light-sensitive clock protein KaiB in E. Coli (Xu et al., 1999).
These issues have been addressed and a new generation BRET assay has been developed 
termed BRET^. In this assay Rluc is again utilised as the donor, however the substrate used 
is a coelenterazine derivative temied DeepBlueC (PerkinElmer). This substrate 
demonstrates distinct spectral properties when oxidised by luciferase and emits light at 
395nm. The fluorescent acceptor used is a modified form of GFP termed GFP  ^which has 
an excitation spectrum adapted to the emission spectrum of DeepBlueC and upon 
excitation re-emits energy at 510nm. This allows much higher spectral resolution between 
donor and acceptor and vastly improving the signal: noise ratios. This technique has been 
extensively utilised for the detection of protein: protein interactions including the 
investigation of receptor oligomerisation and also receptor interaction with intracellular 
proteins including p-arrestin (Mercier et al., 2002; Kroeger et al., 2001; Charest and 
Bouvier, 2003).
1.2.1.3.2 Fluorescence Resonance Energy Transfer (FRET)
FRET is a technique that utilises fluorescent donor and acceptor proteins with overlapping 
donor emission and acceptor excitation spectra. Donor excitation is provided by an 
external light source as opposed to BRET in which excitation was produced via a 
bioluminescent reaction. Several combinations of donor and acceptor proteins have been 
used in FRET of which CFF/YFP has been most exploited (Pfleger and Eidne, 2005). 
Several variations of the FRET technique exist. Excitation of the donor fluorescent moiety
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results in the transfer of energy to the acceptor and a coiTesponding proportional drop in 
fluorescence intensity of the donor protein. Therefore the difference in donor fluorescence 
in the absence and presence of the acceptor is a measure of FRET efficiency. Photo 
bleaching FRET utilises this fact and images of donor fluorescence are compared before 
and after irreversible photochemical destruction of the acceptor moiety by prolonged 
sample illmuination at a wavelength specific to the acceptor. An increase in donor 
fluorescence following acceptor destruction demonstrates FRET occurring between donor 
and acceptor protein conjugates. The technique can also be performed by photo-destruction 
of the donor fluorescent protein. In this variation, if donor and acceptor are within FRET 
permissive distance the resulting energy transfer will compete with the photo bleaching 
process (Pfleger and Eidne, 2005; Zal and Gascoigne, 2004).
Spectral FRET imaging requires thi'ee measurements to be recorded in order to measure 
FRET: sensitised fluorescence and donor and acceptor fluorescence. The close spectral 
overlaps that exist between the donor and acceptor proteins commonly requires 
measurements of bleed-through between filter sets to be recorded. FRET is calculated as 
the ratio of bleed-through corrected sensitised fluorescence to donor or acceptor 
fluorescence. Fluorescence lifetime imaging (FLIM) is a variation of FRET that exploits 
the accelerated decay in donor fluorescence caused by FRET following a short pulse of 
excitation permitting the generation of fluorescence decay profiles.
Time-resolved FRET (Tr-FRET) is a variation that can facilitate the detection of cell 
surface GPCR oligomers in living cells. Whole cells co-expressing differentially N- 
terminally epitope tagged receptors are incubated with epitope specific antibodies 
conjugated to fluorescent moieties eapable of participating in energy transfer. As the
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antibodies only have access to cell surface expressed GPCRs, this technique will only 
report energy transfer occuning at the cell membrane. Tr-FRET confers excellent signal to 
noise ratios. This is achieved by exploiting the finding that in FRET, the lifetime of the 
acceptor’s emission contains a contribution equal to the donor’s emission lifetime during 
energy transfer (Morrison, 1988). Both the donor and acceptor fluorophores commonly 
used in Tr-FRET display prolonged fluorescence characteristics leading to prolonged 
emission by the acceptor moiety. Measurements are generally taken following a delay of 
50ps, allowing the clear distinction of the long-lived acceptor emission signal resulting 
from FRET and the short lived signal resulting from direct excitation. The fluorescent 
donor moieties commonly used in this technique are commonly lanthanide compounds 
such as europium cryptate and europium chelate for which fluorescence is long-lived 
(Bazin et al., 2002). The acceptor moieties commonly used include allophycocyanin and 
Alexa Fluor 647 (Pfleger and Eidne, 2005).
1.2.2 GPCR homo- and hetero-oligomers
A vast number of studies have been performed investigating GPCR homo- and hetero­
oligomerisation as demonstrated in Tables 1.1 and 1.2. The large number of receptors 
found to homo-oligomerise within family A GPCRs suggests that this may be a general 
trend for all members within this subgroup. Hetero-oligomerisation has fmther added to 
the complexity of GPCR signalling. Members of the same class of GPCRs have been 
found to hetero-oligomerise and hetero-oligomers formed of different classes of GPCRs 
have also been shown.
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The majority of studies detailed in Tables 1,1 and 1.2 have utilised systems in which the 
receptors of interest are not endogenously expressed, commonly using recombinant 
systems. However, several studies have demonstrated GPCR oligomerisation in cell lines 
endogenously expressing the receptor of interest. Hetero-oligomer formation has been 
shown for the angiotensin ATi and bradykinin B2 receptors in rat smooth muscle cells, 
human platelets and ormental vessels (AbdAlla et al, 2000; AbdAlla et al., 2001). The 
presence of GABAbRl and GABAbR2 hetero-oligomers in the rat cortex was 
demonstrated using receptor specific antibodies for co-immunoprecipitation (Kaupmann et 
al., 1998). Similarly receptor specific antibodies were used to identify hetero-oligomer 
formation between the calcium sensing receptor and the glutamate receptors mglui and 
mglus in the rat brain (Gama et al., 2001). The adenosine Ai and the purinoceptor P2Yi 
receptors have been found to hetero-oligomerise in membranes obtained from rat brains 
(Yoshioka et al., 2002).
Recently atomic force microscopy has been used to investigate the organisation of native 
mouse rhodopsin in the membrane (Fotiadis et al., 2003; Liang et al., 2003). These studies 
clearly demonstrate the arrangement of rhodopsin receptors in an oligomeric array of 
closely packed receptor dimers as shown in Figure 1.3a. Individual dimers could be 
observed that may have broken away from the regimented rows of receptors while 
occasional monomers were also observed. Although this result may be unique to the 
rhodopsin system in which the receptor is present at high density, these studies do provide 
the first conclusive evidence that receptor oligomers exist in native membranes.
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1.2.3 Mechanisms of oligomerisation
Studies to determine regions important in GPCR oligomerisation have yielded conflicting 
results. Initial reports implicated the C-terminal tail region as being important in 
determining the ability of the delta opioid peptide (DO?) receptor to foim oligomers 
(Cveijic and Devi, 1997). The extracellular N-terminal region was found to be important in 
bradykinin B2 receptor oligomer formation (AbdAlla et al, 1999). More recent studies 
involving the yeast a  factor also implicated a role for the N-terminal region (Overton et ah,
2002) and a possible role of N-terminal glycosylation in oligomerisation of some class A 
GPCRs has been shown (Wu et al., 2003). Attention has more recently focused on the 
potential role of transmembrane domains in oligomerisation. Studies have been performed 
utilising peptides corresponding to transmembrane regions within receptors. For the p2 
adrenoceptor, dopamine D2 and leukotriene B4 BLTi receptors, studies implicated a role 
for TM VI in that introduction of the peptides corresponding to this region abolished 
oligomerisation (Herbert et ai, 1996; Ng et al., 1996; Baneres and Parello, 2003). 
However studies utilising peptides must be carefully interpreted as the binding of the 
peptide to a specific region may prevent oligomerisation not through that region, but by 
preventing the oligomer forming normally via another region of the receptor (Kroeger and 
Eidne, 2004). A glycophorin A-like sequence was identified in TM VI of the p2 
adrenoceptor (Lemmon et al., 1994), a finding that initiated the peptide study diseussed 
previously. The importance of this region was demonstrated when a peptide corresponding 
to the glycophorin A-like sequence was prepared containing three amino acid substitutions. 
This peptide failed to abolish oligomerisation detected via western blotting (Hebert et al., 
1996). A subsequent study identified a similar motif in TMl of the yeast a  factor (Overton 
et al., 2003), a region previously demonstrated to play a role in the oligomerisation of this
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receptor (Overton et ah, 2002). Identification of a similar motif in the aib adrenergic 
receptor stimulated analogous studies: however two independent reports confirmed that 
while TM I is important, the glycophorin A-like motif was not required for receptor homo- 
oligomerisation (Stanasila et al., 2003; Carrillo et al., 2004). A recent study by Trettel et 
al. (2003), used CXCR2 receptor fragments to demonstrate that homo-oligomerisation of 
this receptor occurred via a region consisting of extracellular loop 1, TM III and 
intracellular loop 2. Taken together, this apparently conflicting data gave rise to the notion 
that oligomerisation for different receptors must occur via different mechanisms.
Many of the techniques cunently used cannot distinguish between dimer formation and 
higher order oligomer formation. This was highlighted in a report implicating TM I, II and 
IV as being involved in C5a receptor homo-oligomerisation (Klco et al., 2003). These 
results are difficult to incorporate into a single model of dimer interfaces and the authors 
concluded that higher order oligomers of this receptor must exist. A recent study 
investigating rhodopsin in native mouse membranes provided more evidence for this 
theory. As mentioned previously, rhodopsin was found to exist in an oligomeric array of 
dimers (Fotiadis et al., 2003). Molecular modelling of the results implicated TM IV and V 
as potential contact points between monomers foiming the dimer, and TM I, II and 
intracellular loop 3 to be important in providing contact points for oligomer or rows of 
dimer formation (Liang et al., 2003). This is demonstrated in Figure 1.3b. Further evidence 
in support of this mechanism of oligomer formation was provided by investigations into 
the dopamine D2 receptor implicating TM IV as forming a symmetrical dimer interface 
(Guo et ah, 2003; Lee et al., 2003). Hernanz-Falcon et al., (2004) recently demonstrated 
that single point mutations in TM I and IV of chemokine receptor CCR5 were sufficient to 
abrogate oligomerisation detected using FRET techniques. A recent study investigating aiB
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adrenoceptor homo-oligomer formation utilised data gained from receptor fragments to 
generate a model of oligomer organisation whereby both TM I and TM IV interactions 
were involved in symmetrical dimer interactions (Carrillo et al., 2004). They also 
suggested a possible interaction between TM I + II and TM V + VI receptor fragments, 
indicating a more eomplex aiTay of am adrenoceptors may form. It is possible that the 
wide variation in regions found to be important in oligomerisation within a given class of 
GPCRs could represent different contact points between dimers and higher order 
oligomers, and a common mechanism could yet be identified.
1.2.4 Regulation of GPCR oligomerisation
1.2.4.1 Effect of ligand on oligomerisation state
There have been several conflicting reports on the effect of ligand on receptor 
oligomerisation. The main difficulty in this area is the interpretation of any ligand- 
modulated data as it camiot be ensured that any change in oligomer levels observed are not 
simply due to ligand binding to pre-formed receptor oligomers changing the conformation 
of the oligomer and not the ligand actually either promoting oligomer formation or 
dissociation. Co-immunoprecipitation has been used to investigate the effects of ligand 
binding on oligomer formation for several receptors and an increase in oligomerisation 
levels was reported for the P2 adrenoceptor (Hebert et al., 1996), somatostatin receptor 
subtypes (Rocheville et al., 2000) and TRH receptors (Zhu et al., 2002). The same 
technique also reported no change in oligomer levels for the muscarinic M3 receptor (Zeng 
et al., 1999) and opioid receptors (Jordan and Devi, 1999) and a decrease in reported 
oligomerisation was observed for the DO? opioid receptor (Cveijic and Devi, 1997) and
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dopamine D1 and angiotensin ATi hetero-oligomer (Gines et al., 2000). However the 
technique of co-immunoprecipitation cannot be accurately quantified as changes in the 
observed immunoreactivity could be a result of ligand binding triggering conformational 
changes within the oligomer, altering the ability of the antibody to bind the epitope tag, 
rather than a direct reflection of actual oligomer levels.
RET techniques have also been used to address this issue. RET techniques have 
demonstrated increases in energy transfer following exposure to agonist for the homo­
oligomers: p2 adrenoceptor (Angers et al., 2000; Cheng et ah, 2001), TRH (Kroeger et ah, 
2001), GnRH receptor (Cornea et ah, 2001), somatostatin sstg receptor (Rocheville et ah, 
2000), melatonin MT2 receptor (Ayoub et ah, 2002; Tenillon et ah, 2003; Ayoub et ah, 
2004) and the hetero-oligomers adenosine A;/P2Yi (Yoshioka et ah, 2002), P2 
adrenoceptors/DOP (McVey et ah, 2001), ssts/dopamine D2 (Rocheville et ah, 2000), 
melatonin MT1/MT2 (Ayoub et ah, 2002; Ayoub et ah, 2004) and TRH; and TRH2 
(Hanyaloglu et ah, 2002). A decrease in energy transfer was observed for the 
cholecystokinin CCK; receptor (Cheng et ah, 2001) and the neuropeptide Y4 receptor 
(Berglund et ah, 2003). However in the majority of studies performed, authors did not 
report an alteration in energy transfer following exposui’e to agonist. This was the case for 
homo-oligomers of DOP (McVey et ah, 2001; Ramsey et ah, 2002), Ste2 (Overton et ah, 
2000), aiB adrenoceptor (Stanasila et ah, 2003), complement C5a (Floyd et ah, 2003), 
adenosine A; and A2A receptors (Yoshioka et oh, 2002; Kamiya et al., 2003; Canals et ah, 
2004), Pi adrenoceptor (Mercier et ah, 2002; Angers et al., 2000), angiotensin AT; 
(Hansen et ah, 2004), calcium sensing receptor (Jensen et ah, 2002), cholecystokinin 
CCK2 receptor (Cheng et al., 2001), melatonin MT; receptor (Ayoub et ah, 2002), KOP 
(Ramsey et ah, 2002), oxytocin receptor (Terrillon et ah, 2003; Devost et ah, 2003) and
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the vasopressin Via and V2 receptors (Terrillon et al., 2003). Hetero-oligomers studied 
included adenosine A2A and dopamine D2 receptors (Canals et al., 2003; Kamiya et al.,
2003), Pi and p2 adrenoceptors (Lavoie et al., 2002; Mercier et al., 2002), cholecystokinin 
CCKi and CCK2 (Cheng et al., 2003), MOP and NKi receptors (Pfeiffer et al., 2003), 
oxytocin and vasopressin Via and V2 (Terrillon et al., 2003) and vasopressin Via and V2 
(Terrillon et al., 2003).
The difficulty in inteipreting agonist induced changes in energy transfer is the possibility 
that any modulation observed is in fact a reflection of agonist binding altering the 
conformation of pre-existing oligomers causing the spatial orientation of the donor and 
acceptor moieties to change. This is supported by the findings that while agonist binding 
can cause an increase in BRET for the melatonin MTi and MT2 hetero-oligomer, 
antagonist binding can also cause the same increase in BRET (Ayoub et al., 2002). This 
leads to the conclusion that the observed increase is due to receptor occupancy triggering a 
conformation of donor and acceptor more favourable to energy transfer rather than an 
increase in oligomer levels.
There have been inconsistencies in the data reported for agonist modulation of oligomers 
performed using different techniques. Although some reports detailed previously utilising 
co-immunoprecipitation have demonstrated an increase in oligomerisation following 
agonist exposure for the p2 adrenoceptor, RET studies performed by Mercier et al., (2002) 
have reported no change in energy transfer following agonist exposure. This could be due 
to a ligand induced conformational change occurring that could not be detected using 
BRET.
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Perhaps the most convincing studies investigating ligand modulation was performed 
utilising crystallization studies of extracellular ligand-binding domains. These have shown 
that the mglui receptor (Kunishima et al, 2000) and Wnt-Frizzled (Dann et al., 2001) can 
form oligomers in the presence and absence of ligand.
1.2.4.2 Site of oligomer formation
Research has demonstrated the existence of oligomers pre-formed at the cell surface. 
Several studies have addressed the location of oligomer formation. The example of the 
GABAbRl and GABAbR2 obligate dimer discussed previously, illustrates the formation 
of a hetero-oligomer in the endoplasmic reticulum (ER) and subsequent trafficking of the 
complex to the cell surface. The exit of GPCRs from the ER represents an important 
control point whereby incorrectly folded receptors are retained and eventually degraded in 
the proteosome (Petaja-Repo et al., 2001). Several studies have utilised a cellular 
fractionation approach in conjunction with energy transfer techniques to demonstrate the 
presence of oligomers in the ER. The yeast a  factor receptor homo-oligomers (Overton et 
al., 2002), CCR5 homo-oligomers (Issafi'as et al., 2002) and oxytocin and V2 vasopressin 
receptor homo and hetero-oligomers (Terrillon et ah, 2003) have all been shown to 
demonstrate constitutive energy transfer signals in both plasma membrane and ER 
fractions. Trettel et al. (2003) demonstrated that for CXCR2 homo-oligomerisation, 
oligomers could still be detected in the absence of glycosylated monomeric receptors. This 
indicates that the receptors oligomerise at some point during the biosynthetic pathway and 
before they reach the plasma membrane.
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The observation that truncated mutants of rhodopsin behave as dominant negative mutants 
of the wild-type receptor by acting to prevent the normal cell surface expression pattern 
has further strengthened the hypothesis of oligomer formation in the ER (Colley et al., 
1995). Similar studies on the vasopressin V2 (Zhu and Wess, 1998), dopamine D3 (Karpa 
et al., 2000), gonadotrophin releasing hormone GnRH (Grosse et al., 1997) and CCR5 
chemokine receptors (Benkirane et al., 1997; Shioda et al., 2001) have also yielded similar 
results.
1.2.5 Functional significance of oligomerisation
Several studies have investigated the effect oligomerisation has on receptor function. 
Hetero-oligomerisation has been shown to be required for correct signal transduction by 
the taste receptors. Both sweet and L-amino-acid responses are dependent on the formation 
of hetero-oligomers between T1R3 and T1R2 or TlRl respectively (Nelson et al., 2001; 
Nelson et al., 2002). The idea of a hetero-oligomer possessing distinct pharmacology 
presents an attractive drug target. A drug could potentially be designed to act as a 
bifunctional agonist at the hetero-oligomer, stabilising the oligomer, leading to improved 
signalling (Kenakin, 2002).
1.2.5.1 Oligomer mternalisation
Recently several studies have demonstrated the ability of hetero-oligomers to undergo 
internalisation in response to an agonist directed at only one receptor in the oligomer 
complex. This has been shown for somatostatin ssti and sst^  (Rocheville et al., 2000), 
cc2a/Pi adrenoceptors (Xu et al., 2003), aiA/ocm adrenoceptors (Stanasila et al., 2003),
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DOP opioid and p2 adrenoceptors (Jordan et ah, 2001), somatostatin ssti and MOP opioid 
receptors (Pfeiffer et aL, 2002) and adenosine A%A and dopamine D2 receptors (Hillion et 
al., 2002). The hetero-oligomer complex formed between angiotensin ATi and bradykinin 
B2 demonstrates altered internalisation pathways that are both clathrin and dynamin 
independent (AbdDalla et ah, 2000). In some instances the co-internalisation is 
accompanied by cross-desensitisation (Pfeiffer et al., 2002; Hillion et al., 2002).
Reports also exist demonstrating receptors that have been shown to respond poorly to 
agonist induced internalisation can exert a dominant negative effect on a second GPCR 
that is normally internalised effectively. This has been demonstrated for the KOP receptor 
that can inhibit the internalisation of the DOP receptor (Jordan and Devi, 1999) and P2 
adrenoceptor (Jordan et al., 2001). This is also the case for the Pi adrenoceptor that 
prevented the internalisation of the P2 adrenoceptor (Lavoie et aL, 2002) and the P3 
adrenoceptor that also acted as a dominant negative of the P2 adrenoceptor (Breit et aL,
2004).
1.2.5.2 Pharmacological diversity
Changes in receptor pharmacology have been obseiwed for some hetero-oligomers. The 
initial observation that hetero-oligomerisation resulted in altered ligand binding affinity 
was shown for the DOP and KOP opioid receptors (Jordan and Devi, 1999). Co-expression 
of both receptors resulted in low affinity for ligands specific to either receptor when added 
separately however high affinity was restored when the agonists were applied together, 
demonstrating positive co-operativity. Several other examples of co-operativity resulting 
from hetero-oligomerisation have been shown for and pi adrenoceptors (Werry et aL,
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2003), muscarinic M2 and M3 (Maggio et aL, 1999), DOP and MOP receptors (Gomes et 
aL, 2000), glutamate receptors mglui and mgluz (Galvez et aL, 2001), somatostatin sstg and 
dopamine D2 (Rocheville et aL, 2000) and adenosine A2A and dopamine D1 (Franco et aL, 
2000). This finding represents further complexity and diversity in the GPCR field.
Oligomerisation can lead to crosstalk between the monomer units and can result in 
cooperative binding of ligands to the protomers. An initial radioligand binding study 
investigating p-adrenergic receptors firom frog erythrocytes observed low hill coefficients 
upon ligand binding and interpreted this as evidence for negative cooperativity (Limbird et 
aL, 1975). Positive cooperativity has been reported for ligand binding of the DOP and 
KOP receptors upon co-expression (Jordan and Devi, 1999). Negative cooperativity has 
been observed for D2 dopamine receptor agonist binding in the presence of an adenosine 
A2 receptor agonist when the two receptors are co-expressed (Franco et aL, 2000). 
Negative cooperativity has also been observed in the binding of antagonists to the M2 
muscarinic and the D2 dopamine receptors for which an antagonist for one receptor 
appeared to inhibit another in a non-competitive manner (Park et aL, 2002; Aimstrong and 
Strange, 2001). Complex mathematical analysis of the results indicated that the data were 
consistent with cooperativity existing between two or four interacting sites for the D2 
dopamine and M2 muscarinic receptor respectively. Cooperative effects have also been 
observed for homo-oligomers. Cooperativity in the binding of oxytocin to its receptor has 
been reported in frog bladder epithelial cells (Roy et aL, 1973).
Traditionally it has been assumed that a single heterotrimeric G protein interacts with a 
single receptor monomer. The discovery of GPCR oligomerisation has challenged this 
view leading to the hypothesis of a receptor dimer interacting with a single G protein.
32
Analysis of the crystal structure of the heterotrimeric G-protein has suggested multiple 
contact points between the receptor and the G protein a  and subunits (Hamm, 2001), 
inconsistent with a one receptor: one G protein stoichiometry. When the X-ray crystal 
structure of rhodopsin was resolved, these contact points could be investigated relative to 
the structure. This revealed that the cytoplasmic surface of rhodopsin is no more than 40Â 
across, a surface too small to accommodate interactions between a monomer receptor and 
both a  and py subunits simultaneously (Hamm, 2001, Liang et aL, 2003). Also functional 
studies have investigated cooperativity of binding of transducin to rhodopsin, yielding data 
again consistent with a receptor dimer interacting with a single G protein (Willardson et 
aL, 1993; Clark et aL, 2001). These studies led to the conclusion that two monomers must 
bind a single G protein. Baneres and Parello (2003) investigated the interaction between 
the leukotriene B4 BLTi receptor and the Gaj2piy2 heterotrimer. Utilising chemical cross 
linking followed by size-exclusion chromatography, mass spectroscopy and neutron 
scattering measuiements, this study demonstrated that the complex formed between the 
activated receptor and G protein in cells con’esponds to one GPCR dimer interacting with a 
single heterotrimeric G protein.
1.3 Chemokines
Chemokines are a large family of chemotactic cytokines. Chemokines and their receptors 
are involved in several physiological processes including leukocyte trafficking, 
organogenesis, hematopoiesis and immuno-modulation (Baggiolini, 1998). They have been 
implicated in several disease states including inflammation and allergy and are crucial in 
mediating innate and adaptive immune responses. They are small mostly basic secretory
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proteins of 8 -12kD with four conserved cysteines (Baggiolini et aL, 1994; Baggiolini et 
al., 1997) produced by leucocytes and tissue cells.
There are two main subfamilies of chemokines; CXC and CC chemokines that are 
determined by the position of the first two cysteines. In the CXC subfamily the cysteines 
are separated by one amino acid while in the CC subgroup the cysteine residues are 
adjacent. These residues also determine the three-dimensional folding of the chemokines 
by forming two disulphide bonds (Cysl Cys3; Cys2 -> Cys4). Chemokines generally 
have a short amino-terminal domain of between 3-10 amino acids preceding the first 
cysteine and possess a backbone made of p-strands and the connecting loops formed 
between the second and fourth cysteines. There is a carboxyl terminal a-helix of 20-30 
amino acids. The backbone structure is very rigid while the terminal regions display a high 
degree of structural disorder (Rajarathnam et aL, 1995). Throughout the chemokine family 
there exists similar folding despite highly divergent sequence identity.
Other chemokine family members have been identified which do not belong to either 
subfamily. Lymphotactin has been identified, possessing only two conserved cysteine 
residues (Kennedy et aL, 1995) and fractalkine, which is membrane bound and possesses 
three amino acids between the first two cysteine residues.
There are thought to be as many as 40-50 human chemokines, detailed in Figure 1.4. The 
genes encoding these chemokines have been mapped and found to cluster at specific loci in 
accordance with the subfamily they are classified into. Generally the genes corresponding 
to CC chemokines are grouped at 17ql 1.2-12 and CXC chemokines at 4q21.1. However, 
some exceptions exist to this mle. CCL17 and CCL22 are found at gene locus 16ql3 while
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CCL19, CCL21, CCL25 and CCL27 are found at locus 9pl3.3. CCL24 and CCL26 are 
found at 7qll,23 while CCL20 is found at 2q36.3. CXCL12 is found at 10qll.21 and 
CXCL13 is found at 5q31.1 (Baggiolini, 2001)
CXC- chemokines can be further subdivided on the basis of possessing a three amino acid 
‘ELR’ motif located between the N-terminus and the first cysteine (Clark-Lewis et aL, 
1991; Hebert et aL, 1991). This glutamate -  leucine -  arginine motif has been found in 
several chemokines that possess potent neutrophil chemoattractant properties. One member 
of this subgroup is Interleukin-8 (IL-8) also termed CXCL8 (Yoshimura et aL, 1987). IL-8  
regulates the recruitment and activation of polymorphonuclear leukocytes (PMNs) at 
inflammatory sites. Interestingly, IL-8  has been demonstrated to be present in solution as 
both monomers and dimers, in equilibrium under physiological conditions (Horcher et aL,
1998). However data has suggested that while the monomer is capable of binding the 
CXCRl receptor, the dimeric form is not. The existence of both forms in normal 
physiology has been hypothesised to be a negative regulator in receptor function and 
positive regulator for binding to cell surface glycosaminoglycans (GAGs) (Fernando et aL,
2004). GAGs are important in the immobilization of chemokines and have an important 
role in governing their local concentration.
1.3.1 Chemokine Receptors
The effects of chemokines on target cells are mediated via interactions with seven 
transmembrane receptors that ai’e G-protein coupled (Murphy, 1994). Six receptors have 
been identified that bind the CXC- class of chemokines, termed CXCRl-6 , while the CC 
receptor family comprises ten known receptors, CCRl to CCRIO as detailed in Figure 1.4.
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Receptors for fractalkine and lymphotactin have also been identified. Receptors termed 
Duffy antigen receptor for chemokines (DARC) and D6 have also been identified (Horuk 
et aL, 1993; Nibbs et aL, 1997). Although these receptors are hepta-helical chemokine 
binding proteins they have not been demonstrated to signal therefore were excluded from 
the nomenclature (Murphy et aL, 2000).
Chemokine receptors have 25 -  80% amino acid sequence homology, demonstrating the 
diversity of the family, Chemokine receptors are generally 340-370 amino acids in length. 
The extracellular amino terminus is short, commonly possesses N-linked glycoylation sites 
and may be sulphated on tyrosine residues. There aie seven a-helical transmembrane 
domains with thiee intracellular and three extracellular connecting loops composed of 
hydrophilic amino acid residues. The second intracellular loop demonstrates a highly 
conserved DRYLAIV sequence while the third intracellular loop is short and basic. The 
extracellular loops 1 and 2 are linked via the formation of a disulphide bond between 
highly conseiwed cysteines. The intracellular carboxyl terminal contains serine and 
threonine residues that act as phosphorylation sites, important in receptor regulation 
(Murdoch and Finn, 2000).
Currently 18 different chemokine receptors have been identified (Murphy et al, 2000). As 
mentioned earlier over 50 human chemokines have been identified suggesting a high 
degree of redundancy within the family whereby several chemokines may bind one 
receptor within a given subgroup. The finding that several chemokines possess both 
agonist and antagonist properties under physiological conditions further complicates these 
interactions. This is the case for the CXCR3 agonists CXCLll, CXCL9 and CXCLIO, 
implicated in T helper 1 cell mediated responses. These agonists have been shown to act as
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antagonists at CCR3, a receptor involved in mediating T helper 2 cell type responses 
(Loetscher et aL, 2000). This has also been demonstrated for the CCR3 agonist CCLl 1 that 
is a partial agonist at CCR2 and CCR5 (Martinelli et aL, 2001; Olgilvie et aL, 2001) and 
CCL7 that acts as an agonist at CCRl, CCR2 and CCR3 but as an antagonist for CCR5 
(Blanplain et aL, 1999). This adds further complexity to inteipreting chemokine signalling.
Chemokines interact with their receptors via the N-terminal region and the exposed 
conformationally rigid loop of the backbone between the second and third cysteine (Clark- 
Lewis et aL, 1995). These sites are in close proximity due to the formation of the 
disulphide bonds. It is thought that the receptor recognises the loop region of the 
chemokine initially and this interaction is cmcial for correct presentation of the ‘triggering’ 
N-terminal domain to the receptor (Clark-Lewis et al., 1995). The importance of the N- 
terminal region is highlighted in studies whereby modification of this region has resulted in 
receptor antagonists (Baggiolini et aL, 1994; Zhang et aL, 1994; Simmons et aL, 1997). 
The chemokine receptors have been found to generate Pertussis toxin sensitive responses 
indicating coupling to Gaj proteins.
Chemokine receptors range from being vital, in the case of CXCR4 required for late 
embryogenesis and organogenesis, to being redundant, demonstrated by CCR5 that is 
missing in some populations to no obvious detrimental effect (Murphy et aL, 2000).
1.3.3 CXCRl and CXCR2
In 1991 two groups identified the receptors for IL-8 termed CXCRl (Holmes et aL, 1991) 
and CXCR2 (Mui'phy et aL, 1991). CXCRl is encoded by 350 amino acids and has an N-
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linked glycosylation site at the N-terminus. CXCR2 has a very high sequence homology to 
CXCRl (78%) having almost identical intracellular loops. The main divergence occurs at 
the amino- and carboxyl- terminal (Wu et al, 1993). Both CXCRl and CXCR2 bind ELR 
containing CXC chemokines including IL-8 that binds both receptors with high affinity. 
The genes encoding CXCRl and CXCR2, as well as a pseudogene for CXCR2, are located 
on human chromosome 2q35 located 20kb apart (Ahuja et aL, 1992; White et aL, 1994).
The expression patterns of the two receptors have been determined using receptor specific 
monoclonal antibodies. It was shown that CXCRl and CXCR2 are expressed on all 
granulocytes, monocytes and mast cells. Some CD8+ T-cells and CD56+ natural killer 
cells also express the receptors (Chuntharapai et aL, 1994). Neutrophils were found to 
express equal amounts of CXCRl and CXCR2 however monocytes and positive 
lymphocytes express more CXCR2 than CXCRl (Chuntharapai et aL, 1994). CXCR2 
expression has been detected in some cell types in the Central nervous system (CNS). 
Functional CXCR2 was detected in Purkinje cells in human brain slices, foetal neurons and 
in a human neuronal cell line, hNT, binding IL-8 with affinity in the nano-molar range 
(Horuk et aL, 1997; Hesselgeser et aL, 1997). Interestingly, to date CXCRl expression has 
not been demonstrated in the CNS.
CXCR2 will bind all ELR containing CXC chemokines with close affinity values 
observed. CXCRl is highly selective for IL-8 with a greater than 50-fold difference in 
affinity (Lee et aL, 1992; Loetscher et aL, 1994; Ahuja and Murphy, 1996). GCP-2 
(CXCL6) is equipotent at CXCRl and CXCR2 (Wuyts et aL, 1997). CXCR2 can bind all 
other ELR containing chemokines including GRO-a (CXCLl), NAP-2 (CXCL7) and 
ENA-78 (CXCL5). The N-tenninal region of the two receptors has been shown to
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determine the ligand specificity. A study perfoimed by LaRosa et al, (1992) constructed a 
series of hybrid receptors in which the N-terminus of one receptor was exchanged for the 
other. This demonstrated that when CXCRl had the CXCR2 amino terminus it could bind 
both IL-8  and GROa, however the converse hybrid in which CXCR2 was transplanted 
with the N-terminal region of CXCRl retained the ability to bind IL-8  but was unable to 
bind GROa. These results highlight the importance of the N-terminal region of the 
receptor in determining the specificity of ligand binding. The same study also identified 
two residues present in the third extracellular loop as being critical for ligand binding.
A knockout model for CXCR2 has been generated in mice. CXCR2 (-/-) animals display a 
lack of ability of mobilise neutrophils in response to chemical peritoneal challenge and 
neutrophils were unable to respond chemotactically to chemokine challenge directly at 
CXCR2. The animals also demonstrated lymphadenopathy, caused by an increased level of 
B cells, and splenomegaly, resulting from an increase in metamyelocytes and mature 
neutrophils (Cacalano et al, 1994; Moore et al, 1995). However, it should be noted that 
the mouse model is a poor one as there is no murine equivalent of IL-8 and a mouse 
equivalent of CXCRl has not been identified.
CXCRl and CXCR2 have been reported to vary significantly in their ability to activate 
signal transduction pathways. In neutrophils, both IL-8 and GRO-a can induce calcium 
mobilization and calcium release (Walz et ah, 1991; Schroder et al, 1990), however only 
IL-8  can activate phospholipase-D and the foimation of superoxide by NADPH oxidase 
(L’Heureux et al, 1995). Calcium mobilization also appears to be mediated via different 
mechanism for the two receptors. IL-8  induced calcium release occurs only from 
intracellular stores while GRO-a exposure causes influx of extracellular calcium as well as
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release of calcium from intracellular stores (Damaj et aL, 1996). In neutrophils it has been 
hypothesised that the major receptor for IL-8 is CXCRl. Hammond et aL (1995) utilised 
antibodies selective for CXCRl or CXCR2 capable of preventing agonist binding. The 
anti-CXCR2 antibody was found to almost completely abolish chemotaxis induced by 
GRO-a while having only a slight effect on IL-8 induced mobilisation. The anti-CXCRl 
antibody was shown to completely abrogate chemotaxis induced by IL-8  and only weakly 
effect GRO-a mediated responses.
CXCRl and CXCR2 are rapidly desensitised following exposure to agonist and undergo 
substantial internalisation. Desensitisation is mediated by phosphorylation of serine and 
threonine residues present on the C-terminal tail of CXCRl and CXCR2 (Richardson et 
aL, 1995; Mueller et aL, 1997; Ben-Baruch et aL, 1997; Richardson et aL, 1998). CXCRl 
is capable of generating signals for cross-phosphorylation and cross-desensitisation 
however CXCR2 is not. This is thought to be dependent on the duration of action as 
CXCR2 is rapidly phosphorylated terminating signalling (Richardson et aL, 2003). 
Chuntharapai et aL, (1995) demonstrated that IL-8 induced down-modulation of the 
CXCRl and CXCR2 by >90% in human neutrophils within five minutes of ligand 
exposure. However differences in receptor recycling have been observed with differing 
cell type studied. In neutrophils, which endogenously express CXCRl and CXCR2, 
CXCRl was rapidly recycled to the cell surface with full expression restored 1.5 hours 
following agonist exposuie. However thi’ee hours following agonist exposure CXCR2 was 
still only partially restored to previous levels (Chuntharapai et aL, 1995). A substantial 
amount of CXCR2 was sequestered in early and late endosomal vesicles of neutrophils. In 
epithelial cells both receptors were demonstrated to recycle with similar kinetics (Fan et 
aL, 2003; Samanta et aL, 1990). The reason for these divergent results could be due to the
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existence of cross-regulatory signals existing in neutrophils where both CXCRl and 
CXCR2 are expressed rather than in heterologous systems such as epithelial cells which 
may only express one receptor in isolation. Studies performed in HEK cells have 
demonstrated areas important in receptor internalisation. For CXCRl this was found to be 
an area in the C terminal tail which contains four clusters of serine and threonine residues 
(Prado et aL, 1996; Richardson et aL, 1995) while for CXCR2 an LLKIL motif present in 
the C terminal tail has been shown to be important in internalisation (Fan et aL, 2001).
Internalisation of CXCRl and CXCR2 occurs via p~arrestin coupled pathways involving 
interactions with dynamin and AP-2 and sequestration into clathrin-coated pits (Barlic et 
aL, 1999; Yang et aL, 1999; Fan et aL, 2001). However, p-arrestin complex formation is 
not necessary for CXCR2 sequestration as removal of CXCR2 from the cell membrane has 
been observed even for truncated forms of CXCR2 that cannot interact with P-arrestin (Fan 
et aL, 2001; Zhao et aL, 2004). This arrestin independent internalisation is thought to be 
mediated via an alternative pathway thought to be dynamin/Rac dependent (Schlunck et 
al., 2004).
As mentioned previously, unlike CXCRl, CXCR2 cannot stimulate the respiratory burst 
response. This has recently been attributed to a protective effect of p-arrestin inhibiting the 
respiratory burst in cells expressing CXCR2. Zhao et aL, (2004) demonstrated that in p- 
arrestin knock out cells there is enhanced MAPK activation resulting from the action of 
reactive oxygen species whose formation is normally inhibited by p-anestin. Under 
physiological conditions it is thought that the rapid phosphorylation of CXCR2, occurring 
within 15 seconds, and complex formation with p-arrestin supersedes that of NADPH 
oxidase, preventing the respiratory burst from occurring (Zhao et aL, 2004). This
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represents an important control mechanism in co-ordinating cell responses to bacterial 
infection, p-an-estin has also been implicated in initiating signalling cascades. Following 
ligand activation CXCRl associates with p-arrestin. This interaction has been shown to 
recruit the Src family members Hck and c-Fgr to the receptor-P-arrestin complex. Hck 
becomes activated and the p-anestin-Hck complex can migrate to granules, initiating 
granule fusion and content release. Cells expressing a dominant negative form of p-arrestin 
did not release granules following exposure to IL-8 , illustrating the importance of this p- 
arrestin mediated signal (Barlic et ah, 2000).
Responses to IL-8  and GRO-a in neutrophils are markedly inliibited by Pertussis toxin 
(PTx), suggesting coupling to the Gi family of G proteins (Bacon and Camp, 1990; Thelen 
et aL, 1988; Wuyts et aL, 1997). Physical association of CXCRl and CXCR2 to Gai2 has 
been demonstrated (Damaj et aL, 1996). Four residues located within intracellular loop 2 
and one residue in intracellular loop 3 have been implicated as crucial for calcium 
signalling and have been identified as putative residues involved in G-protein coupling 
(Damaj et al., 1996). However, some studies have observed a small element of PTx 
insensitive signalling suggesting that CXCRl and CXCR2 may be able to couple to other 
PTx insensitive G proteins such as Gq (Wu et aL, 1996; Hall et aL, 1999). Interestingly 
chemokine induced chemotaxis is a PTx sensitive response suggesting coupling to Ga, 
proteins. However, chemotaxis has been shown to be mediated via GPy subunits and Ga, is 
not required for cell migration induced by IL-8  stimulation of CXCRl (Neptune et aL,
1999). Studies have highlighted a coiTelation between RGS protein expression and an 
inhibition of chemokine induced chemotaxis (Bowman et aL, 1998; Reif et aL, 2000). 
CXCR2 has been shown to specifically interact with the PDZ domain of RGS 12 (Snow et 
aL, 1998).
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Recently Rose et aL, (2004) determined that IL-8  could induce maximal chemotaxis and 
calcium flux responses at concentrations 10-fold less that those required for receptor 
endocytosis. Also CXCRl and CXCR2 could be re-activated by the same ligand at a 
concentration sufficient to induce signalling but too low to stimulate receptor 
sequestration. This suggests a role for receptor internalisation as an end point in CXCRl 
signalling when the cell has reached the site of inflammation and the chemokine 
concentration is at its highest (Rose et aL, 2004).
1.3.3 Chemokine receptor oligomerisation
Several conflicting reports exist in the area of chemokine receptor oligomerisation. Initial 
studies indicated that chemokine receptor oligomerisation may be analogous to that of 
cytokine receptor oligomerisation, which is ligand dependent. Oligomerisation of CCR2 
was demonstrated using both immunoprécipitation and antibody fragment cross-linking to 
illustrate the existence of agonist dependent CCR2 oligomers (Rodriguez-Frade et aL, 
1999). This study also utilised a mutant form of CCR2 that is unable to signal and 
demonstrated that upon co-expression with wild type CCR2, noimal function was 
abrogated and immunoprécipitation data showed a complex formed between the mutant 
and wild type receptors. Ligand dependent oligomerisation was also shown for CCR5 and 
CXCR4 homo-oligomers and hetero-oligomer formation between CCR5 and CCR2 (Vila- 
Coro et aL, 2000; Vila-Coro et aL, 1999; Mellado et aL, 2001). Hetero-oligomer formation 
was also found to confer unique signalling properties to the receptors involved. This 
included G protein switching from Ga, to Gaq/u, suggested by a reduced threshold of 
agonist required to trigger PTx-resistant calcium flux. The activation kinetics of
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phosphoinositide 3-kinase (PI 3-K) are distinct from that observed for homo-oligomers and 
cell adhesion is preferentially activated in contrast to cell migration presented for homo­
oligomers. Interestingly hetero-oligomer formation was found to prevent internalisation 
and desensitisation to a second agonist stimulus (Mellado et ah, 2001).
However, subsequent studies utilising energy transfer technique and, interestingly, co- 
immunoprecipitation demonstrated the existence of constitutive chemokine receptor 
oligomers. This is the case for CXCR2, CXCR4 and CCR5 homo-oligomers (Trettel et aL, 
2003; Babcock et al., 2003; Issafras et aL, 2002; Toth et aL, 2004; Hemanz-Falcon et aL, 
2004; Percherancier et aL, 2005). In studies investigating the effect of ligand binding on 
energy transfer for CXCR4 and CCR5, Toth et aL, (2004) and Hernanz-Falcon et aL, 
(2004) demonstrated a significant elevation of RET signal upon ligand binding for CXCR4 
and CCR5 respectively. For CXCR4, binding of the CXCR4 antagonist AMDS 100 was 
able to attenuate the ligand induced increase in energy transfer (Toth et aL, 2004). The 
difficulty in interpretation of ligand modulation of oligomer formation has been discussed 
previously however the authors hypothesized that chemokine oligomers may exist in 
equilibrium between monomeric and dimeric units and ligand binding may influence this 
delicate balance (Toth et aL, 2004). The varied results in this field can be someway 
explained by variation in the technique sensitivity however it is evident that more research 
is required to elucidate the role of ligand in chemokine oligomerisation.
1.3.4 Chemokines as therapeutic targets
Attention was drawn to the possibility of chemokine receptors as potential drug targets 
upon the discovery that CCR5 and CXCR4 act as co-receptors for HIV-1 entry into cells
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(Littman, 1998; Hoffman and Doms, 1998). Infection with HIV-1 involves two interactions 
with cell surface proteins. The initial interaction is between the cell surface protein CD4 
and viral protein gpl2 0 , triggering a conformational change permitting interaction with the 
chemokine receptor. During initial infection this receptor is CCR5 however, as HIV 
progresses to AIDS, CXCR4 dependent strains emerge. Chemokine receptor interaction 
induces a second conformational change exposing the peptide gp41 that fuses with the 
target cell membrane (Proudfoot, 2002). Chemokines have also been implicated in the 
metastasis of several types of cancers especially breast cancer where increased levels of 
CXCR4 have been demonstrated in tumours (Kang et aL, 2003). Muller et aL, (2001) 
demonstrated that a specific monoclonal antibody against CXCR4 could inhibit metastasis 
of breast cancer cells to the lung or lymph nodes in mice. Multiple sclerosis (MS) is an 
autoimmune disease in which chemokine receptors are central to pathogenesis. Excessive 
levels of CCRl, CCR5 and CXCR3 have been demonstrated in brain samples derived from 
MS patients (Sorensen et aL, 1999; Balashov et aL, 1999).
CXCRl and CXCR2 have been implicated in several inflammation disease states. This can 
be explained as these receptors are potent mediators of chemotaxis and inflammation is the 
result of excessive recruitment of leukocytes. CXCRl and CXCR2 have been implicated in 
airway diseases such as chronic obstructive pulmonary disease (COPD) and severe asthma 
where the inflammation pathology is mediated by neutrophils (Owen, 2001). IL-8 has been 
implicated in the pathology of several conditions including psoriasis (Nickoloff et aL, 
1991; Bizzarri et aL, 2003), ulcerative colitis (Mahida et aL, 1992) and cystic fibrosis 
(Bizzarri et aL, 2003). GlaxoSmithKline has developed a low molecular weight antagonist 
to CXCR2. This has been shown to inhibit both rabbit and human neutrophil chemotaxis 
mediated by both IL-8 and GRO-a in vitro. In vivo experiments performed in rabbits
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demonstrated the ability of the antagonist to inhibit chemotaxis in response to IL-8 (White 
et aL, 1999). A separate study utilising a non-peptide antagonist against CXCR2 in a rabbit 
arthritis model demonstrated reduced accumulation of neutrophils, monocytes and 
lymphocytes in the synovial fluid (Podolin et aL, 2002). An IL-8 specific monoclonal 
antibody has been used in clinical trials for the treatment of the inflammatory skin disease 
psoriasis (Yang et aL, 1999). While CXCRl and CXCR2 have not been shown to act as 
CO-receptors for HIV-1 (D’Souza et aL, 2000), a role exists in HIV replication. Blockade of 
CXCRl and CXCR2 has been shown to inhibit HIV-1 replication in both T lymphocytes 
and macrophages (Lane et aL, 2001). This is thought to be due to HIV-1 infection in a cell 
stimulating IL-8 and GRO-a production that can then act to increase HIV-1 replication. 
Increased levels of IL-8  have been found in the lymphoid tissues of patients with AIDS. A 
non-competitive allosteric small-molecule inhibitor of CXCRl and CXCR2 termed 
Repertaxin has been identified as a possible therapeutic agent to combat reperfusion injury 
(RI) that is unavoidable in organ transplant (Bertini et aL, 2004). RI also factors in the 
pathology of several other conditions including myocardial infarction and stroke. This 
molecule acts by locking CXCRl and CXCR2 in an inactive conformation, preventing 
receptor signalling and PMN chemotaxis. Granule release and pro-inflammatory cytokine 
production was also inhibited (Casilli et aL, 2005). Repertaxin has proven safe in animal 
studies and phase I trials performed in human volunteers have demonstrated the drug to be 
well tolerated. All small molecule inhibitors of IL-8 currently described are still in the pre- 
clinical phase (Casilli et aL, 2005)
CXCRl and CXCR2 are involved in cancer pathology. IL-8 is constitutively produced by 
melanoma cells but not by untransformed melanocytes (Dhawan and Richmond, 2002). 
ELR+ chemokines including IL-8  have been demonstrated to mediate angiogenesis and
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tumorigenesis during the development of ovarian carcinoma (Yoneda et aL, 1998). 
Increased expression of CXCR2 by melanoma cells has also been demonstrated and CXC 
chemokines can increase survival, proliferation and tumour cell migration (Dhawan and 
Richmond, 2002). CXCR2 has been implicated in cellular transformation with the 
similarity between CXCR2 and the viral GPCR encoded in Kaposi’s sarcoma herpes virus 
(KSHV) that signal constitutively. Over expression of KSHV GPCR can result in lesions 
analogous to those observed for Kaposi’s sarcoma (Yang et aL, 2000).
1.4 Project aims
The aim of this study was to investigate CXCRl and CXCR2 receptor homo- and hetero­
oligomerisation. This was examined utilising several techniques including co- 
immunoprecipitation, BRET, Tr-FRET and FRET. The selectivity of oligmerisation was 
examined by investigating interactions with an unrelated GPCR. The effect of ligand on 
oligomerisation state was investigated, as was the site of oligomer formation. The over­
lapping expression pattern of CXCRl and CXCR2 with members of the opioid receptor 
family has been demonstrated. Investigation into potential interactions between the 
receptors has been performed in this study.
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Figure 1.1 Diversity of G protein coupled receptor (GPCR) signalling
GPCRs can be activated by a wide variety of ligands that trigger G protein dependent and 
independent signalling pathways. These pathways can influence many biological 
responses. (Adapted from Marinissen and Gutkind, 2001)
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Figure 1.2 Structural classification of GPCRs
GPCRs can be divided into subgroups according to both sequence similarity and 
pharmacological nature of ligand. Schematic representations of the three main sub-families 
are shown, illustrating the main structural determinants unique to each sub-group. (Taken 
from George et ah, 2002)
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Figure 1.3 Organisation of the cytoplasmic surface of rhodopsin
Atomic-force microscopy was used to investigate rhodopsin organisation in the native disc 
membrane. The topograph image shown in (a) demonstrates a paracrystalline arrangement 
of rhodopsin dimers. Rhodopsin dimers are circled while arrows show receptor monomers. 
A model for the packing arrangement of rhodopsin molecules within the array is also 
displayed (b). The contacts between monomers are predicted to be formed by the 
transmembrane regions IV and V shown in yellow-green and yellow respectively, ((a) 
taken from Fotiadis et aL, 2003 and (b) taken from Fotiadis et aL, 2004)
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Table 1.1 GPCR homo-oligomer formation
Several examples of GPCR homo-oligomerisation have been demonstrated using a variety 
of techniques.
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GPCR Technique Reference
aiA-adrenoceptor Immunoprécipitation, FRET Stanasila et aL, 2003
pi-adrenoceptor BRET Lavoie et aL, 2002; Mercier et aL, 2002
ttiB-adrenoceptor Immunoprécipitation, FRET, Stanasila et aL, 2003;Tr-FRET Carrillo et aL, 2003
P2-adrenoceptor Immunoprécipitation, BRET Angers et aL, 2000; Hebert et aL, 1996; Lavoie et aL, 2002; McVey et al., 2001; Mercier 
et aL, 2002; Hebert et aL, 1998
p3-adrenergic receptor BRET Breit et aL, 2004Adenosine Ai BRET Yoshioka et aL, 2002Adenosine A2A BRET, FRET Kamiya et aL, 2003; Canals et al., 2004Angiotensin ATi BRET Hansen et ai., 2004
C5a receptor FRET Floyd et al., 2003Calcium-sensing receptor Immunoprécipitation, BRET Bai et aL, 1999; Jensen et aL, 
2001CCR2 Immunoprécipitation Rodriguez-Frade et aL, 1999CCR5 Immunoprécipitation, BRET Vila-Coro et aL, 2000; 
Issafras et aL, 2002Cholecystokinin receptor BRET Cheng et aL, 2001CCKi
Cholecystokinin receptor BRET Cheng et aL, 2003
CCK2CXCR2 Immunoprécipitation Trettel et aL, 2003CXCR4 BRET, FRET Babcock et aL, 2003; Issafras et al., 2002; Toth et al., 2004Dl dopamine receptor Immunoprécipitation George et al., 1998D2 dopamine receptor Immunoprécipitation, FRET Lee et aL, 2000;Wurch et al., 
2001DOP receptor Immunoprécipitation, Tr- Cveijic et aL, 1997; George
FRET, BRET et aL, 2000; Gomes et aL, 2002; McVey et aL, 2001
Glutamate mglui Immunoprécipitation Robbins et aL, 1999
Glutamate mglus Immunoprécipitation Romano et aL, 1996GnRH receptor Photobleaching FRET, Cornea et aL, 2001; Horvat et
BRET aL, 2001 ; Kroeger et al, 
2001
KOP receptor Immunoprécipitation Jordan et al., 1999LH receptor Photobleaching FRET Roess et al., 2000Melatonin MT] receptor Immunoprécipitation, BRET Ayoub et al., 2002; Ayoub et al., 2004
Melatonin MT2 receptor Immunoprécipitation Ayoub et al., 2002; Ayoub et aL, 2004; Terrillon et al., 
2003
MOP receptor Immunoprécipitation, BRET George et aL, 2000; Gomes 
et al., 2002Neuropeptide Y4 BRET Berglund et al., 2003Oxytocin BRET Terrillon et aL, 2003;Devost 
et al., 2003; Devost et al..
Somatostatin ssts Thyrotropin receptor 
TRHi
TRH2 Vasopressin Via 
Vasopressin V2 
Yeast a  factor receptor
Immunoprécipitation, FRET FRET
Immunoprécipitation, BRET
BRET
BRET
BRETFRET
2004Rocheville et al., 2000 Latif et al., 2002 
Hanyaloglu et al., 2002; 
Kroeger et al., 2001; Zhu et al, 2002 Hanyaloglu et al., 2002 Terillon et al., 2003 
Teriilon et al., 2003 Overton et al., 2000, Overton et al., 2002
Table 1.2 GPCR hetero-oligomer formation
Hetero-oligomerisation between closely related and distinct GPCRs has been shown. These 
hetero-oligomers can form between members of the same receptor class or between 
receptor classes.
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GPCR Technique Reference
Class A : Class A
Pi and p2-adrenoceptors Immunoprécipitation, BRET Lavoie et al., 2002; Mercier et al., 2002
ttiA-adrenoceptor and am- FRET Stanasila et al., 2003
adrenoceptor
p2 and p3-adrenoceptors BRET Breit et al., 2004
a 2A-adrenoceptor and Pi- Immunoprécipitation Xu et al., 2003
adrenoceptor
P2-adrenoceptor and DOP Immunoprécipitation, BRET, McVey et al., 2001; Jordan etTr-FRET al, 2001P2-adrenoceptor and KOP Immunoprécipitation Jordan et al, 2001
5-HTib and 5-HTid Immunoprécipitation Xie et al, 1999Adenosine Ai and Dopamine Immunoprécipitation Gines et al, 2000D1 receptorAdenosine Ai and P2Yi Immunoprécipitation, BRET Yoshioka et al.,2002; Yoshioka et al, 2002Adenosine A2A and dopamine Immunoprécipitation, BRET Hillion et al, 2002;KamiyaD2 receptor et al, 2003Angiotensin ATia and AT2 Immunoprécipitation AbdAlla et al, 2001receptorAngiotensin ATia and Immunoprécipitation AbdAlla et al, 2000Bradykinin B2 receptor
CCR2 and CCR5 Immunoprécipitation, FRET, Mellado et al, 2001; El-BRET Asmar et al, 2005Cholecystokinin CCKi and BRET Cheng et al, 2003CCK2
D2 and D3 dopamine Functional reconstitution Scarselli et al, 2001receptorD2 dopamine receptor and Photo-bleaching FRET Rocheville et al, 2000somatostatin ssts
KOP and DOP Immunoprécipitation, BRET Jordan et al, 1999; Gomes et al, 2002Melatonin MTi and M2 Immunoprécipitation, BRET Ayoub et al, 2002MOP and DOP Immunoprécipitation George et al.,2000; Gomes et al, 2000MOP and NKi BRET Pfeiffer et al, 2003
Muscarinic M3 and a 2A- Chimeric receptor Maggio et al, 1993adrenoceptor reconstitution
Muscarinic M2 and M3 Receptor reconstitution Maggio et al, 1999Oxytocin and Vasopressin V, BRET Terillon et al, 2003" laOxytocin and Vasopressin V2 BRET Terillon et al, 2003Somatostatin ssti and ssts Photo-bleaching FRET Rocheville et al, 2000Somatostatin sstri and MOP Immunoprécipitation Pfeiffer et al, 2002Somatostatin sstri and sstrs Immunoprécipitation Pfeiffer et al, 2001TRHi and TRH2 BRET Hanyaloglu et al, 2002
Vasopressin Via and V2 BRET Terillon et al, 2003Class A : Class C
5-HTiA and GABAbR2 Immunoprécipitation Salim et al, 2002Adenosine Ai and glutamate Immunoprécipitation Ciruelaétal, 2001
mgluiAdenosine A2A and glutamate 
mglus
Class C : Class C
Immunoprécipitation Ferre et ah, 2002
Calcium sensing receptor and 
glutamate mglui
Calcium sensing receptor and 
glutamate mglus GABAbRl and GABAbR2
Immunoprécipitation
Immunoprécipitation
Immunoprécipitation
Gama et al., 2001
Gama et al., 2001
Jones et al., 1998; Kaupmann et al., 1998; White et al., 
1998
Figure 1.4 Chemokine receptors and their ligands
Chemokine receptors are divided in subfamilies in accordance with the position of N- 
terminal cysteine residues. The CXC- receptors are detailed in blue, CC- receptors are 
shown in red and the minor subclass comprising C- and CX3C- receptors in green. 
Receptor ligands are detailed as both common names and systematic names following 
adoption of a systematic nomenclature system. (Taken from Proudfoot, 2002)
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Common Systematicnames names
IL-8 CXCL8
GCP-2 GXCL6
NAP-2 GXCL7ENA78 GXGL5Gro-a GXGL1Gro-P CXCL2Gro-y GXCL3IP-10 GXGL10MIG GXGL9l-TAC GXCL11
SDF-1 GXGL12
BCA-1 GXCL13
RANTES
GXGL16
GCL5
MIP-la GGL3
MCP-3 GGL7
MCP-1 GGL2
MCP-2 GGL8
MOP-4 GCL13
Eotaxin GGL11
TARO e c u  7MDC GCL22
MIP-ip GGL4
MIP-30 GCL20
ELC e c u  9
SLO GCL21
1-309 GGL1
MEG GCL28
CTACK GCL27
TECK GGL25
Fractalkine/
Neurotactin GX3CLI
Lymphotactin XGL1
2.0 M aterials and M ethods
2.1 Materials
2.1.1 General reagents, enzymes and kits
Amersham Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK
Rainbow markers
BDH, Lutterworth, Leicestershire, UK
2 2 mm coverslips, microscope slides, sodium di-hydrogen orthophosphate, potassium 
hydroxide, potassium chloride, methanol, isopropanol
Cell Signalling Technology, Beverly, MA, USA
Polyclonal anti-c-Myc antibody
Chemicon International, Science Centre, Hampshire, UK
ReBlot plus solution
Duchefa, Haarlem, The Netherlands
Yeast extract, tryptone, agar
Fisher Scientific UK Ltd, Loughborough, Leicestershire, UK
Glycine, HEPES, sucrose, SDS, potassium di-hydrogen orthophosphate, calcium chloride, 
manganese chloride
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Interactiva, Ulm, Germany
All oligonucleotides used for PCR reactions
Invitrogen BV, Groningen, The Netherlands
NuPage Novex pre-cast 8-12% Bis-Tris gels, MOPS running buffer
Konica Europe, Hohenbrunn, Germany
X-ray film
PerkinElmer
DeepBlueC, 384 black walled plates, Optiplate white 96 well plates
Pierce, Perbio Science UK Ltd., Tattenhall, Cheshire, UK
Supersignal West Pico chemiluminescent substrate
Promega UK Ltd., Southampton, UK
All restriction endonucleases, T4 DNA ligase, Pfu polymerase, Wizard Plus SV minipreps 
Quiagen, Crawley, West Sussex, UK
QiaQuick PCR purification kit, QiaQuick gel extraction kit, Qiafilter maxi-prep kit.
Roche Diagnostics Ltd., Lewes, East Sussex, UK
Complete EDTA-free protease inhibitor tablets, 1 Kb DNA ladder
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R&D systems, Abingdon, UK
Human recombinant IL-8 and Gro-a
Sigma-Aldrich Company Ltd., Poole, Dorset, UK
Magnesium chloride, sodium chloride, sodium hydroxide, sodium acetate, DTT, di-sodium 
orthophosphate, tris base, EDTA, bromophenol blue, deoxycholic acid (sodium salt), 
Hoechst stain, rubidium chloride, Triton X-100, DMSO, glycerol, tween 20, ethylene 
glycol, paraformaldehyde, ampiciliin, ethidium bromide, IBMX, forskolin
Whatman International Ltd., Maidstone, UK
GF/C Glass filters
2.1.2 Tissue culture plasticware and reagents
American Tissue Culture Collection, Rockville, USA
HEK293T cells
Costar, Cambridge, MA., USA
5mL, lOmL and 25mL pipettes, 75cm  ^ and 125cm  ^ vented tissue culture flasks, 6 well 
plates, lOOcm^  dishes
Invitrogen BV, Groningen, The Netherlands
Lipofectamine transfection reagent, Optimem-1, L-glutamine (200mM)
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Sigma-Aldrich Company Ltd., Poole, Dorset, UK
DMEM, 0.25% trypsin-EDTA, poly-D-Lysine.
2.1.3 Radiochemicals
Amersham Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK
IL-8
2.1.4 Antisera
Amersham Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK
Donkey anti-mouse IgG-HRP conjugate, donkey anti-rabbit IgG-HRP conjugate
Cell Signalling Technologies
Anti-Myc polyclonal antibody
Sigma-Aldrich Company Ltd., Poole, Dorset, UK
Anti-Flag M2 antibody
Roche Diagnostics Ltd., Lewes, East Sussex, UK
12CA5 monoclonal antibody (binds to haemagglutinin epitope tagged proteins), anti-VSV 
antibody
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Molecular Probes, Eugene, Oregon, USA
Anti-mouse Alexa® 594 IgG conjugate, anti-mouse Alexa® 488 IgG conjugate, anti-rabbit 
Alexa® 488 IgG conjugate
2.2 Buffers
2.2.1 General Buffers 
Phosphate Buffered Saline (lOx)
137mM NaCl, 2.7mM KCl, 1.5mM KH2PO4, 10.2mM Na2HP04, dissolved in IL H2O, pH 
7.4. The solution was autoclaved prior to use. IxPBS was prepared by diluting the stock 
1:10 in H2O.
Tris-EDTA (TE) Buffer
lOmM Tris base, O.lmM EDTA, pH 7.4
Laemmli Buffer (2x)
0.4M DTT, 0.17M SDS, 50mM Tris, 5M urea, 0.01% (w/v) bromophenol blue
2.2.2 Molecular Biology solutions 
TAE Buffer (50x)
40mM Tris, ImM EDTA, glacial acetic acid. This solution was diluted 1:50 prior to use.
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DNA loading Buffer (6x)
0.25% bromophenol blue, 40% sucrose (w/v) in H2O 
LB Media (Luria-Bertani Medium)
lOg Bacto-Tryptone, 5g Yeast Extract and lOg sodium chloride dissolved in H2O up to IL 
and pH 7.4. The medium was autoclaved prior to use.
Buffer 1 (for preparation of competent bacteria)
lOOmL of this solution was prepared containing; 3mL IM potassium acetate, ImL IM 
rubidium chloride, ImL IM calcium chloride, 5mL manganese chloride and 18.75mL 80% 
(w/v) glycerol. The solution was adjusted to pH 5.8 and the volume corrected to lOOmL in 
H2O. The solution was filter sterilised and stored at 4°C.
Buffer 2 (for preparation of competent bacteria)
40mL of this solution was prepared containing; 4mL lOOmM MOPS pH 6.5, 3mL IM 
calcium chloride, 0.4mL IM rubidium chloride, 7.5mL 80%(w/v) glycerol. The pH was 
corrected to 6.5 and the volume adjusted to 40mL using H2O. The solution was filter 
sterilised and stored at 4°C until use.
2.3 Molecular Biology Protocols
2.3.1 LB agar plates
LB was prepared as detailed previously. 15g/L of bacto-agar was added to the LB and 
autoclaved. On removal from the autoclave, the bottle was gently inverted to distribute the
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agar throughout the solution. The mix was cooled to 50°C prior to addition of an antibiotic. 
The final concentration of antibiotic used were; ampiciliin -  lOOpg/mL or Zeocin -  
50pg/mL. The medium was mixed gently and approximately 25 mL poured into lOcm  ^
petri dishes. The plates were left to set at room temperature before being stored at 4°C. 
Unused plates were disposed of three weeks following preparation.
2.3.2 Preparation of competent bacteria
Competent bacteria are cells that have been treated to enable them to accept plasmids 
following transformation. A scraping of DH5a cells was taken from lab stocks, streaked 
out onto a minimal agar plate and incubated at 37°C overnight. A single colony was 
selected, innoculated into a 5mL culture of L-Broth and grown in a shaking incubator for 
16 hours. This culture was then sub-cultured into lOOmL L-Broth and grown in a shaking 
incubator at 37°C until the optical density at 550nm was 0.48 -  approximately 90 minutes 
of incubation. The culture was then chilled on ice for 5 minutes before being centrifuged at 
1811 X g for 10 minutes at 4°C. All traces of L-Broth were removed and then the pellet 
was resuspended in 20mL of Buffer 1 (as detailed above) by gently pipetting up and down. 
The suspension was incubated on ice for 5 minutes prior to being centrifuged as before. 
The pellet was resuspended in 2 mL of buffer 2 (as detailed above) by pipetting and the 
suspension incubated on ice for 15 minutes. The cells were then divided into 220pL 
aliquots and stored at -80°C until required.
2.3.3 Transformation
An aliquot of competent bacteria was thawed on ice and 50gL of cells per transformation
60
reaction aliquoted into a sterile tube. Between 1 and lOng of DNA was then added to the 
cells and incubated on ice for 15 minutes. The cells were then subjected to a heat shock at 
42°C for 90 seconds and then returned to ice for 2 minutes. 450pL of L-Broth was added to 
the cells and the mix incubated for 45 minutes at 37°C in a shaking incubator. 200pL of 
the mix was plated onto an LB plate containing the appropriate antibiotic and incubated 
inverted for 12-16 hours at 37°C.
2.3.4 Preparation of plasmid DNA
2.3.4.1 Mini-preps
Mini-prep cDNA was purified from bacterial cultures using the Promega SV minipreps kit. 
5mL of bacterial culture was centrifuged at 16.1 x g for 10 minutes and the supernatant 
removed. The pellet was resusupended in 250pL of cell resuspension buffer (50mM Tris- 
HCl pH 7.5, lOmM EDTA, lOOpg/mL Rnase A) immediately followed by 250pL of lysis 
buffer (0.2 NaOH, 1% SDS). lOpL of alkaline phosphatase was added to each sample and 
incubated for 5 minutes. 350pL of neutralising buffer was then added (4.09M guanidine 
hydrochloride, 0.76M potassium acetate, 2.12M glacial acetic acid, pH 4.2) to precipitate 
the bacterial chromosomal DNA. This was centrifuged for 10 minutes at 16.1 x g and the 
supernatant applied to a DNA purification column. The column was centrifuged briefly to 
bind the DNA and the column washed twice in wash buffer (60mM potassium acetate, 
lOmM Tris-HCl pH 7.4, 60% ethanol). DNA was eluted by adding lOOpL of sterile water.
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23.4.2 Maxi-preps
The Qiagen QIAfilter kit was used to produce larger scale DNA samples. As detailed 
previously, 5mL of bacterial culture was grown up overnight and this culture used to 
inoculate a lOOmL LB culture. This was incubated for 16-18 hours at 3TC in a shaking 
incubator. Bacteria were pelleted by centrifugation for 30 minutes at 3220 x g at 4°C. The 
pellet was then resuspended in lOmL of chilled buffer PI (50mM Tris-HCl pH8.0, lOmM 
EDTA, lOOpg/mL Rnase A) by vortexing and the cells lysed by adding lOmL of buffer P2 
(200mM NaOH, 1% SDS) and incubating for 10 minutes at room temperature. lOmL of 
buffer P3 (3.0M potassium acetate pH 5.5) was added to neutralise the reaction and the 
solution immediately applied to a QIAfilter cartridge. This was left for 10 minutes at room 
temperature to incubate. During this time a QIAGEN tip 500 was equilibrated by adding 
lOmL of buffer QBT (750mM NaCl, 50mM MOPS pH 7.0, 15% isopropanol). The 
plunger was then inserted into the cartridge and the lysate filtered into the equilibrated tip. 
The column was washed with 60mL of buffer QC (l.OM NaCl, 50mM MOPS pH 7.0, 15% 
isopropanol). The DNA was eluted by adding 15mL of buffer QF (1.25M NaCl, 50mM 
Tris-HCl pH 8.5, 15% isopropanol). The DNA was precipitated by the addition of 10.5mL 
isopropanol and the mixture centrifuged at 27216 x g for 30 minutes in a cooled centrifuge. 
The pellet was washed in 5ml of room temperature 70% ethanol and again centrifuged for 
15 minutes at 27216 x g. The supernatent was carefully removed and the pellet allowed to 
air dry prior to being re-suspended in ImL of sterile water.
2.3.5 DNA quantification
Quantification of DNA samples prepared was performed by examining the absorbance of a
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1:200 dilution of the sample at 260nm. An A260 value of 1 unit was taken to correspond to 
50jrg /mL of double stranded DNA.
2.3.6 Digestion of DNA with restriction endonucleases
Restriction digests of DNA were perfoimed in order to prepare for sub-cloning of PCR 
fragments or to ensure the successful ligation of a construct. Digests were prepared in a 
final volume of 20pL using Promega enzymes as directed for each individual enzyme. 
Reactions were incubated at 37°C for 2 hours before being examined using DNA gel 
electrophoresis.
2.3.7 DNA gel electrophoresis
Digested DNA samples were examined using gel electrophoresis to ensure correct ligation 
of a construct. This method was also used to isolate plasmid vector. Samples were mixed 
with 2X loading buffer. A 1% (w/v) agarose gel was prepared by mixing agarose with IX 
TAE buffer and heating until the agarose had melted. 2.5mg/mL ethidium bromide was 
added to the gel and then poured into horizontal gel tanks. The gel was left to set and then 
IX TAE buffer added. The sample was then loaded onto the gel and ran at 75mA until the 
samples were well resolved. The DNA fragments were visualised using ultraviolet light. 
The size of the fragments was assessed by comparison with a 1Kb DNA ladder.
2.3.8 DNA purifrcation from agarose gels
DNA was pmified from the gel by excising the band of interest and using the QiaQuick gel
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extraction kit in accordance with manufacturers instructions. Briefly, the DNA-gel 
fragment was dissolved in buffer QG by heating at 50°C. One gel volume of isopropanol 
was added to the mix and the solution transfeiTed to a QiaQuick column. The DNA was 
bound to the column by centrifugation. The sample was washed using buffer PE 
supplemented with ethanol and then eluted from the column using sterile water.
2.3.9 DNA ligations
Constructs were generated by ligating digested PCR fragments into plasmid vector using 
T4 DNA ligase. For each construct a ratio of 1:3 and 1:6 vector:PCR product was used in a 
volume of 20pL. IpL of T4 ligase was used with 2pL of ligase buffer and the reaction 
incubated at 4°C for at least 16 hours. The ligation reactions were transfoimed as detailed 
in section 2.3.3.
2.3.10 Polymerase Chain Reaction
PCR reactions were established in a volume of 50pL containing lOng of template DNA, 
0.2mM dNTPs (dATP, dCTP, dGTP, dTTP), 25pmol of sense and anti-sense 
oligonucleotide primers, Ix Pfu polymerase buffer and 1 unit of Pfu polymerase enzyme. 
Reactions were carried out on an Eppendorf gradient Thermocycler. PCR cycles used 
were;
Dénaturation Annealing Extension Cycles
95°C, 1 min 50-60°C, 1 min 72T, 2 min 30
95°C, 1 min 50-60T, 1 min 72®C, 2 min 1
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2.4 Generation of CXCRl constructs
Wild type human CXCRl obtained from AstraZeneca was used as a PCR template for all 
CXCRl constructs.
2.4.1 N-terminal tagged constructs
Flag-CXCRl
Primers encoding the Flag epitope sequence were used to generate N-terminally tagged 
Flag-CXCRl and introduce a stop codon;
Sense 5’-
AKAhG AATICGCCACCATGGACTACAAGGACGACGATGATAAGTCAkATATlA 
CAGATCCAC -  3’
Anti-sense 5’ -  AAAAGAATTCTCAGAGGTTGGAAGAGACATTGAC -  3’.
The region encoding the Flag epitope tag is shown in bold italics. The EcoRI site is 
underlined and the amplified fragment digested and ligated into pcDNA3.
c-Myc-CXCRl
Primers encoding the c-MYC epitope sequence were used to generate N-teiminally tagged 
c-Myc-CXCRl and introduce a stop codon;
Sense 5’ -
AAAAQAKÏJCGQCACCATGGAACAAAAACTTATTTCTGAAGAAGATCTGTCAKA. 
TATTACAGATCCAC -  3’
Anti-sense 5’ - AAAAGAATTCTCAGAGGTTGGAAGAGACATTGAC-3\
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The region encoding the c-Myc epitope is shown in bold italics. The EcoRi site is 
underlined and the amplified fragment digested and ligated into pcDNA3.
HA-CXCRl
Primers encoding the HA epitope sequence were used to generate N-terminally tagged HA- 
CXCRl and introduce a stop codon;
Sense5’ -
AAAAGGTkCCGCCA.CCKïGTATCCCTACGACGTCCCCGATTATGCGTCAAKTAi: 
TACAGATCCAC -  3'
Anti-sense 5’ - AAAAGAATTCTCAGAGGTTGGAAGAGACATTGAC -  3’.
The region encoding the HA epitope tag is shown in bold italics. The Kpnl site present in 
the sense primer and the E'coRI site present in the anti-sense primer are underlined and the 
amplified fragment digested and ligated into pcDNA3.
HA-CXCRl-ER
Primers encoding the HA epitope sequence were used to introduce an N-terminally tagged 
HA sequence and remove the stop codon;
Sense 5’ -
AAAAGGTACCGCCACCATGTATCCCTACGACGTCCCCGATTATGCGTCAAATAi: 
TACAGATCCAC -  3’
Anti-sense 5’ -  AAAAGAATTCGAGTTGGAAGAGACATTGAC-3\
The region encoding the HA epitope tag is shown in bold italics. The Kpnl site present in 
the sense primer and the EJcoRI site present in the anti-sense primer are underlined and the 
amplified fragment digested and ligated into pcDNA3.
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Primers encoding the ER sequence (KHILFRRRRRGFRQ) were aimealed;
Sense 5’ -
AATTCAAGCATATCCTCTTTCGAAGGAGGAGAAGGGGCTTCAGGCAATGAT-
3%
Anti-sense 5 ’
CTAGATCATTGCCTGAAGCCCCTTCTCCTCCTTCGAAAGAGGATATGCTTG -  3’. 
The EcoRI present in the sense primer and the site present in the anti-sense primer are 
underlined and the fragment digested and ligated downstream of the HA-CXCRl fragment 
in frame in pcDNA3.
2.4.2 C-terminal tagged constructs
CXCRIGFP^
Primers were designed to amplify the CXCRl receptor and remove the stop codon;
Sense 5' -  AAAAGAATTCGCCACCATGTCAAATATTACAGATCCAC-3%
Anti-sense 5’ -  AAAAGGTACCGAGGTTGGAAGAGACATTGAC-3\ The EcoRI and 
Kpnl sites present in the sense and anti-sense primers respectively are shown underlined. 
The amplified fragment was digested and ligated into pGFP^-N2 in frame with GFP .^
CXCRlRluc
Primers were designed to amplify CXCRl and remove the stop codon;
Sense 5’ -  AAAA AAGCTTGCCACCATGTCAAATATTACAGATCCAC-3% 
Anti-sense 5’ -  AAAACTCGAGGTTGGAAGAGACATTGAC -  3 \ The Nmdîll and 
Khol sites present in the sense and anti-sense primers respectively are shown underlined. 
The amplified fragment was digested and ligated into pcDNA3 upstream and in frame with
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Renilla Luciferase ligated between and A&aL
CXCRIYFP
Primers were designed to amplify CXCRl and remove the stop codon;
Sense 5’ - AAAA AAGCTTGCCACCATGTCAAATATTACAGATCCAC -  3% Anti­
sense 5’ -  AAAAGCGGCCGCGAGGTTGGAAGAGACATTGAC -  3’. The Hindlll and 
Notl sites encoded in the sense and anti-sense primers are underlined. The amplified 
fragment was digested and ligated into pcDNA3.1 (+) upstream and in frame with eYFP 
ligated between Notl and Xhol.
CXCRICFP
Primers were designed to amplify CXCRl and remove the stop codon;
Sense 5’ -  AAAA AAGCTTGCCACCATGTCAAATATTACAGATCCAC -  3% Anti­
sense 5’ -  AAAAGGTACCGAGGTTGGAAGAGACATTGAC -  3’. The Hindlll and 
Kpnl sites encoded in the sense and anti-sense primers are underlined. The amplified 
fragment was digested and ligated into pcDNAS upstream and in frame with eCFP ligated 
between Hindlll and ATioI.
2.5 Generation of CXCR2 constructs
Wild type human CXCR2 obtained from AstraZeneca was used as a PCR template for all 
CXCR2 constructs.
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2.5.1 N-terminal tagged constructs 
Flag-CXCR2
Primers encoding the Flag epitope sequence were used to generate N-terminally tagged 
Flag-CXCR2 and introduce a stop codon;
Sense 5’-
AAAAGAÈEnCGCCACQKÏQGACTACAAGGACGACGATGATAAGGAAGATTlTA 
ACATGGAG - 3%
Anti-sense 5' -AAAAGAATTCGAGAGTGGAAGTGTGCCC - 3%
The region encoding the Flag epitope tag is shown in bold italics. The EcoRl site present in 
both sense and anti-sense primers is underlined and the amplified fragment was digested 
and ligated into pcDNA3.
c-Myc-CXCR2
Primers encoding the c-Myc epitope sequence were used to generate N-terminally tagged 
c-Myc-CXCR2 and introduce a stop codon;
Sense 5’ -
AAAAGAATTCGCCACCATQGAACAAAAACTTATTTCTGAAGAAGATCTGGAAGA 
TTTTAACATGGAG - 3%
Anti-sense 5’ - AAAAGAATTCGAGAGTGGAAGTGTGCCC - 3’.
The region encoding the c-Myc epitope tag is shown in bold italics. The EcoRl site is 
underlined and the amplified fragment was digested and ligated into pcDNA3.
VSV-CXCR2
Primers encoding the VSV epitope sequence were used to generate N-terminally tagged
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VSV-CXCR2 and introduce a stop codon;
Sense 5’ -
AAAAGGTACCQQCACCATGTACACCGACATCGAAATGAACCGCCTTGGTAAGG 
AAGATTTTAACATGGAG- 3%
anti-sense 5’ - AAAAGAATTCGAGAGTGGAAGTGTGCCC - 3 \
The region encoding the VSV epitope tag is shown in bold italics. The Kpnl and EcoRl 
sites present in the sense and anti-sense primers respectively are underlined and the 
amplified fragment was digested and ligated into pcDNA3.
2.5.2 C-terminal tagged constructs
CXCR2GFP^
Primes were designed to amplify CXCR2 and remove the stop codon;
Sense 5’ -  AAAAGAATTCGCCACCATGGAAGATTTTAACATGGAC -  3% antisense 
5’ -  AAAAGGTACCGAGAGTAGTGGAAGTGTGCCC -  3’.
The jEcoRI and Kpnl present in the sense and anti-sense primers respectively are 
underlined. The amplified fragment was digested and ligated into pGFP^-N2 in frame with
g fp I
CXCR2R1UC
Primers were designed to amplify CXCR2 and remove the stop codon;
Sense 5’ -  AAAAAAGCTTGCCACCATGGAAGATTTTAACATGGAG -  3%
Anti-sense 5’ -  AAAACTCGAGGAGCGTCGTGGAAGTGTG -  3’. The Hindlll and 
Xhol sites present in the sense and anti-sense primers respectively are shown underlined. 
The amplified fragment was digested and ligated into pcDNAS upstream and in frame with
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Renilla Luciferase ligated between ATioI m àX bal.
CXCR2YFP
Primers were designed to amplify CXCR2 and remove the stop codon;
Sense 5’ - AAAAAAGCTTGCCACCATGGAAGATTTTAACATGGAG-3% Anti-sense 
5’ -  AAAAGCGGCCGCAGAGTAGTGGAAGTGTGCCC -  3 \ The Hindlll 
and Notl sites encoded in the sense and anti-sense primers are underlined. The amplified 
fragment was digested and ligated into pcDNA3.1 (+) upstream and in frame with eYFP 
ligated between Notl and Xhol.
CXCR2CFP
Primers were designed to amplify CXCR2 and remove the stop codon;
Sense 5’ -  AAAAAAGCTTGCCACCATGGAAGATTTTAACATGGAG-3%
Anti-sense 5' -  AAAAGGTACCGAGAGTAGTGGAAGTGTGCCC -  3’.
The Hindlll and Kpnl sites encoded in the sense and anti-sense primers are underlined. The 
amplified fragment was digested and ligated into pcDNA3 upstream and in frame with 
eCFP ligated between Hindlll and Xhol.
2.6 Routine cell culture
2.6.1 Cell maintenance
Human embryonic kidney cells (HEK293T) were used in this study. The cells were grown 
in 75cm^ flasks in Dulbecco’s modified Eagle’s medium containing 10% newborn calf 
serum and 2mM 1-Glutamine (DMEM/NBCS). The cells were maintained in a humidified 
incubator of 95% air / 5% CO2 at 37°C.
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2.6.2 Cell subculture
Once confluent, cells were sub-cultured by the addition of sterile 0.25% Trypsin-EDTA 
solution. The medium was removed from the flask and 2mL of trypsin solution added. The 
flask was gently rotated to cover the monolayer and replaced in the incubator for 3 
minutes. Once the cells had detached, 3mL of fresh medium was added to the flask and the 
cells resuspended by gently pipetting. The cells were then sub-cultured into either 75cm  ^
flasks to maintain the cell line or lOcm  ^dishes for transfection.
2.6.3 Transient transfection
Transfection of HEK293T cells was performed when the cells had reached 60-70% 
confluency. Plasmid DNA was transfected using Lipofectamine in accordance with the 
manufacturers instructions. Plasmid DNA was diluted to O.lpg/pL and the volume 
corresponding to the amount of DNA to be transfected was transferred to a 15mL tissue 
culture tube. A volume of Optimem was added in order to bring the volume in the tube to 
600pL. A mix of Lipofectamine'*''  ^ and Optimem^ *^  was prepared in the ratio of 20pL 
Lipofectamine and 580pL Optimem for each sample and 600pL of the mix added gently to 
the DNA mix and incubated for 30 minutes. During this time the cells were washed with 
Optimem. Following the incubation period, 4.8mL of Optimem was added to the sample 
tubes and the mix transferred onto the cells. The cells were returned to the incubator for 4- 
5 hours before removing the transfection mix and replacing with DMEM/NBCS media. 
The media was changed 24 hours later and the cells harvested approximately 48 hours
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post-transfection. A similar protocol was used for transfection in a six-well plate however 
the ratio of Lipofectamine to Optimem was 1:29.
2.6.4 Cell harvesting
Transfected cells were harvested 48 houi's post-transfection. The media was removed and 
the cells washed 3 times in 1 X PBS. Cells were scraped off the flask/dish in 5mL of 1 X 
PBS using a cell scraper and transferred to a 15mL centriâige tube. The flask/dish was 
washed again in 5mL 1 X PBS to remove any additional cells, before centrifuging the 
harvested cells for 5 minutes, 1000 x g at 4°C. The PBS was removed and the cell pellet 
frozen at -80”C until required.
2.7 Biochemical assays and other methods of analysis
2.7.1 Cell membrane preparation
Cell pellets from transfected cells were thawed and resuspended in ImL of TE buffer. The 
cells were homogenised using 40 strokes of a glass on Teflon homogeniser. The cells were 
centrifuged at 1000 x g for 10 minutes in order to separate any unbroken cells and nuclei at 
4°C. The supernatent fraction was removed and passed through a 25 gauge needle 10 times 
before being transfeiTed to ultra-centrifuge tubes and subjected to centrifugation at 218000 
X g for 30 minutes using a Beckman Optima TLX Ultracentrifuge (Palo Alto, CA). The 
supernatent was discarded and the pellet resuspended in 200pL of TE buffer using a 25 
gauge needle, passing through 10 times to ensure an even suspension. The protein 
concentration was assessed using a BSA assay and membranes diluted to Ipg/pL and
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stored at -80°C until required.
2.7.2 BCA protein quantification
Protein amount in membrane preparations was assessed using a BCA assay. This assay 
utilises bincinhoninic acid (BCA) and copper sulphate solutions in which proteins reduce 
the Cu(II) ions to Cu(I) ions in correlation with protein amount initiating a colom' change 
caused by BCA binding reduced Cu(I). This coloured solution has an absorption maximum 
of 562nm, allowing quantitation of the protein amount. A standard curve was established 
using standard BSA solutions allowing the concentrations of unknown samples to be 
established. Solutions used consisted of; reagent A -  1% (w/v) BCA, 2% (w/c) NaiCOs, 
0.16%(w/v) sodium tartrate, 0.4% NaOH, 0.95% NaHCOs, pH 11.25 and reagent B -  4% 
CUSO4. 1 part reagent B was mixed with 49 parts reagent A and 200pL of this solution 
added to lOpL of protein standard or unknown sample in a 96 well ELISA plate. The assay 
was incubated at 37°C for 25 minutes before reading the absorbance.
2.7.3 Competition radioligand binding
Reaction mixtures were established in a volume of lOOpL containing 5pg of protein, 50pM 
IL-8 , and a range of competing ‘cold’ ligand concentrations. Samples were incubated 
for 90 minutes at room temperature prior to vacuum filtration through GF/C filters. Data 
were analysed using GraphPad Prism, plotted as % specific radioligand binding against 
‘cold’ ligand concentration and an EC50 value determined via non-linear regression using a 
one-site competition analysis. The equilibrium dissociation constant for the binding of the
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competing ‘cold’ drug (K i) was calculated using the Cheng-Prusoff equation (Cheng and 
Prusoff, 1973) using the homologous competition binding without ligand depletion 
equation. Results for three independent experiments were analysed using one way 
ANOVA statistical analysis and Dunnets post test comparing results obtained for wild type 
receptor to results from modified constructs.
Ligand depletion can occur in experiments where a large proportion of the radioligand is 
bound to the receptors. This results in differing concentrations of free ligand existing 
between assay tubes despite adding the same amount of radiolabelled ligand. When 
performing a competition assay, high concentrations of the cold competing drug can 
compete with the labelled ligand for receptor binding and thus can increase the free 
concentration of the labelled ligand. Non-specific binding values can also be affected by 
ligand depletion as non-specific binding is directly proportional to the free concentration of 
labelled ligand and therefore can vary tube to tube. Ligand depletion was observed in these 
experiments as described in chapter three.
2.7.4 cAMP determination
Second messenger activation was assessed using the HitHunter™ cAMP XS assay kit. 
This assay utilises enzyme fragment complementation technology (ETC) whereby E. coli 
P-galactosidase is split into two fragments -  a large fragment termed enzyme acceptor and 
a small protein fragment termed enzyme donor. These fragments are inactive when present 
individually but when combined they rapidly recombine to fonu an active enzyme. cAMP 
produced from the cells competes for antibody binding against cAMP conjugated to the
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enzyme donor protein fragment. Any unbound ED-cAMP can complement EA forming an 
active enzyme detected by luminescence. Transfected cells were harvested and the cell 
pellet resuspended in IxPBS containing 0.5mM IBMX. A volume corresponding to 20000 
cells/well was added to a white-walled 96-well plate (PerkinElmer) and the assay 
performed in accordance with manufacturers instructions. cAMP was generated using 
lOpM forskolin and agonist applied to the cells acted on adenylyl cyclase to inhibit cAMP. 
Luminescence was measured using a Mithras LB 940 (Berthold Technology, Bad Wildbad, 
Germany).
2.7.5 Co-immunoprecipitation
Cells were harvested 24 hours following transfection and resuspended in 2.5mL of IX 
RIPA buffer supplemented with lOmM NaF, 5mM EDTA pH 8, lOmM NaH2P0 4 , 5% 
ethylene glycol and a Complete EDTA-free protease inhibitor tablet. The cell pellet was 
resuspended using a pipette and placed on a rotating wheel at 4°C for 1 hour. The samples 
were then centrifuged for 10 minutes at 20817 x g at 4°C and the supernatant transferred to 
a fresh tube containing 200pL of IX RIPA and 50pL of Protein G to pre-dear the samples. 
This was incubated at 4°C on a rotating wheel for 1 hour. The samples were then subjected 
to centrifugation at 20817 x g at 4°C for 1 min and the supernatant transferred to a fresh 
tube and the protein concentration determined. The protein concentration was equalised to 
Ipg/pL using 1 X RIPA and 600pL of each sample was incubated overnight with 40pl 
Protein G, 5pg M2 anti-Flag antibody at 4°C on a rotating wheel. 100pi of the equalised 
supernatant was reseiwed in order to investigate protein expression in the cell lysates.
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Approximately 16 horns following incubation, the samples were centrifuged at 20817 x g 
for 1 min at 4°C and the Protein G beads washed in IxRIPA buffer. This was repeated a 
further twice before adding 40pl Laemmli buffer and the samples heated to 85°C for 4 
minutes to elute the protein. Both immunoprecipitated samples and cell lysates were then 
subjected to SDS-PAGE gel electrophoresis.
2.7.6 SDS-PAGE and western blotting
Protein samples were resolved using SDS-PAGE. Precast Novex Bis-tris gels were used at 
4-12% acrylamide concentration. Nupage MOPS SDS buffer was used for electrophoresis 
using the XCell Surelock mini-cell gel tank apparatus. The gels were run at 200V for 
approximately 45 minutes. The proteins were transferred onto nitrocellulose membrane 
using the XCell II blot module apparatus. The membrane and components of the transfer 
apparatus were soaked in transfer buffer (0.2M glycine, 25mM Tris and 20% methanol) 
before initiating transfer. Proteins were transferred at 30V for approximately 1 hour. 
Efficient transfer was investigated by staining with Ponceau stain (0.1% (w/v) Ponceau S, 
3% (w/v) trichloroacetic acid). In order to block non-specific binding sites, membranes 
were incubated in 5% (w/v) low fat milk, 0.1% Tween 20/PBS (v/v) solution at room 
temperature on a rotating shaker for two hours. The membrane was incubated with primary 
antibody overnight in 5% (w/v) low fat milk, 0.1% Tween 20/PBS (v/v) solution at 4°C. 
Approximately 16 hours later the membrane was washed 3 times in 0.1% Tween 20/PBS 
for five minutes each wash. The secondary antibody which was horseradish peroxidase 
linked was incubated again in 5% (w/v) low fat milk, 0.1% Tween 20/PBS (v/v) solution 
and incubated for 20 minutes at room temperature. Again the membrane was washed 3 
times in 0.1% Tween 20/PBS for five minutes each wash prior to application of ECL
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solution and developing of the blot. The membranes were exposed to blue Kodak film and 
developed using a Xomat machine. For co-immunoprecipitation reactions the blot was 
stripped and re-probed using different antibodies. The membrane was washed using ReBlot 
Plus solution diluted 1:10 in H2O for 15 minutes and then again incubated with 5% (w/v) 
low fat milk, 0.1% Tween 20/PBS (v/v) solution to block non-specific sites.
The antibody dilutions for western blot analysis were;
Primary Antibody Dilution Factor Secondary Antibody
A nti-c-M yc 1:1000 Anti-rabbit
Anti-Flag M2 1:2000 Anti-m ouse
The dilution factor for secondary antibody in each case was 1:10000.
2.7.7 BRET^
2,1.1 A Single point BRET^
Cells were washed twice in IX PBS supplemented with Ig/L glucose and resuspended in a 
final volume of ImL. 160p,L of cells were dispensed into a white-walled 96 well plate and 
either 20pL of agonist added or PBS/glucose. If agonist was tested then the plate was 
incubated for 30 minutes at 37°C. DeepBlueC substrate was diluted 1:20 in PBS/glucose 
and the mix kept protected from light until required. 20pL of substrate was added to each 
well resulting in final concentration of lOpM and BRET^ measured using a Mithras LB940 
(Berthold Technology, Bad Wildbad, Germany). Readings were taken using a 410nm 
(band pass 80nm) filter corresponding to light emission resulting from luciferase catalysing 
the substrate to coelenteramide. Energy transfer emitted by GFP^ was detected using a 
515nm (band pass 30nm) filter and a ratiometric reading obtained corresponding to the
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ratio of light intensity (515nm) to light intensity (410nm).
2.1.1,2 Saturation BRET^
In saturation experiments cells were transfected with a constant amount of Renilla 
Luciferase-linked (Rluc) construct and a varying amount of acceptor GFP  ^construct. These 
cells were harvested and cell membranes prepared and diluted to 0.5pg/pL. BRET^ was 
assessed as previously described for intact cells. Luminescence and fluorescence 
measurements were also obtained. 50pL of cell membranes were dispensed into white- 
walled 96-well plates (PerkinElmer) for luminescence measurements and black-walled 
386-plates (Costar, Cambridge, MA) for fluorescence measurement. For luminescence 
measurement h-Coelenterazine (Prolume) was added to the cell membranes yielding a final 
concentration of 5pM and the plate incubated at room temperature for 30 minutes prior to 
reading at 410nm using the Mithras LB 940 (Berthold Technology, Bad Wildbad, 
Germany). GFP  ^ fluorescence was assessed using the Victor^ 1420 Multilabel counter 
(PerkinElmer). BRET^ readings were corrected for energy transfer resulting from 
‘bleedthrough’ of the Rluc construct expressed alone but detected in the GFP  ^ channel. 
Fluorescence readings were corrected for the endogenous fluorescence detected for non­
transfected HEK293T cell membranes. Fluorescence readings were expressed over 
luminescence and ratios plotted forming a saturation curve. GraphPad Prism 4 was
used to analyse data using a one site binding hyperbola equation yielding BRETmax and 
BRET50 values.
2.7.8 Time resolved FRET
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lOcm  ^ dishes of HEK293T cells were transfected to express CXCRl or CXCR2 N- 
terminally modified to express either c-Myc or Flag epitope tags. 48 hours following 
transfection the cells were harvested and the samples containing singly tagged receptors 
mixed to form a negative control. The cell pellets were resuspended in 200pL of ice-cold 
PBS. Antibodies directed against the epitope tags c-Myc and Flag conjugated to the donor 
and acceptor moieties Europium^^ (Eu^ "^ ) and Allophycocyanin (APC) were used to 
investigate energy transfer. The anti-c-Myc Eu^ "^  and anti-Flag APC antibodies were 
diluted in 50% NCBS: 50% PBS to a final concentration of 5nM and 15nM respectively. A 
dilution containing the anti-c-Myc Eu^  ^ antibody only was also prepared. 250pL of the 
antibody dilutions were aliquoted into fresh tubes and 50pL of resuspended cells 
transferred resulting in antibody incubations containing only anti-c-Myc Eu^ "^  or containing 
both anti-c-Myc Eu^  ^ and anti-Flag APC antibodies for each sample. The samples were 
mixed and then incubated on a rotating wheel at room temperature for 2 hours. The 
samples were covered in aluminium foil to minimise exposme of the fluorophores to light. 
The samples were then centrifuged at 1000 x g for 1 minute and the antibody mix removed 
from the cell pellet. The pellet was then washed 2X in ice-cold PBS and re suspended in 
250pL of PBS. To investigate agonist effect on energy transfer, 90pL of cells were 
transferred to a fresh tube and ineubated with the chosen concentration of agonist at 37°C. 
In order to measure the energy transfer, 40 pL of each sample was dispensed in triplicate 
into a black 384-well plate. Blank wells containing PBS were also included.
Tr-FRET was determined using a Victor^ plate reader (PackardBioseience). Excitation was 
at 340nm and emission filters generated data representing donor (615nm) and acceptor 
(665mn) emission. Normalized FRET was calculated using the equation;
80
Normalized FRET = ((A665-BLK)/D6i5)-C
Where Aô65 is the fluorescent emission from the acceptor, Deis is the fluorescent emission 
from the donor and BLK represents the background reading at 665nm from the wells 
containing PBS. C represents the crosstalk between the donor and acceptor windows for 
the samples incubated with only anti-c-Myc Eu^  ^and is equal to Aees-BLK/Deis.
2.7.9 Fluorescent microscopy and FRET imaging in living cells
HEK293T cells were grown on coverslips treated with poly-D-lysine and transiently 
transfected with the different CFP/YFP fusion proteins. Coverslip fi-agments were placed 
into a microscope chamber containing physiological saline solution (130mM NaCl, 5mM 
KCl, ImM CaCb, ImM MgCB, 20mM HEPES, lOmM D-glucose pH 7.4). Cells were 
visualised using a Nikon Eclipse TE2000-E fluorescence inverted microscope and images 
obtained individually for YFP, CFP and FRET filter channels using a Optoscan 
monochromator (Cairn Research, Faversham, Kent, UK) and a dichroic mirror 86002v2bs 
(Chroma Inc., Rockingham, VT). The filter sets used were; eYFP (excitation -  500/5nm; 
emission -  535/30mn), CFP (excitation 430/12nm; emission -  470/3Onm) and FRET 
(excitation -  430/12nm; emission -  535/30nm). The illumination time was 250ms and 
birming modes 2x2. MetaMorph imaging software (Universal Imaging Corp., West 
Chester, PA) was used to quantify the FRET images using the sensitised FRET method. 
Corrected FRET was calculated using a pixel-by-pixel methodology using the equation 
FRETc = FRET -  (coefficient B x CFP) -  (coefficient A x eYFP), where CFP, eYFP and 
FRET values correspond to background corrected images obtained through the CFP, eYFP 
and FRET channels. B and A correspond to the values obtained for the CFP (donor) and
81
eYFP (acceptor) bleedthrough coefficients respectively, calculated using cells singly 
transfected with either the CFP or YFP protein alone. The values obtained for the 
eonstructs used in this study were;
Construct Coefficient
CXCRIYFP 0.197
CXCRl CFP 0.662
CXCR2YFP 0.197
CXCR2CFP 0.660
aiA-YFP 0.196
DOP-YFP 0.197
MOP-YFP 0.192
KOP-YFP 0.200
To correct the FRET levels for the varying amounts of donor (CFP) and acceptor (eYFP), 
normalised FRET was calculated using the equation FRETn = FRETc / CFP x eYFP, 
where FRETc, CFP and eYFP are equal to the fluorescence values measured for each
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individual cell. FRET was measuied for 6-8 cells per experiment with at least three 
individual transfections performed.
2.7.10 Confocal laser scanning microscopy
Cells were imaged using a laser scanning confocal microscope (Zeiss LSM 5 Pascal, Carl 
Zeiss Inc., Thornwood, NY) equipped with a 63x oil-immersion Plan Fluor Apochromat 
objective lens with a numerical aperture of 1.4. A pinhole of 20 and an electronic zoom of 
1 or 2.5 was used. The excitation laser line for GFP and YFP was 488nm argon laser and 
detected with a 505-530 band pass filter. Alexa 594 label was detected using a 543nm 
helium/neon laser and detected with a 560 long-pass filter. The images were manipulated 
using MetaMorph imaging software (Version 6.1.3; Universal Imaging Corporation, 
Downing, PA, USA).
2.7.10.1 Fixed cell samples
Cells grown on coverslips were transiently transfected and washed three times with ice- 
cold PBS. Cells were fixed for 10 minutes at room temperature using 4% 
paraformaldehyde in PBS/5% sucrose solution. The cells were washed a further three times 
in ice-cold PBS prior to being fixed onto microscope slides with 40% glycerol in PBS.
2.7.10.2 Immunostaining protocol
Immunostaining was performed to monitor agonist-induced internalisation of the N- 
terminal tagged receptors. Cells were grown onto coverslips and transiently transfected. 24
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hours following transfection the medium was removed and the cells incubated with 20mM 
HEPES/DMEM containing the appropriate dilution of primary antibody and incubated for 
40 minutes at 37°C in 5% CO2. Either IL-8 or GRO-a was added to yield a final 
concentration of 50nM and the coverslip incubated for a further 30 minutes at 37°C, 5% 
CO2. Coverslips were washed three times with PBS and cells fixed by incubating with 4% 
paraformaldehyde in PBS/5% sucrose solution for 10 minutes at room temperatme. The 
coverslips were washed a further three times in PBS prior to being permeabilised in 0.15% 
Triton-X~ 100/3% low fat milk/PBS for 10 minutes at room temperature. The coverslips 
were incubated with a secondary antibody conjugated to an Alexa 488/594 fluorophore at a 
dilution of 1:400 corresponding to an antibody concentration of 5pg/pL. This incubation 
was performed with the coverslip cell side down onto Nescofilm, for 1 hour at room 
temperature. Following incubation the cells were washed twice in 0.15% Triton-X-100/3% 
low fat milk/PBS and three times in PBS. Coverslips were then mounted onto microseope 
slides with 40% glycerol in PBS. The antibody dilutions were;
Primary antibody Dilution factor Secondary antibody
Anti-c-Myc 1:100 Anti-rabbit
Anti-Flag 1:100 Anti-mouse
Anti-HA 1:2000 Anti-mouse
Anti-VSV 1:2500 Anti-mouse
Anti-CXCRl 1:50 Anti-mouse
Anti-CXCR2 1:50 Anti-mouse
2.7.11 Retention motif - cell surface expression quantification
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Cells were co-transfected with Flag-CXCRl and either HA-CXCRl or HA-CXCRl-ER. 
48 hours following transfection cells were harvested and counted using a haemocytometer. 
Approximately 500 000 cells were dispensed into a tube and the cells incubated with 15nM 
anti-Flag APC antibody and IpM Hoescht stain diluted in 50% NBCS: 50% PBS on a 
rotating wheel for 1 hour. The cells were centrifuged at 1000 x g for 1 minute and the cell 
pellet washed three times in PBS. The cells were resuspended in 200|ul of PBS and 40pl 
replicates dispensed into a black 384-well plate. The fluorescence was quantified using the 
Victor^ 1420 Multilabel counter (PerkinElmer). A control in which fluorescence was 
measured in non-transfected HEK293T cells was performed and this value removed from 
the other readings, representing endogenous fluorescence of the cell type. As a further 
control to ensure equal cell number between wells, fluorescence coiTesponding to Hoechst 
staining was measured and the data analysed to ensure cell number did not exceed 20% 
variance from well to well.
85
Chapter 3
3.1 Introduction
In order to utilise cuiTently available biochemical and biophysical techniques to investigate 
oligomerisation, several different N- and C- terminal epitope tags and fluorescent moieties 
were introduced to both CXCRl and CXCR2.
N-terminal epitope tags have been used extensively as tools in biochemical techniques 
facilitating protein detection without the requirement for receptor specific antibodies. 
Antibodies to several commonly used epitope tags are commercially available and can be 
used for several puiposes including subcellular protein localisation and investigation of 
protein-protein interactions. In this study N-terminal Flag, c-Myc, HA and VSV epitope 
tags have been used, located immediately following the initiating methionine. Several of 
the currently available epitope tags are derived from naturally occurring proteins. The c- 
Myc epitope is a decapeptide sequence originating from the human c-Myc protein, found 
in several types of human tumouis (Evan et al, 1985). The HA epitope originates from the 
hemagglutinin protein which is a surface glycoprotein required for the infectivity of the 
human influenza virus (Wilson et al, 1984). The VSV epitope tag is an eleven amino acid 
sequence derived from the vesicular stomatitis virus (VSV) glycoprotein, a virally encoded 
transmembrane protein (Kreis, 1986). The FLAG tag is a synthetic octapeptide (Chubet 
and Brizzard, 1996).
Green fluorescent protein (GFP) from the jellyfish Aequoria Victoria is a commonly used 
reporter molecule permitting the detection of protein expression and localisation within the
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cell. GFP is an auto-fluorescent protein of 27kDa that can be located either at the N- or C- 
terminal of the protein of interest. Several variants of GFP have been isolated, possessing 
distinct spectral properties that have been exploited in several resonance energy transfer 
techniques. GFP  ^ is a modified form of GFP that has been developed by PerkinElmer to 
maximally absorb the energy released by the oxidation of the substrate DeepBlueC by 
Renilla luciferase. Oxidation of DeepBlueC to coelenteramide results in the release of 
energy at 395nm overlapping with the excitation spectrum of GFP^ and resulting in 
subsequent emission at 51 Onm. Enhanced cyan fluorescent protein (eCFP) is a variant of 
GFP that has a blue-green colom' (Cubitt et ah, 1999; Heim and Tsien, 1996). It has an 
excitation maximum of 43Onm and emission maximum 470nm. A red-shifted GFP variant 
termed enhanced yellow fluorescent protein (eYFP) presents an excitation maximum of 
500nm and emission maximum of 535nm. The spectral properties of eCFP and eYFP have 
been extensively exploited as donor and acceptor moieties in FRET to demonstrate 
molecular interactions between proteins that are both cytoplasmic and membrane 
associated, including GPCRs (Tsien, 1998; Zhou et al., 2003; Dinger et al., 2003). In this 
study the fluorescent moieties have been ligated onto the C-terminal of the chemokine 
receptors.
As mentioned previously CXCRl and CXCR2 bind their ligands via an interaction with 
the N-terminal region and the third extracellular loop of the receptor (LaRosa et al., 1992). 
Therefore it is important to ensure that the addition of N-terminal epitope tags onto these 
receptors does not interfere with the ability of the receptors to bind ligand or the affinity of 
this ligand interaction. The addition of C-terminal fluorescent moieties could potentially 
interfere with the ability of the receptor to interact with the endocytic machinery 
responsible for receptor sequestration and/or influence G protein coupling.
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The aim in this chapter was to investigate the ability of modified CXCRl and CXCR2 
constructs to display native pharmacology. The ability of the modified receptors to 
undergo ligand-induced internalisation was investigated using confocal microscopy. 
Radioligand binding was used to ensuie the ligand binding profiles of the modified 
receptors did not differ substantially from wild type receptor. The ability of the modified 
receptors to couple to G proteins was assessed by investigating the reduction in forskolin- 
stimulated cAMP release, caused by interaction of CXCRl and CXCR2 with Gai. (Wu et 
ah, 1993; Damaj etaL, 1996).
3.2 Internalisation of modified forms of CXCRl and CXCR2
The ability of the modified constructs to undergo agonist-induced internalisation was 
assessed by immunocytochemical staining of N-terminal epitope tags and direct 
visualisation of C-terminal fluorescent moieties using confocal microscopy. HEK293T 
cells were transiently transfected with receptor cDNA 24 hours prior to visualisation. 
Figure 3.1 demonstrates that, prior to exposure to agonist, the modified CXCRl constructs 
were clearly plasma membrane delineated. CXCRl GFP ,^ CXCRIYFP and CXCRl CFP 
presented some cytoplasmic retention, however the majority of these receptors were 
expressed at the plasma membrane. Following treatment with 50nM IL-8 for 30 minutes at 
37°C, a clear punctate pattern conesponding to a loss of cell surface expression could be 
observed for all constructs and representing the internalisation of the receptor into 
intracellular vesicles. Although no quantitative measurements were made, the 
internalisation of the CXCRl-fluorescent protein conjugates appeared to be to a lesser 
extent than observed for N-terminally epitope tagged receptor forms, with a proportion of
the receptor conjugate remaining membrane delineated following agonist exposure.
Figure 3.2 illustrates the expression patterns of the modified CXCR2 constructs. In the 
absence of ligand the receptors were clearly plasma membrane localised. Some 
cytoplasmic retention of the CXCR2GFP^, CXCR2CFP and CXCR2YFP constructs was 
observed, but as with CXCRlGFP^ the majority of the receptors were plasma membrane 
delineated. Following incubation with 50nM IL-8 for 30 minutes at 37°C, the modified 
forms of CXCR2 underwent pronounced internalisation demonstrated by the absence of 
membrane localisation and the appearance of punctate intracellular vesicles. As was 
observed for CXCRl, the extent of internalisation of CXCR2-fluorescent protein 
conjugates was less than observed for N-terminally tagged CXCR2 constructs.
Figure 3.3 demonstrates the plasma membrane expression pattern of CXCRl Rluc and 
CXCR2Rluc. These receptors were visualised using antibodies specific to the N-terminal 
regions of CXCRl and CXCR2 that prevent ligand binding. Therefore the ability of these 
receptors to undergo agonist-induced internalisation could not be investigated.
3.3 [^ ^®I]IL-8 binding to modified forms of CXCRl and CXCR2
Competition binding experiments were performed for both native and modified forms of 
CXCRl and CXCR2 in order to ensure that the affinities of the recombinant receptors for 
IL-8 were similar to that of native receptor protein. HEK293T cells were transiently 
transfected with the various forms of CXCRl cDNA and harvested 48 hours following 
transfection. Membranes were prepared and used in competition binding experiments, the 
results of which are detailed in Figure 3.4. Unlabelled IL-8 fully competed for the binding
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of native CXCRl with radiolabelled IL-8 yielding a pKi value of 9.5±0.3 M. Homologous 
competition binding experiments performed investigating IL-8 affinity on modified forms 
of CXCRl yielded pKi values that did not vary significantly from that obtained for native 
receptor when assessed by one way ANOVA statistical analysis using a Dumiett post test. 
Ligand depletion was calculated in each reaction. Unfortunately due to the experimental 
conditions used ligand depletion at levels greater than 10% was observed as detailed in 
Table 3,1. However, when the data was examined using the GraphPad prism calculation 
homologous competition binding with ligand depletion. This demonstrated that the pKi 
values recorded did not vary significantly.
Similar experiments were performed on the modified forms of CXCR2. The native 
CXCR2 yielded a pK, value of 9.51±0.1 M (Figure 3.5). Statistical analysis performed on 
pKi values obtained for the modified foims of CXCR2 did not highlight any significant 
variation in affinity from native CXCR2.
3.4 IL-8 induced inhibition of forskolin-stimulated cAMP release
Cyclic AMP levels were measured using the DiscoverX cAMP XS kit optimised to detect 
Gai activation. Cells transiently expressing CXCRl were incubated with lOpM forskolin 
and various levels of IL-8 for 30 minutes and cAMP levels recorded (Figure 3.6). The 
concentration of IL-8 causing maximal inhibition of forskolin-induced cAMP production 
was used to investigate the ability of modified forms of CXCRl to interact with G protein. 
Figure 3.7 demonstrates the ability of lOOnM IL-8 to inhibit forskolin stimulated cAMP 
release. In all cases IL-8 caused some degree of inhibition of forskolin-induced cAMP 
generation. However, statistical analysis demonstrates that the inhibition of forskolin-
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stimulated cAMP was not significantly different from basal values for every receptor 
examined.
Similar studies were performed for the modified forms of CXCR2. A dose-inhibition curve 
demonstrating agonist-induced inhibition of forskolin-induced cAMP generation for 
CXCR2 is shown in Figure 3.6. Again the concentration of IL-8 yielding maximal 
inhibition was selected and used to investigate G protein activation for the modified forms 
of CXCR2 (Figure 3.8). This demonstrated the ability of all the modified forms of CXCR2 
to attenuate forskolin-induced cAMP production via interaction with G protein. As 
obseiwed for CXCRl, variations in degree of inhibition were observed and statistical tests 
demonstrated that the extent of foskolin-induced cAMP generation was not significantly 
different from basal for some receptors examined.
3.5 Discussion
The introduction of N- and C-terminal modifications to GPCRs could potentially have a 
large impact on receptor function. The N-terminal region of chemokine receptors has been 
implicated in ligand binding and the modification of this region could influence the 
capacity of receptors to bind ligand and also affect ligand binding affinity. The C-terminal 
region of GPCRs is frequently very important in regulating receptor endocytosis and G 
protein interactions. A single amino acid change in the C-terminal tail of the Pz-adrenergic 
receptor was sufficient to disrupt interactions with intracellular endocytic machinery and 
influence GPCR trafficking (Hall et al, 1998; Cao et al, 1999). The addition of large 
fluorescent moieties to the C-teiminal region of GPCRs could therefore potentially 
abrogate receptor endocytosis.
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Experiments performed in this study investigating the internalisation properties of the 
modified foims of CXCRl and CXCR2 demonstrated the ability of the N-and C-terminally 
modified receptors to undergo pronounced receptor endocytosis following exposure to 
agonist. However, CXCRl and CXCR2 receptors conjugated to fluorescent C-terminal 
moieties demonstrated comparatively higher levels of residual plasma membrane 
expression following exposure to agonist than obsei*ved for N-terminally modified 
constructs. Studies performed using GPCR-GFP fusions have reported markedly slower 
internalisation kinetics in comparison to the wild type GPCR (McLean and Milligan, 
2000). This could explain the residual membrane delineation observed for GPCR- 
fluorescent protein conjugates in this study.
Some intracellular retention of C-tenninally modified forms of CXCRl and CXCR2 was 
observed. Retention of CXCRl GFP within the Golgi apparatus was also obseiwed by 
Barlic et al, (1999) following transient expression in unstimulated HEK293 cells. This 
could be due to the long half-life of the fluorescent moieties used in this study resulting in 
the maintained presence of the receptor-fluorescent protein fusion within intracellular 
vesicles (McLean and Milligan, 2000). However, it is possible that expression levels 
resulting from the transient expression of these constructs are at a level sufficient to 
overwhelm N-terminal glycosylation capacity, resulting in intracellular accumulation of 
the receptor.
The cell line used in these experiments was the HEK293T line, Barlic et al., (1999) 
investigated internalisation of CXCRl GFP in HEK293 cells. However, receptor 
internalisation could not be obseiwed in this cell type unless the receptor was co­
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transfected with p-arrestins and GRK2, thought to be due to low endogenous levels of 
these proteins in the cell line used. Internalisation of the modified forms of CXCRl and 
CXCR2 in this study did not require the enhanced expression of these proteins, suggesting 
endogenous expression levels in the HEK293T cell line used were sufficient for receptor 
endocytosis. A study performed by Rose et al, (2004) compared the internalisation 
kinetics of CXCRl and CXCR2 expressed both endogenously in neutrophils and in 
transiently transfected HEK293 cells. The authors reported very similar internalisation 
kinetics between neutrophils and HEK293 cells, however the recycling properties of the 
two receptors differed markedly between the two cell types.
The addition of N- or C- terminal tags to CXCRl and CXCR2 did not alter the affinity of 
these receptors for IL-8 which yielded pKj values of ~ 9.5 M for all constructs tested. The 
Kj values determined in this study are consistent with binding affinities determined in both 
cell types that endogenously express these receptors and recombinant systems (Lee et al, 
1992; Loetscher et al, 1994; Ahuja and Murphy, 1996; Wu et al, 1996). Binding affinities 
of receptor-fluorescent protein conjugates have been investigated for several receptors with 
no change in reported ligand binding characteristics. This has been demonstrated for 
several GPCRs including the CCKi receptor (Tarasova et al, 1997), Pi adrenoceptor 
(Mercier et al, 2002), p% adrenoceptor (Kallal et al, 1998; Barak et al, 1997), TRHl 
receptor (Drmota et al, 1998), ai a and am adrenoceptors (Hirasawa et al, 1997; Stanasila 
et al, 2002), vasopressin V2 receptor (Schulein et al, 1998), melatonin MT; and MT2 
receptors (Ayoub et al, 2002) and the GnRH receptor (Nelson et al, 1999). The addition 
of N-terminal epitope tags has also been shown to have no effect on ligand binding. This 
has been shown for several GPCRs including the a%A adrenoceptor (Stanasila et al, 2002) 
and vasopressin Via and V2 vasopressin receptors (Teii'illon et al, 2004).
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In this study, G protein coupling was assessed by investigating agonist-induced reduction 
in forskolin-stimulated cAMP levels. The assay system used in these experiments was the 
DiscoverX cAMP assay. This kit did not yield a high signalinoise ratio and several 
difficulties were experienced while trying to optimise the assay. This is reflected in the 
data shown in figures 3.7 and 3.8 in which the reduction in forskolin-induced cAMP 
production has been found not to differ significantly from basal values. Therefore, 
conclusions concerning the ability of the modified receptors to activate G proteins cannot 
be drawn based on this data. The ability of GPCR-fluorescent protein conjugates to interact 
with G proteins has been investigated for several other GPCRs including the CCKi 
receptor (Tarasova et ah, 1997), Pi adrenoceptor (Mercier et al., 2002), P2 adrenoceptor 
(Kallal et al., 1998, Mercier 2002), TRHi receptor (Drmota et al,, 1998), am adrenoceptor 
(Awaji et al., 1998), NK% receptor (McConalogue et al., 1999), aiA adrenoceptor (Stanasila 
et al., 2003), adenosine A2A (Canals et al., 2004) and melatonin MTi and MT2 receptors 
(Ayoub et al., 2002). The addition of epitope tags has also been shown to have no effect on 
interaction with G proteins for several receptors including the aiA adrenoceptor (Stanasila 
et al,, 2003).
Several studies have investigated the pharmacology of N and C terminal tagged CXCRl 
and CXCR2. Barlic et al., (1999) demonstrated the ability of CXCRl GFP to induce the 
release of granule contents following agonist exposure, demonstrating that the modified 
receptors retain the ability to transduce signals. An extensive study perfoimed by Hall et 
al., (1999) investigated the pharmacology of N-terminal epitope tagged forms of CXCRl 
and CXCR2. Several points within the GPCR signalling cascade were investigated 
including ligand binding affinities, [^ S^] GTPyS activation and inhibition of adenylyl
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cyclase and demonstrated native receptor pharmacology for the modified receptors.
The data shown in this chapter confirm that the N- and C- terminal modifications 
introduced to CXCRl and CXCR2 did not substantially influence the ability of these 
receptors to bind ligand, undergo receptor endocytosis or couple to G protein.
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Figure 3.1 Agonist-induced internalisation of N- and C- terminally modified forms 
of CXCRl
HEK293T cells were transiently transfected with (a) CXCRl GFP  ^ (b) c-Myc CXCRl (c) 
Flag-CXCRl (d) HA-CXCRl (e) CXCRl-eYFP or (f) CXCRl CFP. Cells were challenged 
with vehicle or 50nM IL-8 for 30 minutes prior to fixing. Cells were imaged using 
confocal microscopy by either immunostaining (b, c, d) or direct visualisation (a, e, f). 
Results shown are of a single experiment, representative of three experiments performed.
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Figure 3.2 Agonist-induced internalisation of N- and C- terminally modified forms 
ofCXCR2
HEK293T cells were transiently transfected with (a) CXCR2GFP^ (b) c-Myc-CXCR2 (c) 
Flag-CXCR2 (d) CXCR2YFP (e) VSV-CXCR2 or (f) CXCR2CFP. Cells were challenged 
with vehicle or 50nM IL-8 for 30 minutes prior to fixing. Cells were imaged using 
confocal microscopy by either immunostaining (b, c, e) or direct visualisation (a, d, f). 
Results shown are of a single experiment, representative of three experiments performed.
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Figure 3.3 Cell membrane expression of CXCRlRluc and CXCRZRluc
HEK293T cells were transiently transfected with CXCRlRluc (a) or CXCR2Rluc (b). 
Cells were fixed and immunostained with antibodies specific for either CXCRl or CXCR2 
respectively and visualised using confocal microscopy. Results shown are of a single 
experiment, representative of three experiments performed.
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Figure 3.3
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Figure 3.4 N- and C- terminal modifications of CXCRl have little effect on ligand
affinity
Homologous competition binding experiments were performed using IL-8 and IL-8 
for each modified form of CXCRl. Data represent mean ± S.E.M of three individual 
experiments. Statistical analysis of results was performed using a one-way ANOVA and 
Dumiett post test (GraphPad Prism) comparing results from modified receptors to that 
determined for unmodified CXCRl, demonstrating no significant variance.
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CXCRl GFP^ 9.4±0.2
CXCRl RLuc 9.1 ±0.1
Flag-CXCRl 9.610.1
c-Myc-CXCRl 9.710.1
CXCRl YFP 9.410.1
CXCRICFP 9.510.2
HA-CXCRl 9.210.1
Figure 3.5 N- and C- terminal modifications of CXCR2 have little effect on ligand
affinity
Homologous competition binding experiments were performed using IL-8 and IL-8 
for each modified form of CXCR2. Data represent mean ± S.E.M of three individual 
experiments. Statistical analysis of results was performed using a one-way ANOVA and 
Dunnett post test (GraphPad Prism) comparing results from modified receptors to that 
determined for unmodified CXCR2 demonstrating no significant variance.
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CXCR2 9.51 ±0.1
CXCR2GFP^ 9.5±0.1
CXCR2RLUC 9.510.1
Flag-CXCR2 9.510.1
c-Myc-CXCR2 9.510.5
CXCR2YFP 9.710.1
CXCR2CFP 9.410.1
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Table 3.1 Ligand depletion figures.
The percentage of maximum bound radioligand over actual radioligand added to 
theassay was calculated for each construct testes. Results are shown as mean ± S.E.M.
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Table 3.1
Construct Ligand Depletion (%)
CXCRl 20.0+1.6
CXCRIGFP^ 25.1+5.1
CXCRlRLuc 8.411.7
Flag-CXCRl 12.310.6
c-Myc-CXCRl 21.917.9
CXCRl YFP 18.911.7
CXCRICFP 19.013.3
HA-CXCRl 26.910.6
CXCR2 4.310.8
CXCR2GFP^ 4.910.9
CXCR2RLUC 9.611.7
Flag-CXCR2 5.110.9
c-Myc-CXCR2 6.313.8
CXCR2YFP 13.312.6
CXCR2CFP 21.013.3
VSV-CXCR2 6.610.6
Figure 3.6 Agonist-induced inhibition of forskolin-induced cAMP generation by 
CXCRl and CXCR2
Appropriately transfected cells were stimulated with lOpM forskolin and exposed to 
varying concentrations of IL-8 for 30 minutes prior to cAMP detection using the 
DiscoverX XS cAMP kit. Data were analysed using the sigmoidal dose-response equation 
in GraphPad Prism 4. Data shown are representative of three individual experiments.
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Figure 3,7 Agonist-induced inhibition of forskolin-induced cAMP generation by 
modified forms of CXCRl
Appropriately transfected cells were stimulated with lOpM forskolin and exposed to 
lOOnM IL-8 for 30 minutes prior to cAMP detection using the DiscoverX XS cAMP kit. 
Data are expressed as percentage of forskolin induced cAMP release. Open bars represent 
cAMP released following exposure to forskolin (basal) while closed bars represent cAMP 
levels detected following exposure to IL-8 (+ agonist). Data shown are mean ± S.E.M and 
representative of three individual experiments.
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Figure 3.8 Agonist-induced inhibition of forskolin-induced cAMP generation by 
modified forms of CXCR2
Appropriately transfected cells were stimulated with lOpM forskolin and exposed to 
1 OOnM IL-8 for 30 minutes prior to cAMP detection using the DiscoverX XS cAMP kit. 
Data are expressed as percentage of forskolin induced cAMP release. Open bars represent 
cAMP released following exposure to forskolin (basal) while closed bars represent cAMP 
levels detected following exposure to IL-8 (+ agonist). Data shown are mean ± S.E.M and 
representative of three individual experiments.
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Chapter 4
4.1 Introduction
Oligomerisation within the chemokine receptor family was shown to have important 
physiological relevance with the discovery of a natural genetic mutation of CCR5, termed 
ccr5-32A, which conferred resistance to HIV-1 infection. Individuals homozygous for this 
mutation, approximately 1% of the population, were found to be resistant to HIV-1 
infection (Liu et al.  ^ 1996). Individuals heterozygous for this allele, up to 20% in some 
populations, displayed a delayed progression from HIV-1 to AIDS (Dean et a/., 1996; 
Samson et al., 1996; Huang et al., 1996; Michael et al., 1997). The 32 base pair deletion in 
the open reading frame results in a frame shift premature stop codon within the third 
intracellular domain. This results in a truncated protein product that is not transported to 
the cell surface and thus caimot function as a co-receptor facilitating HIV-1 infection 
(Gharagozloo et al., 2005). The delayed progression of infection observed in heterozygous 
individuals has been hypothesized to result from the homo-oligomerisation of ccr5-32A 
with wild type CCR5, resulting in a reduced level of CCR5 expressed at the cell surface 
(Benkirane et al., 1997). However, Venkatesan et ah, (2002) demonstrated that the 
reduction in wild type CCR5 expression is a result of gene dosage rather than receptor 
sequestration. This study demonstrated that a molar excess of ccr5-32A does not 
significantly impair wild type CCR5 cell surface density when transiently transfected in 
HER and Jurkat cells. The resistance to HIV-1 infection of ccr5-32A individuals has also 
been attributed to a gain-of-function effect. Agrawal et al., (2004) found that ccr5-32A 
expression in primary CD4+ cells resulted in down-regulation of surface CXCR4 and wild- 
type CCR5, conferring resistance to HIV-1. CD4+ cells purified fr'om individuals
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homozygous for ccr5-32A also displayed lower levels of CXCR4. These findings have led 
to the hypothesis that ccr5-32A can alter expression of both CCR5 and CXCR4.
A polymorphism also exists for the CCR2 receptor in which valine at position 64 is 
replaced by isoleucine within the first transmembrane region, tenned CCR2V64L This 
mutation was shown to occur at an allelic frequency of 10-25% depending on the ethnic 
group of the population. Individuals possessing this polymorphism have demonstrated a 
delay in progression from HIV-1 to AIDS of 2-4 years (Smith et ah, 1997). Although 
CCR2 has not been shown to act as a co-receptor for HIV-1, it can form hetero-oligomers 
with CCR5 and CXCR4 (Mellado et al., 1999). This is thought to form the basis of the 
delayed HIV-1 to AIDS progression. A recent study performed by Rodriguez-Frade et ah, 
(2004) utilised a monoclonal antibody directed against CCR2 to induce CCR2 hetero­
oligomer formation with CCR5 or CXCR4. The authors showed that hetero-oligomer 
formation prevented HIV-1 entry via these receptors.
CXCRl and CXCR2 have been implicated in the pathology of several disease states 
including chi’onic obstructive pulmonary disease and asthma (Owen, 2001). Interestingly, a 
non-competitive small molecule inhibitor of CXCRl and CXCR2 has been developed to 
treat reperfusion injury occurring following organ transplant. The molecule acts by locking 
CXCRl and CXCR2 in the inactive conformation preventing receptor signaling, 
chemotaxis and the release of inflammatory mediators. The drug named Repertaxin has 
proven to be well tolerated in animal tests and is progressing to phase I clinical trials 
(Casilli et ah, 2005). A recent study performed by Kaneider et ah, (2005) investigated the 
effect of pepducins directed against intracellular loops 1 and 3 of CXCRl and CXCR2. 
The pepducins were found to prevent the IL- 8 response of both receptors. IL-8 is a potent
106
pro-inflammatory mediator in sepsis and the intracellular loop pepducins were shown to 
reverse sepsis when tested in mice. This studies clearly demonstrate the relevance of 
CXCRl and CXCR2 in disease and the importance of further investigating interactions 
between these receptors.
These studies demonstrate the physiological relevance of chemokine receptor 
oligomerisation. The aim of the studies in this chapter was to investigate potential homo- 
and hetero-oligomerisation of CXCRl and CXCR2, Several techniques were utilised 
including co-immunoprecipitation, Tr-FRET, FRET, and BRET. The selectivity of the 
observed oligomer formation was also investigated. The issue of ligand modulation of 
oligomerisation and the site of oligomer formation have been addressed. The 
internalisation properties of the observed hetero-oligomer were also studied.
4.2 Co-immunoprecipitation allows detection of CXCRl and CXCR2 homo- and 
hetero-oligomers
In order to investigate the potential homo-oligomerisation of CXCRl, Flag- and c-Myc N- 
terminally tagged constructs were transiently expressed individually or co-expressed in 
HEK293T cells. Samples were solubilised by resuspending the transfected cells in Ix 
RIPA buffer. As a negative control, a mixed cell sample was included in which cells 
individually expressing the two constructs were mixed prior to immunoprécipitation. The 
cell lysates were incubated with anti-Flag antibody and SDS-PAGE perfoimed on the 
precipitated material. Proteins were transfeiTed onto nitrocellulose membrane and a 
western blot performed using anti-c-Myc antibody. Figure 4.1 demonstrates the co- 
immunoprecipitation of Flag and c-Myc-CXCRl. A band representing the 38kDa c-Myc-
107
CXCRl receptor can be obseived in the co-expressed sample, consistent with an 
interaction between Flag-CXCRl and c-Myc-CXCRl. A band can also be obseived at a 
slightly higher molecular mass, which may represent a differentially glycosylated form of 
the receptor. In addition a band at ~80kDa con’esponding to the mobility of a homodimer 
was also detected, suggesting that a proportion of the immunoprecipitated oligomer was 
not completely separated by the SDS-PAGE conditions used. There was no 
immunoreactivity observed when each of the constructs was expressed alone. A control in 
which cell lysates corresponding to Flag-CXCRl and c-Myc-CXCRl were mixed prior to 
immunoprécipitation also did not demonstrate any immunoreactivity, confirming that 
expression of both epitope tagged receptors within the same cell is required to allow 
interaction. Cell lysates from the experiment were subjected to western blot analysis using 
anti-Flag and anti-c-Myc antibodies to ensure the coiTect expression of the constructs.
This protocol was repeated for Flag- and c-Myc-CXCR2 (Figure 4.2). Again this resulted 
in an immunoprecipitated band consistent with a complex of Flag-CXCR2/c-Myc-CXCR2. 
As observed for CXCRl, there was no immunoreactivity observed when each construct 
was expressed individually or cell lysates were mixed prior to immrmoprecipitation. 
Consistent with results obseived for CXCRl, immunoreactivity coiTCSponding to a dimer 
was obseived demonstrating that a fraction of the oligomeric complex was resistant to 
SDS-PAGE conditions.
The existence of a CXCRl/CXCR2 heterodimer was investigated. Flag-CXCRl and c- 
Myc-CXCR2 were transiently transfected individually or co-expressed, and hetero­
oligomerisation investigated as before. Figure 4.3 illustrates immunoreactivity representing 
c-Myc-CXCR2 immunoprecipitated using anti-Flag antibody when the two receptors have
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been co-expressed, consistent with a Flag-CXCRl/c-Myc-CXCR2 complex. No 
immunoreactivity was observed in the other samples examined. The hetero-oligomer was 
also detected when Flag-CXCR2 and c-Myc-CXCRl were co-expressed (data not shown).
4.3 Oligomerisation of CXCRl and CXCR2 demonstrated nsing FRET in living cells
In order to investigate the existence of CXCRl and CXCR2 oligomers in living cells, 
single cell FRET was used. Receptors were modified by attachment of either CFP or YFP 
at the C-terminus and expression of the modified receptors in HEK293T cells could be 
visualised (Figure 4.4). Expression of CXCRICFP alone resulted in a FRETnqrm signal of 
0.014+0.002. Upon co-expression of CXCRICFP with CXCRl fused to the acceptor 
protein YFP, a significant FRETnorm signal of 0.93+0.06 was detected. Previous studies 
performed within the Milligan group have demonstrated that co-expression of the isolated 
forms of CFP and YFP did not result in significant levels of FRET (Carrillo et ah, 2004). 
Donor and acceptor fluorescence levels were monitored to ensuie relatively equal amounts, 
illustrated by the images shown.
The aiA-adrenoceptor was used to investigate the specificity of the FRET signal detected. 
The expression pattern of this receptor does not overlap with either CXCRl or CXCR2 and 
would not be predicted to interact with either receptor. Therefore the interactions between 
CXCRl/CXCR2 and aiA-adrenoceptor were investigated as an indication of the selectivity 
of the obseived oligomer formation. Co-expression of CXCRICFP with a  i A-adrenoceptor- 
YFP yielded a FRET signal of 0.15+0.03 demonstrating low energy transfer between the 
two receptors (Figure 4.4). Donor and acceptor expression levels were observed at similar 
levels to that observed for the CXCRl CFP/CXCRl YFP pairing, ensuring that the low
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energy transfer observed was not an artefact of low acceptor expression.
CXCR2 homo-oligomerisation was also investigated using this method (Figure 4.5). 
Expression of CXCR2CFP alone resulted in a low energy transfer of 0.014+0.001. Co­
expression of CXCR2CFP and CXCR2YFP resulted in strong energy transfer yielding a 
FRETnorm of 0.89+0.08. As with CXCRl, the interaction between CXCR2CFP and (%iA- 
adrenoceptor-YFP was investigated and resulted in a FRETnorm of 0.16±0.07 
demonstrating low levels of energy transfer between the two receptors. Images shown 
demonstrate the equal levels of donor and acceptor fluorescence when investigating 
oligomerisation.
Hetero-oligomerisation between CXCRl and CXCR2 was investigated using this 
technique (Figure 4.6). CXCRICFP and CXCR2YFP were co-expressed yielding a 
FRETnorm of 0.82+0.04. The opposite pairing, CXCR2CFP and CXCRl YFP resulted in 
energy transfer of 0.83+0.05. Results are shown in comparison to ‘bleedthrough’ resulting 
from expression of donor receptor alone into the FRET channel.
4.4 Oligomerisation of CXCRl and CXCR2 investigated using BRET
A modified version of bioluminescence resonance energy transfer termed bRET^ was 
utilised to demonstrate the oligomerisation of CXCRl and CXCR2 (Figure 4.7). The level 
of energy transfer was assessed by transfecting an equal amount of cDNA coiTesponding to 
receptor fused to Renilla luciferase and GFP  ^ and measuring BRET^ in intact cells. The 
level of apparent BRET^ obseived in cells transfected with the Renilla luciferase construct
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alone was recorded to determine any ‘bleed through’ from the luciferase emission 
spectrum into the GFP  ^emission spectrum. Apparent BRET^ resulting from expression of 
CXCRlRluc alone yielded a ratio of 0.15+0.003 while the co-expression of CXCRl fused 
to both donor and acceptor moieties resulted in a BRET^ ratio of 0.4±0.01 demonstrating 
energy transfer. Consistent with FRET experiments, energy transfer between CXCRl and 
the a  1 A-adrenoceptor was studied to investigate the specificity of oligomer formation. Co­
expression of a  1 A-adrenoceptor-GFP^ with CXCRlRluc yielded a BRET^ ratio of 
0.18+0.003. This was repeated using CXCR2Rluc and GFP .^ Expression of CXCR2Rluc 
alone resulted in an apparent BRET^ ratio of 0.2±0.001 while the co-expression of 
CXCR2Rluc and CXCR2GFP^ yielded robust energy transfer of 0.5±0.005. Co-expression 
of CXCR2Rluc with aiA-GFP^ resulted in a BRET^ ratio of 0.2±0.002.
Hetero-oligomerisation of CXCRl and CXCR2 was assessed using this technique. Co­
expression of CXCRlRluc and CXCR2GFP^ resulted in a BRET^ ratio of 0.5+0.004 while 
the reciprocal pairing yielded a ratio of 0.4+0.014.
In order to investigate the propensity of the homo- and hetero- oligomers to form, BRET^ 
was used in saturation BRET^ experiments. Satui'ation BRET^ experiments have been 
extensively used to investigate the propensity of a given receptor pair to form oligomers 
(Mercier et al, 2002). BRET^ is measured in cells expressing varying ratios of acceptor 
protein to donor protein allowing BRET^ saturation cuives to be constructed. BRETmax is 
a function of the total number of oligomers formed and the distance and orientation of the 
donor and acceptor moieties to each other. BRET50 values are an indication of the relative
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affinity of the receptor conjugated to the receptor for the receptor conjugated to the donor 
moiety (Mercier et al., 2002). BRET^ ratios were corrected for apparent BRET^ resulting 
from ‘bleedthrough’ of CXCRlRluc and CXCR2Rluc into the GFP  ^channel. This permits 
the determination of the relative affinity of the interaction at half-maximal signal. 
Following expression of a constant amount of CXCRl-RLuc with an increasing amount of 
CXCRl-GFP^, addition of DeepBlueC resulted in BRET^ signals which generated a 
hyperbolic cmve approaching an asymptote with increasing [acceptor/donor] ratios 
yielding a BRETmax of 0.28+0.05 and a BRET50 of 3.6+0.4 (Figure 4.8). Potential energy 
transfer between CXCRlRluc and GFP  ^vector was used as a control in this experiment 
and was found to yield very low levels of energy transfer demonstrating that the energy 
transfer observed did not result from a mutual affinity between donor and acceptor 
moieties. Analysis of the data demonstrated that it generated a linear relationship with 
increasing [A]/[D] ratios, inferring that the interaction was non-specific.
The characteristics of the CXCR2 oligomer were then investigated. Again a constant 
amount of CXCR2Rluc was co-expressed with increasing amounts of CXCR2GFP^ and 
the BRET^ signal recorded following the addition of the substrate. As can be observed in 
Figure 4.8 the CXCR2 homo-oligomer pairing yielded a BRETmax of 0.36+0.03 and 
BRET50 of 2.2+0.1 demonstrating that high affinity interactions occur, similar to that 
obseiwed for CXCRl. In order to investigate the specificity of the homo-oligomer 
interaction, the interaction of CXCR2Rluc and aiA-adrenoceptor-GFP^ was investigated. 
BRET^ signals generated by this pairing were analysed using statistical comparison of 
model fitting. This yielded r^  values of 0.95 and 0.90 for linear and non-linear models 
respectively. This indicates that a linear model is the best fit with BRET^ ratios
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proportional to [A]/[D] levels. This suggests that the pair had low affinity for each other. 
Hetero-oligomerisation between CXCRl and CXCR2 was then investigated (Figure 4.8). 
This yielded a BRETmax of 0.42±0.04 and BRET50 of 3.6±0.1.
The ability of ligand to modulate oligomerisation was investigated using BRET^. Intact 
cells transfected with an equal amount of donor and acceptor cDNA were incubated with 
50nM IL-8 for 30 minutes at 37°C before the addition of DeepBlueC substrate. The results 
presented in Figure 4.9 demonstrate that the exposure of ligand did not cause any 
significant alteration in the BRET^ levels detected.
4.5 Oligomerisation of CXCRl and CXCR2 demonstrated using Tr-FRET
Tr-FRET was utilised to investigate if chemokine receptor oligomers exist pre-formed at 
the cell sui’face. Both FRET and BRET can report energy transfer occumng throughout the 
cell therefore it is important to determine if the observed receptor oligomers are present at 
the cell surface. Firstly Flag- and c-Myc-CXCRl and CXCR2 were expressed transiently 
in HEK293T cells. As a control mixed cells expressing the differentially tagged constructs 
individually were also used. In order to investigate the specificity of this energy transfer 
the aiA adrenoceptor was selected as a control. Cells were incubated with anti-c-Myc 
antibody conjugated to Europium (Eu^ )^ that acts as the energy donor and anti-Flag 
antibody conjugated to allophycocyanin (APC) as the energy acceptor. Figure 4.10 
demonstrates the strong energy transfer signal observed for CXCRl homo-oligomers 
yielding a Tr-FRET ratio of 0.062+0.004. Very low energy transfer of -0.001+0.001 for 
CXCRl was observed for mixed cells individually expressing the constructs. When the c-
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Myc-aiA-adrenoceptor construct was co-transfected with Flag-CXCRl, a Tr-FRET ratio 
of 0.026+0.003 was obtained. This was repeated using Flag-aiA-adrenoceptor and c-Myc- 
CXCRl yielding a Tr-FRET ratio of 0.03+0.01. As previously, the mixed cell controls for 
these combinations demonstrated a negligible amount of Tr-FRET.
A slightly stronger energy transfer was observed for the CXCR2 homo-oligomer of 
0.075+0.005 as demonstrated in Figure 4.11. The mixed cell control presented a very low 
energy transfer ratio of 0.001 ±0.001. Again using the c-Myc-aiA-adrenoceptor construct to 
investigate specificity of the interaction, the Flag-CXCR2 and c-Myc-aiA-adrenoceptor 
combination yielded a value of 0.026±0.002. This was repeated using Flag-aiA~ 
adrenoceptor and c-Myc-CXCR2 obtaining 0.04+0.01. The mixed cell controls for these 
pairs again indicated very low levels of energy transfer.
Hetero-oligomerisation was investigated using this technique (Figure 4.12). A robust 
energy transfer was observed for the Flag-CXCRl/c-Myc-CXCR2 hetero-oligomer 
presenting a Tr-FRET ratio of 0.07+0.02. As had been observed previously, the mixed cell 
control yielded very low energy transfer of 0.002+0.002 for this pairing. The alternative 
combination of tagged receptors was tested using c-Myc-CXCRl and Flag-CXCR2. The 
pairing demonstrated similar high levels of Tr-FRET presenting a ratio of 0.06+0.01. The 
mixed cell controls for these combinations yielded negligible Tr-FRET ratios.
As this technique only detects cell surface oligomerisation, it is a useful tool when 
investigating ligand modulation of oligomers. Cells were incubated with lOOnM IL-8 for 
15 minutes. Figure 4.13 clearly demonstrates that agonist had no effect on the levels of Tr- 
FRET observed for the homo-oligomers. This protocol was repeated to investigate ligand
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modulation of the hetero-oligomer with no detectable change in the energy transfer 
observed (Figure 4.13).
4.5 Oligomerisation of CXCRl and CXCR2 investigated using ER retention assay
In order to determine the location of the oligomer formation, an ER retention assay was 
developed. This assay system utilised an approach that had been previously used to 
investigate the formation of channel complexes (Schwappach et ah, 2000). These 
channels are multimeric complexes containing an ER retention sequence that is masked 
upon complex formation (Schwappach et ah, 2000). This study described a trafficking trap 
assay, reasoning that if one subunit in a receptor complex contains an ER retention 
sequence that is not hidden by co-assembly, then any interacting protein will also be 
trapped within the ER. Therefore, if a protein that is normally membrane expressed is 
retained in the ER, it must be interacting with the protein containing the strong retention 
signal. The retention signal used in this study was derived from the C-terminal of the a 2c- 
adrenoceptor that has been shown to contain an ER retention motif (Zerangue et aL, 1999; 
Margeta-Mitrovic, 2002). HA-CXCRl was modified by the addition of 14 amino acids 
encompassing the ER retention sequence onto the C-terminal tail of the receptor, to 
produce the construct termed HA-CXCRl-ER.
In order to investigate the distribution pattern of the wild type receptor, unmodified 
CXCRl was transiently expressed in HEK293T cells and subjected to 
immunocytochemistry using an anti-CXCRl antibody on both intact and permeabilised 
cells. As shown in Figure 4.14 (a), staining of intact and permeabilised cells demonstrated 
that the majority of the receptor was cleai'ly membrane delineated with very little
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intracellular staining. An N-terminally HA-tagged form of the aic-adrenoceptor was 
transiently expressed in HEK293T cells (Figure 4.14 (b)) and immunocytochemistry on 
intact cells using an antibody directed against the HA epitope tag, revealed a small degree 
of surface staining while analysis of permeabilised cells revealed a strong signal 
corresponding to receptors retained in vesicles in the cell. This is consistent with data 
showing that the a 2c-adrenoceptor, when expressed in HEK293 cells, was localised in 
intracellular compartments with little membrane expression observed (Daunt et aL, 1997). 
Examination of HA-CXCRl-ER that contains the retention sequence C-terminally fused 
also demonstrated a similar pattern of intracellular retention as the HA-a2c-adrenoceptor 
upon staining of permeabilised cells. Very little membrane expression of HA-CXCRl-ER 
was observed following examination of intact cells (Figure 4.14 (c)).
The overlapping expression of c-Myc CXCRl and HA-CXCRl-ER was investigated. As 
demonstrated in chapter three, c-Myc-CXCRl is cell surface expressed however upon co­
expression with HA-CXCRl-ER, permeabilisation of cells prior to immunocytochemistry 
reveals an overlapping expression pattern of intracellular receptor staining (Figure 4.15
(a)). This suggests an interaction is occurring between c-Myc-CXCRl and HA-CXCRl- 
ER resulting in the intracellular retention of c-Myc-CXCRl. Similar results were obtained 
for the co-expression of c-Myc-CXCR2 and HA-CXCRl-ER (b).
The ability of the receptor containing the retention sequence to prevent cell surface 
expression of other receptors was assessed (Figure 4.16). Cell surface expression of Flag- 
CXCRl was quantified using whole cell immunostaining following co-transfection with 
either HA-CXCRl or HA-CXCRl-ER. There was a significant reduction in cell surface
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expression of Flag-CXCRl observed upon co-expression with HA-CXCRl-ER. A similar 
reduction in cell surface expression was shown for Flag-CXCR2 upon co-expression with 
HA-CXCRl -ER. In order to investigate the selectivity of the interaction, the cell surface 
expression of Flag-aiA-adrenoceptor was examined upon co-transfection with HA-CXCRl 
or HACXCRl-ER. There was no significant difference in the amount of Flag-aiA- 
adrenoceptor expression at the cell surface when expressed with HA-CXCRl-ER in 
comparison to expression with HA-CXCRl, consistent with a lack of specific interaction 
between CXCRl and aiA-adrenoceptor.
4.6 Do CXCRl and CXCR2 co-internalise?
As detailed in section 1.2.5.1, there have been several reports detailing that GFCR hetero­
oligomers can undergo internalisation in response to an agonist directed against only one 
component of the hetero-oligomer complex. Tr-FRET data demonstrated the existence of 
CXCRl/CXCR2 hetero-oligomers at the cell surface. The ability of the hetero-oligomer 
complex to undergo co-intemalisation was investigated. c-Myc-CXCRl and VSV-CXCR2 
were transiently co-expressed in HEK293T cells grown on coverslips. 
Immunocytochemistry was performed to visualise the receptors in the absence and 
presence of 50nM IL-8, a ligand with high affinity for both CXCRl and CXCR2, and 
lOOiiM GRO-a, which has high affinity for CXCR2 but low affinity for CXCRL Figure 
4.17 demonstrates that in non-stimulated cells both c-Myc-CXCRl (red) and VSV-CXCR2 
(green) were clearly membrane delineated. Upon stimulation with IL-8, both c-Myc- 
CXCRl and VSV-CXCR2 undergo internalisation into punctate vesicles that were found 
to co-localise yielding a yellow colour in the overlay image. Upon stimulation with GRO- 
a, VSV-CXCR2 underwent internalisation into punctuate vesicles however Myc-CXCRl
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remained membrane localised. This suggests that the CXCR1/CXCR2 hetero-oligomer 
does not undergo co-intemalisation with only the CXCR2 homo-oligomers internalising in 
response to GRO-a.
4.7 Discussion
As discussed previously several members of the class A GPCR family have been shown to 
form homo- and hetero-oligomers. In this study the formation of constitutive CXCRl and 
CXCR2 homo-oligomers and CXCRl/CXCR2 hetero-oligomers has been demonstrated 
using several different techniques. These receptor homo- and hetero-oligomers have been 
shown to exist pre-formed at the cell membrane. Investigation into the site of oligomer 
formation demonstrated that the receptors form oligomers during protein synthesis and 
maturation. The selectivity of the oligomer formation was shown by the lack of substantial 
interactions between the aiA-adrenoceptor and CXCRl or CXCR2.
A co-immunoprecipitation approach was used in this study. This is a technique that 
requires cell lysis and solubilisation, a procedme that could result in ai'tefactual results 
being observed due to the highly hydrophobic nature of GPCRs (Salim et ah, 2002). 
However, the inclusion of a mixed cell control in which cells expressing each epitope 
tagged receptor alone were mixed prior to immunoprécipitation served to address this 
caveat. This control was performed in my studies but yielded no immunoreactivity, 
demonstrating that the positive result obseived was not an artefact of the experimental 
protocol. Figures 4.1, 4.2 and 4.3 show that a proportion of the immunoprecipitated 
oligomer was not fully separated by the SDS-PAGE conditions used as immunoreactivity 
corresponding to the predicted molecular mass of both the monomer and dimer of CXCRl
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and CXCR2 was observed. This observation suggests that a fraction of the CXCRl and 
CXCR2 homo- and hetero-oligomers demonstrated in this study exist as oligomers using 
non-covalent interactions. However, it is possible that the levels of homo- and hetero­
oligomers formed in these experiments were very high and therefore the reducing 
conditions employed may have been insufficient to fully reduce all oligomers. A recent 
study investigating oxytocin receptor oligomerisation demonstrated that at low levels of 
receptor expression the formation of SDS-resistant oligomers is favoured while at higher 
levels of receptor expression of 400 fmol/mg and above, the formation of SDS-sensitive 
oligomers are observed (Devost and Zingg, 2004).
The presence of both SDS-sensitive and resistant CXCR2 homo-oligomers has been 
observed previously (Trettel et aL, 2003). This study utilised a co-immunoprecipitation 
approach to demonstrate the existence of constitutive CXCR2 homo-oligomers in HEK293 
cells and rat cerebellar granule neurons. Interestingly the authors did not observe CXCRl 
homo-oligomer foimation or indeed CXCRl/CXCR2 hetero-oligomer formation, both of 
which have been shown in this study using several techniques.
Single cell FRET is a RET technique that allows protein: protein interactions to be 
recorded in living cells. This technique has the advantage of allowing the relative ratios of 
donor and acceptor fluorescent moieties to be defined in order to ensure they are 
comparable. This permits the comparison of FRET signals generated from different GPCR 
combinations by excluding the factor of receptor expression levels influencing energy 
transfer. As can be observed in Figures 4.4, 4.5 and 4.6, constitutive homo- and hetero­
oligomerisation was observed for CXCRl and CXCR2. This positive FRET signal is not a 
result of mutual affinity between the donor and acceptor fluorescent proteins as a study
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performed by Carillo et aL, (2004) demonstrated that no significant amount of FRET was 
detected upon co-expression of isolated forms of CFP and YFP. A low FRET signal was 
observed between CXCRl/2 and aiA-adrenoceptor. The cell images shown demonstrate 
that the relative levels of donor and acceptor fluorescent conjugates in these experiments 
were similar. This suggests that the low FRET levels reported are a reflection of a lack of 
interaction as opposed to an artefact resulting from insufficient acceptor levels to produce a 
FRET signal. In order to confirm energy transfer was occurring between the two receptor- 
fluorophore conjugates, photo-bleaching FRET could be employed. As mentioned 
previously, this technique involves images of donor fluorescence compared before and 
after the prolonged excitation of the acceptor moiety resulting in irreversible 
photochemical destruction. An increase in donor fluorescence following destruction of the 
acceptor protein indicates energy transfer occumng between the donor and acceptor 
protein conjugates.
Saturation BRET is an application of BRET that permits the determination of relative 
affinities of the donor and acceptor receptor constructs for each other. This is achieved by 
exploiting the theory that upon expression of a constant amount of donor and an increasing 
amount of acceptor, energy transfer should increase until all donor molecules are 
interacting with acceptor molecules. This results in a plateau after which increasing 
concentrations of acceptor has no further effect on the energy transfer levels observed 
(Mercier et aL, 2002). Theoretically, specific interactions between donor and increasing 
concentrations of acceptor should result in BRET signals permitting generation of a 
saturation cuive. BRET signals resulting from the random collision of donor and acceptor 
moieties are predicted to result in the formation of a quasi-linear relationship between 
BRET signal and acceptor concentration. Several studies have utilised this approach to
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generate BRET50 values, indicating the selectivity of the oligomer formation (Canals et aL, 
2004; Canals et aL, 2003 Mercier et aL, 2002; Breit et aL, 2004; Ayoub et aL, 2004; 
Temllon et aL, 2003). In this study the relative affinities of the CXCRl and CXCR2 
homo- and hetero-oligomers are very similar suggesting that they have an equal propensity 
to form homo- and hetero-oligomers. As mentioned previously, neutrophils were found to 
express equal amounts of CXCRl and CXCR2, however, monocytes and positive 
lymphocytes express more CXCR2 than CXCRl (Chuntharapai et aL, 1994). This could 
have a potential implication on the theoretical equilibrium that exists between homo- and 
hetero-oligomer formation under physiological conditions. The excess of CXCR2 receptor 
expression in comparison to CXCRl receptor levels found in monocytes and positive 
lymphocytes could lead to preferential formation of hetero-oligomers in these cells.
Values obtained corresponding to BRETmax for CXCR2 homo-oligomers and 
CXCRl/CXCR2 hetero-oligomers were higher than those values observed for CXCRl 
homo-oligomer formation. This is likely to be the result of the orientation of donor and 
acceptor moieties within CXCRl homo-oligomers being less conducive to energy transfer 
than observed for CXCR2 homo-oligomers and CXCRl/CXCR2 hetero-oligomer 
formation. Also the interaction observed between CXCR2Rluc and aiA-adrenoceptor-GFP^ 
yielded BRET signals that increased linearly with increasing amounts of acceptor, 
suggesting that the energy transfer was the result of random interactions. This was also 
observed for CXCRlRluc and GFF^ vector alone albeit with lower BRET values obtained.
RET techniques have been criticised in the past due to the high levels of receptor 
expression commonly used in these experiments. Protein over-expression could potentially 
result in energy transfer occurring as a result of random interactions and not from oligomer
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formation. A study performed by Mercier et aL, (2002) investigated the impact of receptor 
expression levels on energy transfer observed for the Pi-adrenoceptor. BRET was recorded 
from a range of samples expressing receptors at levels ranging from 1.4 to 87.2 pmol/mg. 
For protein expression between 1.4 - 26.3 pmol/mg, the energy transfer that occuiTed 
between donor and acceptor moieties did not increase. However, at receptor densities of 
47.3 pmol/mg and above, the BRET signal increased. This could be due to artefactual 
aggregation caused by the high expression levels used or random interactions between 
donor and acceptor molecules already engaged in dimers. Similar experiments have been 
performed for CCR5, CXCR4 and opioid receptors yielding data indicating that at 
relatively low expression levels, BRET is independent of receptor density (Issafras et aL, 
2002; Babcock et aL, 2003). In this study protein expression levels were not monitored due 
to experimental difficulties in obtaining reliable receptor expression data. Further evidence 
supporting the independence of RET from receptor expression levels was reported by 
Terrillon et aL, (2003). This study fi'actionated transiently transfected cells expressing 
BRET donor and acceptor protein conjugates on the basis of YFP expression. The 
subpopulations of cells were then examined and BRET recorded. It was found that energy 
transfer observed for these fractions did not differ significantly from that obseiwed for the 
whole cell population, supporting the theory that maximal RET levels are independent of 
receptor density.
The results gained from Tr-FRET demonstrated that CXCRl and CXCR2 homo- and 
hetero-oligomers exist at the cell surface. However, the data yielded from these 
experiments when investigating the interaction of CXCRl or CXCR2 with aiA- 
adrenoceptor was suggestive of a degree of oligomerisation occurring between the two 
receptors. This is in disagreement with previous data generated from FRET and BRET
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studies in which the co-expression of CXCR1/CXCR2 and aiA-adrenoceptor donor and 
acceptor conjugates yielded low energy transfer and, most convincingly, BRET saturation 
analysis demonstrated the non-specific nature of these interactions. Both orientations of 
CXCRl/CXCR2 and aiA-adrenoceptor were tested in that Tr-FRET was recorded when 
the a  1 A-adrenoceptor was N-terminally tagged with either c-Myc or Flag epitope tags, 
corresponding to the donor and acceptor antibodies respectively. Figure 4.10 and 4.11 
demonstrate that Tr-FRET levels were increased when the Flag epitope tagged foim of the 
a  1 A-adrenoceptor was used. As mentioned previously energy transfer is an acceptor 
dependent process and it is possible that in these experiments the levels of expression of 
the N-terminally Flag tagged aiA-adrenoceptor acting as an energy acceptor exceeded 
CXCRl and CXCR2 receptor expression levels, resulting in increased energy transfer 
observed. This is suggested by the control experiments detailed in Figure 4.10 (b) and 4.11
(b) demonstrating higher levels of Flag-APC fluorescence corresponding to Flag-aiA- 
adrenoceptor than observed for Flag-CXCRl/2. Receptor expression levels were not 
monitored in this study and it is possible that expression of the ai A-adrenoceptor reached 
high levels that would permit Tr-FRET irrespective of whether an interaction was actually 
occurring.
Tr-FRET utilises antibodies raised to N-terminally expressed epitope tags that are 
conjugated to suitable donor and acceptor moieties. The possibility of antibody binding 
causing receptor aggregation and therefore generating a false positive result has been 
suggested (McVey et aL, 2001). However, although the antibodies used are bivalent, 
antibody-induced receptor clustering would only induce dimer formation between 
receptors expressing the same epitope tag. Tr-FRET reports on energy transfer between 
two differentially epitope tagged receptors, therefore any clustering effect would be
123
predicted to have no influence on the energy transfer reported in this assay. This is 
confiiTued in Figures 4.10, 4.11 and 4.12 in which a control composed of cells individually 
expressing differential epitope tags mixed prior to antibody incubation was included, 
yielding very low levels of energy transfer. If the antibodies were to induce receptor 
aggregation leading to false positive results, then Tr-FRET should have been observed in 
these controls.
Recently several studies have addressed the possibility that energy transfer could be a 
result of receptor aggregation in membrane microdomains yielding an artefactual result 
rather than resulting from oligomer formation. Zacharias et ah, (2002) highlighted that 
energy transfer between closely located receptor molecules can occur even when they are 
not directly interacting when expressed in heterologous expression systems. Localisation 
of receptors within membrane rafts would permit close association of receptors (<10nm), 
facilitating energy transfer. Canals et aL, (2003) utilised methyl-p-cyclodextrin treatment 
in order to demonstrate that the disruption of membrane rafts by this chemical had no 
effect on the BRET signal obseiwed corresponding to adenosine A2A and dopamine D2 
hetero-oligomers. A similar protocol was used to investigate membrane raft contribution to 
adenosine A2A homo-oligomer formation (Canals et aL, 2004). Following methyl-P- 
cyclodextrin treatment, cells were repleted with cholesterol but this also had no effect on 
the BRET signal observed. A dominant negative mutant of dynamin was used to 
investigate the formation of TRH receptor aggregates within clathrin-coated pits (Kroeger 
et aL, 2001). Expression of this mutant had no effect on the levels of BRET recorded. 
Although the possibility of receptor aggregation in membrane microdomains was not 
addressed directly in this study, any RET resulting from artefactual results should have 
been observed between CXCRl/CXCR2 and aiA-adrenoceptor assuming they are directed
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to the same micro-domains. As can be observed in Figures 4.4, 4.5 and 4.8, the levels of 
energy transfer observed were substantially less than obseiwed for either CXCRl/CXCR2 
homo- or hetero-oligomerisation. Also, a recent study performed by Rose et aL, (2004) 
demonstrated that CXCRl and CXCR2 were excluded from Triton-X-100 insoluble lipid 
rafts, both at basal conditions and following chemokine treatment, thus reducing further the 
likelihood of energy transfer resulting from receptor aggregation within these domains.
In this study incubation with IL-8 had no significant effect on energy transfer observed in 
either BRET or Tr-FRET. This is consistent with a study perfoimed by Trettel et aL, 
(2003) in which incubation with ligand had no effect on CXCR2 oligomerisation detected 
using co-immunoprecipitation. Ligand-dependent increases in energy transfer have been 
reported for CXCR4 and CCR5 (Toth et aL, 2004; Hernanz-Falcon et aL, 2004). For 
CXCR4, binding of the CXCR4 antagonist AMD3100 was able to attenuate the ligand- 
induced increase in energy transfer, leading to the hypothesis that chemokine receptors 
exist in an equilibrium of monomers and higher order oligomers that is influenced by 
ligand binding (Toth et aL, 2004). The effects of IL-8 on BRET were assessed using cells 
transfected with a ratio of donor and acceptor yielding energy transfer at a level close to 
BRETmax- It could be possible that the orientation of donor and acceptor moieties at 
BRETmax do not permit any small changes in energy transfer resulting from ligand 
binding to be observed. However, Canals et aL, (2004) investigated BRET signals 
following agonist exposure to adenosine A2A receptor homo-oligomers at donor: acceptor 
ratios corresponding to minimum, half-maximum and maximum BRET signals and 
observed no alteration in energy transfer. Detecting ligand-induced changes in BRET is 
complicated by the fact that the Renilla luciferase substrate DeepBlueC is cell permeable 
and therefore the energy transfer represents donor and acceptor interactions throughout the
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cell. As the ligand was incubated with whole cells, only receptor oligomers that are surface 
expressed will bind ligand and any modulation in BRET signal may not be discernable as 
the signal is representative of energy transfer occurring throughout the cell. As 
demonstrated in chapter 3, the majority of the modified CXCRl and CXCR2 are cell 
surface expressed with only a small proportion observed within the cell. However, it is 
possible that energy transfer could be observed between receptors that have been 
incorrectly folded and retained within the cell and could influence any significant 
modulation of energy transfer observed following ligand binding. In order to address this 
problem associated with BRET, Tr-FRET was used. This technique, when performed in 
whole cells, only reports Tr-FRET occurring at the cell surface therefore eliminating any 
contribution to energy transfer resulting from interactions within the cell. In this study 
incubation with IL-8 had no effect on the Tr-FRET signal observed for CXCRl and 
CXCR2 homo- and hetero-oligomers. For CXCR1/CXCR2 hetero-oligomer formation, 
both orientations of donor and acceptor were tested to exclude the possibility that the 
different receptor-donor/acceptor conjugate pairings conferred a conformational 
arrangement permitting detection of any ligand-induced modulation. The lack of ligand 
modulation of CXCRl and CXCR2 oligomerisation is consistent with several reports 
investigating oligomerisation of several class A GPCRs detailed in section 1.2.4.1.
An ER retention assay was developed in this study to demonstrate that homo­
oligomerisation of CXCRl and hetero-oligomerisation of CXCRl/CXCR2 occurs in the 
ER. As described in section 1.2.4.2 several studies have demonstrated the presence of 
GPCR oligomers in the ER (Overton et aL, 2002; Issafras et aL, 2002; Terrillon et aL, 
2003). The assay developed in this study utilised a form of CXCRl that was C-terminally 
modified to express an ER retention sequence derived from the azc-adrenoceptor. This
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modified form of CXCRl was capable of acting as a dominant negative on wild type 
CXCRl and CXCR2, inhibiting normal cell surface expression. This suggests that CXCRl 
homo-oligomerisation and CXCRl/CXCR2 hetero-oligomerisation occurs in the ER. This 
is consistent with observations made by Trettel et aL, (2003) who demonstrated that for 
CXCR2, homo-oligomers were still detected in the absence of glycosylated monomeric 
receptors. This suggests that oligomerisation occurred prior to plasma membrane delivery 
and at some point during the biosynthetic pathway. Retention of wild type receptor by 
intracellularly retained naturally occurring mutant forms has been demonstrated 
physiologically for the CCR5 receptor. A mutation exists that is not cell surface expressed 
and serves to reduce wild type cell surface expression by hetero-oligomer fo|:mation 
(Benkirane et aL, 1997).
There is a possibility that export from the ER could be inhibited because accumulation of 
the retained form of CXCRl could potentially cause congestion of the secretory pathway. 
This could result in the retention of wild type receptor regardless of whether the ER 
retained form of CXCRl and the wild type receptor are interacting. However, if this was 
the case a reduction in cell surface expression should also have been observed for the co­
expression of CXCRl possessing the ER retention motif and the aiA adrenoceptor, which 
was not obseived.
Recently oligomer formation has been suggested to be necessary for targeting of GPCRs 
from the ER to the plasma membrane. This has been shown for the pi-adrenoceptor where 
mutations of a previously identified putative oligomerisation motif present in TMVI 
(Hebert et aL, 1996) perturbed receptor cell surface targeting (Salahpour et aL, 2004). This 
has also been shown for the yeast a  factor receptor by targeting an oligomerisation motif
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present in TMI (Overton et aL, 2003). Hov^ever, recent investigation into CCR5 
oligomerisation demonstrated that two amino acid substitutions performed in TMI and IV 
were sufficient to abrogate receptor function and oligomerisation detected by FRET but 
were cell surface expressed (Hernanz-Falcon et aL, 2004). This result suggests that 
oligomerisation does not have a role in CCR5 export from the ER. It could be suggested 
that these mutations have simply resulted in a conformation of oligomers in which the 
orientation of donor and acceptor moieties is not permissive to energy transfer, however 
further studies would be required in order to confirm this theory.
As CXCRl and CXCR2 hetero-oligomers were shown to exist constitutively at the cell 
membrane, hetero-oligomer function was investigated. As discussed in section 1.2.5.1, the 
ability of hetero-oligomers to undergo internalisation in response to an agonist directed at 
only one receptor within the oligomer complex has been shown for several receptor pairs 
(Rocheville et aL, 2000; Xu et aL, 2003; Stanasila et aL, 2003; Jordan et aL, 2001; Pfeiffer 
et aL, 2002; Hillion et aL, 2002). In this study N-terminally tagged c-Myc-CXCRl and 
VSV-CXCR2 were co-expressed and stimulated with the agonist GRO-a, a CXCR2 
agonist with only weak activity at CXCRl. Co-internalisation was not observed as VSV- 
CXCR2 clearly underwent internalisation into punctate intracellular vesicles while c-Myc- 
CXCRl remained membrane delineated. This observation could be due to preferential 
formation of CXCR2 homo-oligomers rather than CXCR1/CXCR2 hetero-oligomers, and 
subsequent visualisation of CXCR2 homo-oligomer internalisation. However, the BRET^ 
saturation experiments performed in section 4.8 demonstrated highly similar' propensities 
of homo-oligomer and hetero-oligomer formation, suggesting this is not the case. It is also 
conceivable that the CXCRl/CXCR2 hetero-oligomer may be resistant to agonist-induced 
internalisation. As both CXCRl and CXCR2 undergo prominent agonist-induced
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internalisation in response to IL-8 when coexpressed, the lack of hetero-oligomer co- 
intemalisation caimot be attributed to one component of the complex that is poorly 
internalised exerting a dominant negative effect on the other component. Upon ligand 
activation the hetero-oligomer may dissociate into its monomeric state. This possibility is 
not supported by the BRET and Tr-FRET data that reported no change in energy transfer 
levels following exposure to agonist, interpreted as no change in oligomer levels. Hetero­
oligomerisation of the DOP and p2-adrenoceptor has been demonstrated (McVey et aL, 
2001; Jordan et aL, 2001). However, a study performed by Tsao et aL, (2000) reported that 
when p2-adrenoceptor and DOP were stably co-expressed, internalisation of each receptor 
was achieved only upon exposure to the receptor specific agonist. The study continued to 
resolve the fate of the receptors following endocytosis. Despite utilising the same 
endocytic pathway, the receptors were differentially targeted to recycling and degradation 
pathways. Recently a study performed by El-Asmar et aL, (2005) described CCR2/CCR5 
hetero-oligomer formation. The authors utilised BRET saturation experiments to 
demonstrate that hetero-oligomer and homo-oligomer formation occuiTed with similar 
propensity, however, co-intemalisation of the CCR2/CCR5 complex was not observed 
using internalisation assays. This is obviously an area that requires further investigation to 
accurately determine the mechanisms regulating co-internalisation.
As mentioned previously, studies performed investigating chemokine receptor 
oligomerisation have generated conflicting results. Initial reports suggested that 
oligomerisation of chemokine receptors was a ligand-dependent process (Rodriguez-Frade 
et aL, 1999; Vila-Coro et aL, 2000; Vila-Coro et aL, 1999; Mellado et aL, 2001). However, 
several reports have now shown constitutive chemokine receptor oligomerisation 
consistent with the data in this study (Babcock et aL, 2003; Issafras et aL, 2002 Trettel et
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aL, 2003; Toth et aL, 2004; Hernanz-Falcon et aL, 2004). A pattern governing the 
oligomerisation of these receptors is difficult to observe at the present time.
CXCR2 oligomerisation has previously been demonstrated (Trettel et aL, 2003). This study 
demonstrated the existence of CXCR2 oligomers expressed in HER cells and cerebellar 
neuron cells. Co-immunoprecipitation of differentially tagged foims of the CXCR2 
receptor was also shown. However, this group did not report CXCRl homo­
oligomerisation or CXCRl and CXCR2 hetero-oligomerisation. The experimental protocol 
detailed in the study did not differ significantly from the methods employed in this study 
and very little detail was given relating to the experiments investigating CXCRl homo- 
and hetero-oligomerisation. Therefore, it is difficult to identify a reason for the conflicting 
results.
The mechanisms of chemokine receptor oligomerisation have been studied. Trettel et aL, 
(2003) utilised N- and C- terminal tirmcations of the CXCR2 receptor to identify a region 
potentially involved in oligomerisation. Results demonstrated that a region between Ala- 
106 and Lys-163, predicted to contain the first extracellular loop, TM III and the second 
intracellular loop, was required for CXCR2 homo-oligomer formation detected by co- 
immunoprecipitation. The authors also interpreted the presence of SDS-resistant CXCR2 
oligomers as support that TMIII is involved in oligomer formation. As mentioned 
previously two amino acid substitutions, 152V and V150A, located in TMI and IV of 
CCR5 resulted in a non-funetional receptor that was unable to foim oligomers when 
assessed by FRET (Hernanz-Falcon et aL, 2004). The location of these point mutations 
was the result of bioinformatic analysis that predicted that these regions are important in 
oligomerisation. Amino acid substitution in CCR2 of residues V64A and VI64A in TM I
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and IV respectively also resulted in a non-functional form of the receptor than could not 
form oligomers when assessed by FRET. The amino acids predicted to be involved in 
oligomerisation are receptor specific. The regions containing the amino acids mutated in 
this study are present in motifs conserved across the chemokine receptor family, indicating 
that these regions could be important in chemokine receptor oligomerisation. However, 
recently Lemay et aL, (2005) have attempted to utilise the mutated forms of CCR5 and 
investigate oligomerisation using co-immunoprecipiation and BRET. This group 
demonstrated that oligomerisation could still be detected in those receptors possessing 
these mutations. Hernanz-Falcon et aL, responded by stating that it is a issue of 
interpretation of results from different techniques. In the original paper Hernanz-Falcon et 
aL, (2004) utilised a single cell FRET approach that the group claim is much more 
sensitive in comparison to BRET. However, the group also states that energy transfer could 
be observed for both wild type and mutant forms of CCR5 at high levels of receptor 
expression while at medium expression levels FRET was observed only for the wild-type 
receptors. It is clear that the mechanisms involved in receptor oligomerisation are complex 
and further studies are required to accurately resolve if there is a general mechanism for 
oligomer formation across the chemokine receptor family or if each receptor has an 
individual mechanism for oligomerisation. The latter possibility is somewhat unsatisfying 
given the large degree of sequence homology observed among the chemokine receptor 
family.
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Figure 4.1 Co-immunoprecipitation of differentially epitope-tagged forms of the
human CXCRl receptor.
HEK293 cells were transfected to transiently express Flag-CXCRl (lane 2) or c-Myc- 
CXCRl (lane 3). Flag-CXCRl and c-Myc-CXCRl were coexpressed (lane 4). A non­
transfected HEK293T (lane 1) and a mixed cell control (lane 5) were included. The mixed 
cell control represents cells individually expressing the constructs and mixed prior to 
immunoprécipitation. Cell lysates were immunoprecipitated with anti-Flag antibody, 
samples resolved by SDS-PAGE and then immunoblotted with anti-c-Myc antibody (upper 
panel). Western blot analysis of cell lysates using anti-Flag and anti-c-Myc antibodies was 
also performed in order to ensure correct protein expression (lower panels). One 
experiment representative of three experiments is shown.
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Figure 4.2 Co-immunoprecipitation of differentially epitope-tagged forms of the
human CXCR2 receptor
HEK293 cells were transfected to transiently express Flag-CXCR2 (lane 2) or c-Myc- 
CXCR2 (lane 3). Flag-CXCR2 and c-Myc-CXCR2 were coexpressed (lane 4). A non­
transfected HEK293T (lane 1) and a mixed cell control (lane 5) were included. The mixed 
cell control represents cells individually expressing the constructs and mixed prior to 
immunoprécipitation. Cell lysates were immunoprecipitated with anti-Flag antibody, 
samples resolved by SDS-PAGE and then immunoblotted with anti-c-Myc antibody (upper 
panel). Western blot analysis of cell lysates using anti-Flag and anti-c-Myc antibodies was 
also performed in order to ensure correct protein expression (lower panels). One 
experiment representative of three experiments is shown.
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Figure 4.3 Co-immunoprecipitation of differentially epitope-tagged forms of the
human CXCRl and CXCR2 receptor
HEK293 cells were transfected to transiently express Flag-CXCRl (lane 2) or c-Myc- 
CXCR2 (lane 3). Flag-CXCRl and c-Myc-CXCR2 were coexpressed (lane 4). A non­
transfected HEK293T (lane 1) and a mixed cell control (lane 5) were included. The mixed 
cell control represents cells individually expressing the constructs and mixed prior to 
immunoprécipitation. Cell lysates were immunoprecipitated with anti-Flag antibody, 
samples resolved by SDS-PAGE and then immunoblotted with anti-c-Myc antibody (upper 
panel). Western blot analysis of cell lysates using anti-Flag and anti-c-Myc antibodies was 
also performed in order to ensure correct protein expression (lower panels). One 
experiment representative of three experiments is shown.
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Figure 4.4 FRET imaging of constitutive CXCRl homo-oligomerisation in single
cells
CXCRlCFP and CXCRlYFP were co-expressed (a) or expressed individually 
(CXCRl CFP- b, CXCRl YFP - c) in HEK293T cells. As a control interactions with the 
aiA-adrenoceptor were recorded, a ,A-adrenoceptor-YFP was expressed alone (d) or co­
expressed with CXCRl CFP (e). Left hand panels represent CFP images, centre panels 
represent YFP images and right hand panels represent corrected FRET. FRET signals 
(FRETnorm) were quantified as described in section 2.6.9, shown in (f). Data shown are 
mean ± S.E.M. from three experiments.
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Figure 4.5 FRET imaging of constitutive CXCR2 homo-oligomerisation in single
cells
CXCR2CFP and CXCR2YFP were co-expressed (a) or expressed individually 
(CXCR2CFP- b, CXCR2YFP - c) in HEK293T cells. As a control interactions with the 
a  1 A-adrenoceptor were recorded. aiA-adrenoceptor-YFP was expressed alone (d) or co­
expressed with CXCR2CFP (e). Left hand panels represent CFP images, centre panels 
represent YFP images and right hand panels represent corrected FRET. FRET signals 
(FRETnorm) were quantified as described in section 2.6.9, shown in (f). Data shown are 
mean ± S.E.M. from three experiments.
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Figure 4.6 FRET imaging of constitutive CXCR1/CXCR2 hetero-oligomerisation
in single cells
CXCRl CFP was co-expressed with CXCR2YFP (a) or expressed alone (b) in HEK293T 
cells. The opposite pairing of CXCR2CFP and CXCRl YFP were co-expressed (c) and 
CXCR2CFP was expressed alone (d). Left hand panels represent CFP images, centre 
panels represent YFP images and right hand panels represent corrected FRET. FRET 
signals (FR ETnorm ) were quantified as described in section 2.6.9, shown in (f). Data 
shown are mean ± S.E.M. from three experiments.
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Figure 4.7 Single point BRET^ analysis of CXCRl and CXCR2 homo- and hetero-
oligomers
BRET^ ratio was measured in intact cells transfected with equal amounts of cDNA 
corresponding to donor and acceptor. Donor was expressed alone or co-expressed with 
acceptor for CXCRl and CXCR2 homo-oligomer pairs (a). CXCRlRluc and CXCR2Rluc 
were also co-expressed with aiA-adrenoceptor-GFP^ and energy transfer recorded. BRET^ 
signals resulting from CXCRl/CXCR2 hetero-oligomer formation are also shown (b). Data 
are means ± S.E.M. from three experiments.
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Figure 4.8 BRET^ saturation analysis of CXCRl and CXCR2 homo- and hetero-
oligomerisation
Homo-oligomerisation of CXCRl (inverted triangles) and CXCR2 (diamonds) was 
investigated using saturation BRET^. Varying amounts of receptor-Rluciferase conjugate 
(donor) and receptor-GFP^ conjugate (acceptor) were expressed in HEK293T cells and 
BRET recorded following addition of DeepBlueC substrate. Hetero-oligomer formation 
between CXCRl and CXCR2 was also assessed (squares). The specificity of CXCR2 
receptor interactions was investigated following co-expression of CXCR2Rluc with aiA- 
adrenoceptor-GFP^ (circles). A lack of inherent interaction between Rluc and GFP  ^was 
demonstrated by co-expression of CXCRlRluc and GFP  ^(triangles).
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Figure 4.9 IL-8 incubation does not modulate BRET^ resulting from CXCRl and 
CXCR2 homo- and hetero-oligomeric interactions
BRET^ ratio was measured in intact HEK293T cells expressing equal ratios of 
CXCRlRluc and CXCRlGFP^ CXCR2Rluc and CXCR2GFP^ and CXCR2Rluc and 
CXCRlGFP^. Cells were incubated for 30 minutes with 50nM IL-8 and BRET^ measured. 
Graph shown is representative of results obtained for three individual experiments.
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Figure 4.10 Constitutive CXCRl homo-oligomer formation at the cell surface
detected using Tr-FRET
HEK293T cells were transiently transfected with N-terminally tagged Flag-CXCRl and c- 
Myc-CXCRl either together (co) or individually and mixed prior to antibody incubation 
(mix). To investigate the specificity of energy transfer N-terminally Flag or c -M y c-a iA -  
adrenoceptor was coexpressed with Flag- or c-Myc-CXCRl. Data represent means ± 
S.E.M. from three independent experiments. To ensure correct expression of the Flag- 
tagged receptor acting as an energy acceptor, APC fluorescence was measured at 665nm 
(b). Data shown are representative of three individual experiments.
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Figure 4.11 Constitutive CXCRl homo-oligomer formation at the cell surface
detected using Tr-FRET
HEK293T ceils were transiently transfected with N-terminally tagged Flag-CXCR2 and c- 
Myc-CXCR2 either together (co) or individually and mixed prior to antibody incubation 
(mix). To investigate the specificity of energy transfer N-terminally Flag or c -M y c-a iA -  
adrenoceptor was coexpressed with Flag- or c-Myc-CXCR2. Data represent means ± 
S.E.M. from three independent experiments. To ensure correct expression of the Flag- 
tagged receptor acting as an energy acceptor, fluorescence was measured at 665nm (b). 
Data shown are representative of three individual experiments.
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Figure 4.12 Constitutive CXCRl/2 hetero-oligomer formation at the cell surface
detected using Tr-FRET
HEK293T cells were transiently transfected with N-terminally tagged Flag-CXCR2 and c- 
Myc-CXCRl either together (co) or individually and mixed prior to antibody incubation 
(mix). The opposite pairing of Flag-CXCRl and c-Myc-CXCR2 was also tested. Data 
represent means ± S.E.M. from three independent experiments. To ensure correct 
expression of the Flag-tagged receptor acting as an energy acceptor, fluorescence was 
measured at 665nm (b). Data shown are representative of three individual experiments.
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Figure 4.13 CXCRl and CXCR2 homo- and hetero-oligomerisation at the cell 
surface monitored by Tr-FRET is not modulated by incubation with 
IL-8
HEK293T cells were transiently transfected with combinations of N-terminally tagged 
Flag-CXCRl/2 and c-Myc-CXCRl/2 either together (co) or individually and mixed prior 
to antibody incubation (mix). Cells were treated with vehicle (open bars) or lOOnM IL-8 
(closed bars). Data represent means ± S.E.M. from three independent experiments.
144
Figure 4.13
u.
0.08
0.07
0.06
0.05
0.04
0.03
0.02
—^ 3 B asai
lOOnWl lL-8
0.01
0.00
- 0.01
Figure 4.14 Transient expression of CXCRl, HA-a^c-adrenoceptor and HA-
CXCRl-ER constructs in HEK293T cells
HEK293T cells were transiently transfected with CXCRl (a), HA-aic-adrenoceptor (b) 
and HA-CXCRl-ER (c). 24 hours post-transfection immunocytochemistry was performed. 
Images are shown for non-permeabilised samples (left hand panel) and permeabilised 
samples (right hand panel). Images shown are representative of three individual 
experiments.
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Figure 4.15 Overlapping expression patterns of HA-CXCRl-ER and c-Myc-
CXCRl and CXCR2.
HEK293T cells were transiently transfected with HA-CXCRl-ER and c-Myc-CXCRl (a) 
or c-Myc-CXCR2 (b). 24 hours post-transfection immunocytochemistry was performed. 
Cells were permeabilised prior to staining with anti-HA antibody (green) and anti-c-Myc 
antibody (red). Left hand panel represents anti-HA staining, centre panel represents anti-c- 
Myc staining and the right hand panel represents the image overlay. Images shown are 
representative of three individual experiments.
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Figure 4.16 HA-CXCRl-ER intracellularly retains CXCRl and CXCR2 but not the 
ttiA-adrenoceptor
HEK293T cells were transfected with either HA-CXCRl (open bars) or HA-CXCRl-ER 
(closed bars) along with Flag-CXCRl, Flag-CXCR2 or Flag-aiA-adrenoceptor. An equal 
amount of cells were incubated with anti-Flag antibody conjugated to APC for 2 hours 
prior to washing. APC fluorescence was then quantified and background fluorescence of 
HEK293T was measured and removed from the values obtained. Data are means ± S.E.M. 
from three individual experiments. Data were analysed using Students unpaired T-test 
(GraphPad prism 4). ***, p<0.001.
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Figure 4.17 Lack of co-internalisation of CXCRl and CXCR2
c-Myc-CXCRl and VSV-CXCR2 were transiently co-expressed in HEK293T cells grown 
on coverslips and immunocytochemistry performed using anti-c-Myc (red) and anti-VSV 
(green) antibodies. Cells were stained prior to agonist stimulation (a), following exposure 
to a CXCRl and CXCR2 agonist IL-8 (50nM) for 30 minutes (b) and following exposure 
to a CXCR2 selective agonist GRO-a (lOOnM) for 30 minutes (c). Left hand panel 
represents anti-c-Myc staining, centre panel represents anti-VSV staining and the right 
hand panel represents the image overlay. Images shown are representative of three 
independent experiments.
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5.1 Introduction
Opioid receptors are members of the class A GPCR family. Pharmacological binding and 
anatomical distribution analyses have identified thi*ee opioid family members p (MOP), 5 
(DOP) and k (KOP) receptors expressed in human brain tissue (Chen et al., 1993; Li et al, 
1993; Evans et al., 1992). The MOP, DOP and KOP receptors are homologous to each 
other. The MOP receptor has -68% sequence homology to the KOP receptor and -63% 
homology to the DOP receptor (Chuang et al, 1995). There is substantial pharmacological 
evidence suggesting that additional receptor phenotypes may exist. However, to date no 
cDNA corresponding to further receptor subtypes have been identified. It has been 
hypothesised that the observed pharmacology could result from posttranslational 
modifications, alternative mRNA splicing (Pasternak, 2001) or homo- and hetero­
oligomerisation (Jordan and Devi, 1999) of the identified receptor subtypes yielding 
unique pharmacological profiles.
Opioid receptors are activated by endogenously produced opioid peptides and by 
exogenously administered compounds. Endogenous opioid agonists include endorphin-1 
and 2 that are selective agonists for the MOP receptor and dynorphin which acts as a 
selective agonist for the KOP receptor (Bradbury et al, 1976; Cox et al., 1976). The pro­
enkephalin products leu- and met- enkephalin demonstrate the highest affinity for DOP 
receptors (Hughes et al., 1975). The pro-opiomelanocoi1in product (3-endorphin interacts 
with high affinity with MOP and DOP receptors.
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Activation of opioid receptors can cause a variety of physiological effects including 
bradycardia, general sedation and depression of flexor reflexes (Jordan et al., 2000). 
Opioid receptors are of great interest to pharmaceutical companies as they have been 
demonstrated to influence pain control. Activation of opioid receptors by ligand has been 
shown to inhibit nem*otransmitter release from dorsal root ganglion projections in the 
dorsal horn of the spinal chord (MacDonald and Nelson, 1978; Mudge et al., 1979; Yaksh, 
1993).
The three subtypes of opioid receptor have been shown to form homo- and hetero­
oligomers. Co-immunoprecipitation and BRET studies have demonstrated the existence of 
DOP receptor homo-oligomers (Cveijic et al., 1997; McVey et al., 2001). The KOP 
receptor has also been shown to form homo-oligomers and hetero-oligomer formation 
between KOP and DOP receptors has also been demonstrated (Jordan et al., 1999). 
Interestingly, KOP and MOP receptors do not appear to form hetero-oligomers. Hetero­
oligomer formation between MOP and DOP has been shown and displayed a unique 
pharmacological profile (George et al., 2000; Gomes et al., 2000). Whereas opioid 
receptors generally couple to Gi, hetero-oligomer formation resulted in receptor signalling 
that was insensitive to pertussis toxin treatment. This suggested unique G protein coupling 
to G proteins other than G/Go (George et al., 2000). A recent study performed by Gomes 
et al., (2004) demonstrated that DOP receptor occupancy by an antagonist enhanced MOP 
receptor binding and signalling activity. The study also demonstrated that DOP receptor 
antagonists potentiate morphine-mediated analgesia.
Opioid and chemokine receptors have been shown to have overlapping expression patterns. 
Functionally active opioid receptors have been identified in immune cells also expressing
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chemokine receptors and expression of both opioid and chemokine receptors have been 
demonstrated on glial cells in the brain (McCarthy et al, 2001). Activation of opioid 
receptors has been demonstrated to modulate antibody and cellular immune responses 
(Taub et al, 1991; Pellis et al, 1986), inhibit natural killer cell activity (Weber et al, 
1989), modulate cytokine expression (Chao et al, 1993; Peterson et al, 1987; Belkowski 
et al., 1995) and inhibit phagocytic activity (Szabo et al, 1993; Rojavin et al, 1993). The 
general immunosuppressive effects of opioid receptor activation may account for the 
increased incidence of infection obseived in heroin addicts that was originally attributed to 
the use of non-sterile needles and impurities in the drug. Opioids also possess chemotactic 
activity and receptor activation can induce the chemotaxis of monocytes and neutrophils 
(Van Epps et al, 1984; Grimm et al, 1998). Opioid agonists also have the capacity to alter 
the expression of a large number of cytokines and cytokine receptors (Miyagi et al, 2000). 
The MOP receptor agonist DAMGO ([D-ala^ V-Me-Phe\ Gly-ol^] enkephalin) has been 
shown to produce a dose-dependent induction of the pro-inflammatory cytokines CCL5, 
CCL2 and CXCLIO (Wetzel et al, 2000). Studies performed in cells infected with HlV-1 
also demonsti ate the expression of these pro-inflammatory chemokines following exposure 
to DAMGO. This effect is thought to assist infection of HIV-1 by mobilising uninfected 
ceils to the sites of HIV-1 infection (Steele et al, 2003). DAMGO and morphine have also 
been found to increase expression of CXCR4 and CCR5, the HlV-1 co-receptors, in 
several cell types including astroglial cells and monocytes (Mahajan et al, 2002).
Chemokines have been shown to participate in both normal physiological processes and 
pathological responses in the brain. The expression of several chemokine receptors, 
including CXCR2, has been shown within several regions of the brain including neurons in 
the hippocampus, regions of the cerebral cortex, amygdala, thalamus and basal ganglia
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(Gabuzda et ah, 1998; Meucci et al., 1998; Bajetto et al., 1999). The production of IL-8 
and GRO-a in the brain under normal physiological conditions has also been shown 
(Bajetto et al., 2001; Robinson et al., 1998). GRO-a also plays an important role in brain 
development as it synergises with platelet derived growth factor to promote the growth of 
immature oligodendrocytes (Robinson et al., 1998).
Cross-desensitisation has been reported between several opioid and chemokine receptors. 
Both MOP and DOP receptor agonists have been found to induce the de-sensitisation of 
the chemokine receptors CCRl, CCR2, CXCRl and CXCR2 (Grimm et al., 1998). 
Additionally, treatment with the DOP receptor agonist met-enkephalin was found to induce 
cross-phosphorylation of both CXCRl and CXCR2. Cross-desensitisation has also been 
reported for opioid receptors following exposure to chemokines. Exposmo of several cell 
types to chemokines activating CCR2, CCR5, CCR7 and CXCR4 resulted in 
desensitisation of the chemotactic activity of MOP and DOP receptors (Szabo et al., 2002). 
However, activation of CXCRl and CXCR2 did not result in opioid receptor 
desensitisation. It has been suggested that a hierarchy exists in producing desensitisation 
that is inversely correlated with their susceptibility to desensitisation (Ali et ah, 1999). 
Results have shown that CXCRl and CXCR2 are poor desensitisers but ai*e relatively 
susceptible to desensitisation by other GPCRs (Ali et al., 1999; Tomhave et al., 1994). 
Exceptions have been noted in that CXCRl and CXCR2 are capable of inducing cross­
phosphorylation and cross-desensitisation of CCRl in the human basophil cell line, RBL- 
2H3 (Richardson et al., 2000). Interestingly CCRl could cross-desensitise CXCR2 but not 
CXCRl, leading to the hypothesis that the duration of signalling induced by ligand 
activation of CCRl was insufficient to cross-desensitise CXCRl. This theory is supported
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by results demonstrating that phosphorylation deficient mutants of CCRl that deliver a 
more sustained signal can desensitise CXCRl.
The observed cross-desensitisation occuiiing between the chemokine and opioid receptors 
may be indicative of an interaction occun'ing. Recently hetero-oligomerisation between 
CCR5 and MOP, DOP and KOP receptors has been demonstrated (Chen et ah, 2004; 
Suzuki et ah, 2002). Chen et ah, (2004) utilised a co-immunoprecipitation approach to 
demonstrate hetero-oligomers formed between CCR5 and MOP receptors. Suzuki et ah, 
(2002) demonstrated CCR5 hetero-oligomerisation with MOP, DOP and KOP receptors 
also using a co-immunoprecipitation approach.
It has been demonstrated that CXCR2 ligands can induce chemotaxis of PMNs containing 
opioids to the site of inflammation where they mediate anti-nocieption (Brack et al., 2004). 
Interestingly, it was also shown that almost all opioid-containing leukocytes expressed 
CXCR2. The aim in this chapter was to examine hetero-oligomerisation between CXCR2 
and MOP, KOP and DOP receptors. This has been shown using co-immunoprecipitation 
and single cell FRET.
5.2 Co-immunoprecipitation of CXCR2 with MOP, KOP and DOP receptors
To investigate hetero-oligomerisation occurring between CXCR2 and MOP, MOP-YFP 
and Flag-CXCR2 were transiently expressed in HEK293T cells both individually and 
together. A HEK293T control was included as was a control composed of cells 
individually expressing the two receptors that had been mixed prior to
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immunoprécipitation with an anti-GFP antibody that recognises YFP. Immunoprecipitated 
material was subjected to SDS-PAGE and detected by western blotting using an anti-Flag 
antibody. Figure 5.1 demonstrates the hetero-oligomer detected between CXCR2 and 
MOP. A band corresponding to the 38kDa CXCR2 receptor was detected in the lane 
corresponding to the sample in which the two receptors had been co-expressed. Bands 
corresponding to the predicted molecular weight of a dimer and higher order oligomers can 
also be observed, suggesting that a proportion of the CXCR2-M0P hetero-oligomer was 
not fully separated by the SDS-PAGE conditions used. No immunoreactivity was observed 
in the control sample in which cells expressing the two receptors individually were mixed 
prior to immimoprecipitation, suggesting that the hetero-oligomers observed are not an 
artefact of the protocol. No immunoreactivity was obseiwed when the receptors were 
expressed individually. Appropriate receptor expression was confirmed by western blot 
analysis of cell lysates and detection of YFP fluorescence using a Victor^ plate reader.
This protocol was repeated to detect hetero-oligomerisation between Flag-CXCR2 and 
KOP-YFP (Figure 5.2). Immunoreactivity at 38kDa corresponding to Flag-CXCR2 was 
observed in the lane corresponding to receptors co-expression suggesting hetero-oligomer 
formation. Interestingly, no immunoreactivity corresponding to higher order oligomers was 
detected suggesting that the CXCR2/KOP hetero-oligomer was fully separated by the 
SDS-PAGE conditions employed. As obseived previously, no immunoreactivity was 
observed in the sample in which the individually expressed receptors had been mixed prior 
to immunoprécipitation, demonstrating that the hetero-oligomer obseived is not simply an 
artefact of the conditions used in the experiment.
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Hetero-oligomer formation between c-Myc-DOP and Flag-CXCR2 was investigated using 
this technique (Figure 5.3). Samples were immunoprecipitated with anti-Flag antibody and 
the immunoprecipitated material subjected to SDS-PAGE and western blotting analysis 
using an anti-c-Myc antibody. Immunoreactivity corresponding to the 60kDa c-Myc-DOP 
receptor was observed. Immunoreactivity was also observed at 30kDa and multiple bands 
at greater than 75kDa. No immunoreactivity was obseived when the individually tagged 
receptors were expressed alone or mixed prior to immunoprécipitation. Western blots of 
cell lysates are shown to confirm correct expression.
5.3 Hetero-oligomerisation of CXCR2 with MOP, KOP and DOP detected using 
FRET in living cells.
Hetero-oligomerisation between CXCR2 and MOP, KOP and DOP was assessed using 
single cell FRET performed in live cells. As shown in Figure 5.4, FRET corresponding to 
CXCR2-CFP expressed alone was 0.014 + 0.001. Upon co-expression of CXCR2-CFP and 
MOP-YFP, a FRET signal of 0.33 ± 0.03 was observed. Similar levels of donor and 
acceptor fluorescence were observed as shown in Figure 5.4. Co-expression of CXCR2- 
CFP and KOP-YFP yielded an energy transfer of 0.4 ± 0.04 shown in Figure 5.5. However, 
it can be observed that the KOP-YFP receptor conjugate was not expressed at equivalent 
fluorescence levels to the CXCR2-CFP donor. As FRET is an acceptor dependent process 
this may mean that the energy transfer reported is lower than could be expected if both 
donor and acceptor were present at an equal ratio. Hetero-oligomerisation between CXCR2 
and DOP was also investigated. CXCR2-CFP and DOP-YFP yielded a FRET signal of 
0.41 ± 0.02, shown in Figure 5.6. Similar levels of donor and acceptor fluorescent moieties 
were obseived as shown in Figure 5.6.
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5.4 Discussion
In this chapter, co-immunoprecipitation results indicated that CXCR2 can form hetero­
oligomers with each of MOP, DOP and KOP receptors. A control in which cells expressing 
each epitope tagged receptor individually were mixed prior to immunoprécipitation was 
included and yielded no immunoreactivity. This demonstrates that the positive result 
observed for the interaction between CXCR2 and the opioid receptors was not an artefact 
of the immunoprécipitation protocol. Figure 5.2 represents the interaction observed 
between CXCR2 and the KOP receptor that was fully sensitive to the SDS-PAGE 
conditions used in this study, yielding a single band at the molecular mass corresponding 
to the CXCR2 monomer. Figures 5.1 and 5.3 demonstrate that the hetero-oligomers 
detected between CXCR2 and MOP and DOP receptors respectively were not fully 
separated by the SDS-PAGE conditions employed. Immunoreactivity corresponding to the 
predicted molecular mass of both the receptor monomer and higher order oligomers was 
observed, indicating that a proportion of the hetero-oligomers are resistant to separation by 
SDS-PAGE. SDS-resistant oligomers were also observed in chapter 4 representing CXCRl 
and CXCR2 homo- and hetero-oligomers. The SDS-PAGE conditions used in this study 
may not have been sufficient to fully reduce all the hetero-oligomers present leading to the 
obseivation of apparent SDS-insensitive oligomers. In this study, fluorescent assessment of 
the KOP-YFP receptor has indicated that it is expressed at comparatively lower levels than 
DOP-YFP and MOP-YFP receptors in heterologous systems and therefore the lower levels 
of CXCR2/K0P hetero-oligomer formed may have been within a range to be fully reduced 
by the SDS-PAGE conditions. Additional immunreactivity was observed for c-Myc-DOP 
that could not be explained by higher order oligomers. Immunoreactivity was obseived at
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30kDa and 75kDa that does not correspond to the predicted mass of the receptor. Suzuki et 
al., (2002) also observed multiple immunoreactive bands representing DOP receptor when 
investigating expression in a human B cell line constitutively expressing opioid receptors. 
A similar pattern of immunoreactivity has also been obseived corresponding to DOP 
receptor expressed by activated murine splenocytes (Miller et al., 1998).
Single cell FRET experiments performed in this study further indicated that hetero­
oligomerisation may occm between CXCR2 and the opioid receptors. The levels of FRET 
observed were much lower than that observed for the CXCRl/2 homo- and hetero­
oligomer but greater than the energy transfer monitored between either CXCRl /CXCR2 
and the aiA-adrenoceptor. This could be due to the conformation of the hetero-oligomer 
being such that there is a large distance between the donor and acceptor fluorescent 
moieties rather than the levels of hetero-oligomer formed being less than observed for the 
CXCR1/CXCR2 homo- and hetero-oligomers. To fully investigate the relative affinity of 
the CXCR2-opioid hetero-oligomers, saturation BRET experiments could be employed 
which would yield data indicating the relative propensity of the hetero-oligomers to form.
Hetero-oligomerisation between chemokine and opioid receptors has been shown 
previously. CCR5 has been shown to form hetero-oligomers with MOP, DOP and KOP 
receptors using co-immunoprecipitation techniques on monkey and human lymphocytes 
(Suzuki et al., 2002). This study also employed chemical cross-linking to demonstrate that 
the hetero-oligomers exist on the cell surface as a complex with an intramolecular distance 
much less than 11.4Â. Agonist stimulation of either receptor within the complex had no 
effect on the immunoreactivity observed.
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A recent study performed by Chen et aL, (2004) demonstrated CCR5 and MOP receptor 
hetero-oligomerisation using co-immunoprecipitation. This study also reported no effect of 
agonist on the level of immunoreactivity observed. Interestingly, this study yielded data 
suggesting that the activation of either CCR5 or MOP affected the G protein coupling of 
the other assessed by GTPyS binding. This effect was attributed to the enhanced 
phosphoiylation of CCR5 or MOP upon stimulation with agonist for the opposite receptor.
The relationship between pain and inflammatory conditions is well acknowledged. Upon 
the receipt of an injury, an inflammatory response is triggered that involves the migration 
of immune cells to the injury site. These immune cells can release a range of substances 
that include cytokines and chemokines. Both cytokines and chemokines can influence the 
sensation of pain by sensitisation of the dorsal horn neurons in the spinal chord (Sacerdote 
et al., 2000). Chemokines can also influence pain perception in the brain. A study 
performed by Giovannelli et al., (1998) demonstrated directly the participation of IL-8 and 
GRO-a in the regulation of neuronal transmission. In in vitro studies, exposure to these 
chemokines was found to enhance postsynaptic currents and reduce the magnitude of 
neurotransmitter release from Purkinje neuions. Hyperanalgesia has been demonstrated to 
occur during the inflammatory response (Watkins et al., 1995; Junger and Sorkin, 2000). 
Recent human studies have confiimed results obtained from several animal experiments 
detailing that MOP receptors in the brain are crucial for the sensation of sustained 
peripheral pain (Zubieta et al., 2001). In inflammation states, elevated levels of 
chemokines are detected in the brain causing altered nemonal function and reduced MOP 
receptor-mediated analgesia. This has led to the theory that the decreased analgesia may 
contribute to the pain in the periphery that is associated with a number of inflammatory 
diseases including rheumatoid arthritis (Szabo et ah, 2002). The presence of chemokine:
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opioid hetero-oligomers suggests a new therapeutic route for the treatment of inflammatory 
conditions.
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Figure 5.1 Co-immunoprecipitation of epitope-tagged forms of the human CXCR2
and MOP receptors
HEK293 cells were transfected to transiently express Flag-CXCR2 (lane 1) or MOP-YFP 
(lane 2). Flag-CXCR2 and MOP-YFP were coexpressed (lane 3). A non-transfected 
FIEK293T (lane 5) and a mixed cell control (lane 4) were included. The mixed cell control 
represents cells individually expressing the constructs and mixed prior to 
immunoprécipitation. Cell lysates were immunoprecipitated with an anti-GFP antiserum 
that also recognises YFP, samples resolved by SDS-PAGE and then immunoblotted with 
anti-Flag antibody (upper panel). Western blot analysis of cell lysates using anti-Flag 
antibody was also performed in order to ensure correct protein expression (lower panel). 
Expression of MOP-YFP was detected by monitoring cell lysate fluorescence using a 
Victor^ plate reader (b). One experiment representative of three experiments is shown.
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Figure 5.2 Co-immunoprecipitation of epitope-tagged forms of the human CXCR2
and KOP receptors
HEK293 cells were transfected to transiently express Flag-CXCR2 (lane 2) or KOP-YFP 
(lane 3). Flag-CXCR2 and KOP-YFP were coexpressed (lane 4). A non-transfected 
HEK293T (lane 1) and a mixed cell control (lane 5) were included. The mixed cell control 
represents cells individually expressing the constructs and mixed prior to 
immunoprécipitation. Cell lysates were immunoprecipitated with an anti-GFP antiserum 
that also recognises YFP, samples resolved by SDS-PAGE and then immunoblotted with 
anti-Flag antibody (upper panel). Western blot analysis of cell lysates using anti-Flag 
antibody was also performed in order to ensure correct protein expression (lower panel). 
Expression of KOP-YFP was detected by monitoring cell lysate fluorescence using a 
Victor^ plate reader (b). One experiment representative of three experiments is shown.
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Figure 5.3 Co-immunoprecipitation of epitope-tagged forms of the human CXCR2
and DOP receptors
HEK293 cells were transfected to transiently express Flag-CXCR2 (lane 2) or c-Myc-DOP 
(lane 3). Flag-CXCR2 and c-Myc-DOP were coexpressed (lane 4). A non-transfected 
HEK293T (lane 1) and a mixed cell control (lane 5) were ineluded. The mixed cell control 
represents cells individually expressing the constructs and mixed prior to 
immunoprécipitation. Cell lysates were immunoprecipitated with anti-Flag antibody, 
samples resolved by SDS-PAGE and then immunoblotted with anti-c-Myc antibody (upper 
panel). Western blot analysis of cell lysates using anti-Flag and anti-c-Myc antibodies was 
also performed in order to ensure correct protein expression (lower panels). One 
experiment representative of three experiments is shown.
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Figure 5.4 FRET imaging of constitutive CXCR2 and MOP hetero­
oligomerisation in single cells
CXCR2-CFP and MOP-YFP were co-expressed (b) or MOP-YFP expressed individually
(a) in HEK293T cells. Left hand panels represent CFP images, centre panels represent YFP 
images and right hand panels represent corrected FRET. FRET signals (FRETnorm) were 
quantified as described in section 2.6.9 and are shown in (c). Data shown are mean ± 
S.E.M. from three experiments.
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Figure 5.5 FRET imaging of constitutive CXCR2 and KOP hetero-oligomerisation in
single cells
CXCR2-CFP and KOP-YFP were co-expressed (b) or KOP-YFP expressed individually
(a) in HEK293T cells. Left hand panels represent CFP images, centre panels represent YFP 
images and right hand panels represent corrected FRET. FRET signals (FRETnorm) were 
quantified as described in section 2.6.9 and are shovm in (c). Data shown are mean ± 
S.E.M. from three experiments.
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Figure 5.6 FRET imaging of constitutive CXCR2 and DOP hetero-oligomerisation in
single cells
CXCR2-CFP and DOP-YFP were co-expressed (b) or DOP-YFP expressed individually
(a) in HEK293T cells. Left hand panels represent CFP images, centre panels represent YFP 
images and right hand panels represent corrected FRET. FRET signals (FRETnorm) were 
quantified as described in section 2.6.9 and are shown in (c). Data shown are mean + 
S.E.M. from three experiments.
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Chapter 6 Final Discussion
CXCRl and CXCR2 have been implicated in several inflammation disease states including 
psoriasis and ulcerative colitis (Nickoloff et al., 1991; Bizzarri et al., 2003; Mahida et al, 
1992). Therefore, these receptors represent potential drug targets for phaimaceutical 
intervention in these conditions. Chemokine receptor oligomerisation has been 
demonstrated to be physiologically relevant. Oligomerisation of CCR5 with the naturally 
occurring CCR5 mutant ccr5-32A confen*ed a delay in progression of HIV-1 to AIDS 
(Benkirane et al., 1997). A similar protective effect was observed in individuals possessing 
a mutant form of CCR2 teimed CCR2V64I that was attributed to oligomerisation of this 
receptor with CCR5 or CXCR4 (Mellado et al., 1999).
In this study, constitutive homo- and hetero-oligomerisation of CXCRl and CXCR2 has 
been comprehensively demonstrated using several biochemical and biophysical techniques 
including co-immunoprecipitation, single-cell FRET, time resolved FRET and BRET. 
Each technique indicated that both CXCRl and CXCR2 homo-and hetero-oligomers are 
constitutively formed. The selectivity of oligomerisation was investigated in this study. 
Saturation BRET experiments indicated that CXCR1/CXCR2 homo- and hetero-oligomers 
form with equal propensity as indicated by similar [A]/[D] ratios obseiwed at half maximal 
BRET signals. Saturation BRET experiments have been used extensively in an attempt to 
quantify the likelihood of a GPCR pair to fonn oligomers (Canals et ah, 2004; Canals et 
al., 2003 Mercier et al., 2002; Breit et al., 2004; Ayoub et al., 2004; Temllon et al., 2003). 
Ramsay et al., (2004) utilised this technique to determine the specificity of aiA- 
adrenoceptor homo-oligomerisation. The authors demonstrated that interactions between 
the a  I A-adrenoceptor and the DOP receptor were some 75 times lower affinity than
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ob served  for the a iA -adrenoceptor h om o-o ligom er. M any studies in vestigatin g  GPCR 
o lig o m erisa tion  have se lec ted  a GPCR w ith  lo w  sequence sim ilarity  to  the receptor o f  
interest to  act as a n egative  control. T he aiA -adrenoceptor w as se lec ted  as a control in  th is 
study. A  recent p h y lo g en etic  an a lysis id en tified  both  CXCRl/CXCR2 and the a iA - 
adrenoceptor as m em bers o f  the rh osop sin  fam ily  (Fredriksson et ah, 2003). H ow ever , 
further an alysis dem onstrated that the rhodopsin -like receptors co u ld  be further sub d iv id ed  
into four groups o f  w h ich  there w ere 13 d istinct branches. T he a iA -adrenoceptor w as found  
to be a m em ber o f  the a -g ro u p  o f  rhodopsin  receptors w ith in  an am ine receptor cluster. 
CXCRl and CXCR2 w ere found  to be m em bers o f  the y-group o f  rhodopsin  receptors 
w ith in  the chem ok in e receptor cluster. T his su ggests that although both  the ch em ok in e and  
the aiA -adrenoceptors share a co m m o n  evolu tionary  origin , th ey  do n ot share sign ifican t  
seq u en ce sim ilarity. CXCRl/CXCR2 and the aiA -adrenoceptor h ave not b een  sh o w n  to  
share an overlapp ing  exp ression  pattern therefore th is receptor w a s  se lec ted  to act as a 
n eg a tiv e  control in  th is study. O ligom erisa tion  b etw een  CXCRl/CXCR2 and the ajA - 
adrenoceptor w a s in vestiga ted  u sin g  Tr-FRET, sin g le  ce ll FRET and BRET. S o m e energy  
transfer w as detected  u sin g  T r-FR ET and sin g le  ce ll FRET, h ow ever, B R E T  saturation  
exp erim en ts su ggested  that th is interaction  w as n on -sp ec ific  as a linear relationship  ex isted  
b etw een  sign a l and acceptor/donor ex p ressio n  ratio. T he ER retention  a ssay  a lso  
dem onstrated  that CXCRl conjugated  to an ER retention seq u en ce did  not prevent export 
o f  the a iA -adrenoceptor from  the ER to the ce ll surface and w a s in teipreted  as a lack  o f  
in teraction b etw een  the tw o  receptors. A  further approach to in vestigate  the se lec tiv ity  o f  
o ligom erisa tion  w o u ld  have b een  to  restrict receptor exp ression  to le v e ls  com parable w ith  
that ob served  p h y sio lo g ica lly . IssaE as et al,, (2002) u tilised  th is approach in  BRET studies  
in vestiga tin g  CCR5 and CXCR4 o ligom erisa tion . A t p h y sio lo g ica lly  relevant ex p ression  
le v e ls , CCR5 and CXCR4 h o m o -o lig o m erisa tio n  cou ld  be obseiw ed  h o w ev er  no hetero-
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oligomerisation was observed. In this study receptor expression levels were not quantified, 
however, several studies have demonstrated the independence of receptor density and 
BRET at relatively low levels of receptor expression (Mercier et al., 2002; Issafras et al., 
2002; Babcock et al., 2003).
Oligomerisation monitored by Tr-FRET indicated that CXCRl and CXCR2 homo- and 
hetero-oligomers exist at the cell surface. However, CXCRl and CXCR2 hetero-oligomers 
were found not to undergo internalisation in response to GRO-a. This was surprising as 
saturation BRET experiments suggested that CXCRl/CXCR2 homo- and hetero-oligomers 
had an equal propensity to form. Similar experiments were performed in which one 
receptor within the hetero-oligomer complex was stably expressed and the other transiently 
expressed. The cells were stimulated with GRO-a 24 hours following transient 
transfection, however no co-intemalisation was observed (data not shown). Subsequent 
experiments performed within the Milligan group have suggested that the 24-hour time 
frame following transfection and stimulation of receptors with drug may have been 
insufficient to permit the co-synthesis of both the stably and transiently expressed 
receptors. It would be interesting to create a stable cell line co-expressing both CXCRl and 
CXCR2 and investigate co-internalisation. The Flp-In T-REX 293 system (Invitrogen) has 
been used successfully to create double stable cell lines within the Milligan group. This 
system permits the inclusion of one receptor that is constitutively expressed and one 
receptor to be expressed within a doxycycline inducible region. A 48-hour time period 
should be observed following doxycycline exposure to permit co-synthesis of the 
receptors. Also by using increasing concentrations of doxycycline, the expression level of 
the inducible receptor may be increased. This would allow the expression of one receptor 
within the hetero-oligomer to be expressed at higher levels than the other, potentially
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favouring hetero-oligomer formation as opposed to homo-oligomerisation. This method 
may provide more information concerning the internalisation properties of the CXCRl and 
CXCR2 hetero-oligomers.
An ER-trapping assay developed in this study revealed that CXCRl/CXCR2 homo- and 
hetero-oligomeric interactions began duiing protein synthesis and maturation. This assay 
could be adapted to investigate oligomerisation of other GPCRs. In this study the amount 
of cell surface receptor was quantified by incubation of whole cells in suspension with 
antibody conjugated to a fluorescent moiety. This assay could be adapted into an ELISA 
format performed on whole cells which would remove any antibody labelling of broken 
cells that would inevitably occur while performing the assay on cells in suspension. An 
ELISA format would also allow cell number to be regulated as a controlled number of cells 
would be sub-cultured into each well of a 96-well plate, permitting direct comparison of 
cell surface fluorescence.
Tr-FRET and BRET data indicated that oligomerisation was unaffected by the presence of 
agonist. However, this was assessed by comparing maximal energy transfer observed in the 
absence and presence of ligand. Any change in energy transfer obseiwed could represent 
ligand binding inducing a confoimational change within the oligomer resulting in the 
orientation of the donor and acceptor moieties to be more conducive to energy transfer. It 
would have been beneficial to examine any effect ligand had on the BRET50 values 
generated in saturation BRET experiments, indicating change in affinity of the donor and 
acceptor for each other. The single cell FRET technique utilised in this study would have 
been very useful in identifying any effect ligand binding had on oligomerisation. BRET 
has the disadvantage of utilising the cell peimeable substrate DeepBlueC that reports on
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energy transfer occurring thi'oughout the cell therefore any small alterations in energy 
transfer caused by ligand binding may be masked by energy transfer occurring between 
receptors within the cell that have not been exposed to ligand. Single cell FRET permits 
the measurement of energy transfer occurring only at the cell membrane exposed to ligand 
and would be highly useful in investigating this area of oligomerisation. Unfortunately, this 
technique requires a large amount of ligand that was not economically viable in this study.
Due to time constraints the functional properties of CXCRl/CXCR2 hetero­
oligomerisation could not be investigated. Mellado et ah, (2001) outlined a hypothesis 
regarding chemokine receptor oligomerisation. This theory detailed that hetero­
oligomerisation foimation conferred unique pharmacology to the receptors involved such 
as G protein switching from Ga, to Gaq/n, distinct PI3-K activation kinetics and 
preferential activation of cell adhesion. Hetero-oligomers were also shown to be resistant 
to internalisation and desensitisation to a second stimulus. This theory was based on 
chemokine receptor oligomerisation being ligand induced, however, several reports have 
now demonstrated constitutive chemokine receptor oligomerisation. Initial experiments 
investigating the influence of CXCRl/CXCR2 hetero-oligomer formation on CXCR2 
ligand binding have been perfoiined. These experiments have shown that the efficacy of 
GRO-a to inhibit forskolin-stimulated cAMP release in cells co-expressing CXCRl and 
CXCR2 is no different than that observed for cells singly expressing CXCRl and CXCR2 
and mixed prior to the experiment. This suggests that CXCR2 ligands bind to 
CXCRl/CXCR2 hetero-oligomers and demonstrate no unique pharmacology. However, it 
would be beneficial to fully investigate and characterise the phaimacology conferred by the 
hetero-oligomers.
170
Hetero-oligomerisation between CXCR2 and opioid receptor subtypes was shown using 
co-immunoprecipitation and single cell FRET. Oligomerisation between these receptors is 
of great interest as physiologically both CXCRl and CXCR2 are involved in mediating 
inflammation that is associated with pain. Due to time constraints it was not possible to 
investigate the pharmacology of these hetero-oligomers. This would be of great interest as 
previous reports have suggested that hetero-oligomerisation between opioid receptor 
subtypes results in G protein switching to G proteins other than Gai/Gao. It would be 
useful to investigate if any unique pharmacology was observed as a result of 
chemokine/opioid receptor interaction.
Several variations of RET were utilised in this study including BRET, FRET and Tr- 
FRET. Both the variations of FRET and TR-FRET used in this study would not be 
amenable to high-throughput screening commonly used by major phaimaceutical 
companies due to multiple washing steps and expensive equipment required. BRET has 
been adapted into a high-throughput system to allow investigation into the activation state 
of the insulin receptor. The action of insulin is mediated by a tyrosine kinase receptor that 
upon ligand binding undergoes a conformational change that brings the two p subunits of 
the receptor into close proximity. This change in conformation permits the trans­
phosphorylation of one receptor p subunit by the other subunit (Combettes-Souverain and 
Issad, 1998). Phosphorylation stimulates the tyrosine kinase activity of the receptor. The 
BRET assay involved the generation of receptor chimeras where one receptor p subunit 
was fused to the energy donor Rluc and the other conjugated to the energy acceptor YFP. 
Any conformational change induced in the insulin receptor results in an increase in energy 
transfer (Boute et al., 2001). High throughput screening in this manner permits the rapid 
screening of compounds thought to possess insulin-like activity (Boute et al., 2002). In this
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study ligand incubation had no effect on the BRET signal coiTesponding to CXCRl and 
CXCR2 homo- and hetero-oligomers and would therefore not be a useful technique for 
pharmaceutical companies interested in activating the receptors within homo- or hetero- 
oligomeric complexes. However, if further functional studies were to indicate a therapeutic 
value in homo- or hetero-oligomer dissociation, this assay would provide a useful platform 
for the screening of multiple compounds.
A recent study performed by Hlavackova et al, (2005) investigated the requirement for 
both heptahelical domains to be switched on upon activation of a dimeric class C GPCR, 
the mGluRi receptor. This study utilised the quality control system of the heterodimeric 
GABAb receptor in which the GABAbRl subunit contains a retention sequence within its 
C terminus, preventing the cell surface expression of this subunit. Upon eoexpression with 
GABAbR2, the retention sequence is masked and the heterodimer is trafficked to the cell 
surface (Jones et ah, 1998; Kaupmann et al., 1998; White et al., 1998; Reiner et al., 1999, 
Sullivan et al., 2000). The mGluRi receptor was modified by introducing the C terminal 
tails of GABAbRl and GABAbR2. A mutation was made to intracellular loop 3 of the 
mGluRi receptor conjugated to the C terminal tail of GABAbR2 that had been shown to 
suppress the ability of the receptor to activate phospholipase C and adenylyl cyclase. This 
permitted the determination of mGluRi hetero-oligomer function as only hetero-oligomers 
would be trafficked to the cell surface with homo-oligomers being either retained 
intracellularly or non-functional. This system could potentially be adapted to investigate 
CXCRl and CXCR2 hetero-oligomer function. In this study CXCRl and CXCR2 hetero­
oligomers were found to exist constitutively at the cell membrane. CXCRl could be 
modified by the addition of the C terminal tail of GABAbRl containing the retention 
sequence followed by the C-teiminal tail region of the GABAbR2 receptor containing the
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masking region. CXCRl could be similarly modified but with the addition of the C 
terminal tail of GABAbRl containing the masking region proximal to the receptor 
followed by the C terminal tail region of GABAbRl. This is illustrated in Figure 6.1. As 
the two receptors share high sequence homology and are similar in size, it could be 
predicted that the receptors would be synthesised in a manner allowing the combination of 
retention/masking sequences to act as a ‘lock and key’ mechanism allowing export from 
the ER. This would only permit the export of hetero-oligomers to the cell surface while 
homo-oligomers would be retained as the retention sequences present would not be 
masked. This would allow CXCRl/CXCRl hetero-oligomers only to be studied and could 
potentially provide useful data regarding the physiological function of the hetero­
oligomers.
As discussed previously, Hemanz-Falcon et al. (2004) demonstrated two amino acids 
present in TM I and IV of CCR5 (I52V and V150A) that were crucial for receptor 
oligmerisation and function. The study extended this analysis to identify two residues 
present in CCR2 (V64A and VI64A) also crucial for receptor oligomerisation and 
function. Analysis of CXCRl and CXCR2 has identified three analogous residues present 
within each receptor to which mutations could potentially abrogate oligomerisation. These 
have been identified as V63A, I64V and LI581 in CXCRl and V63A, I64V and LI671 in 
CXCR2. Due to time constraints this could not be pursued however this would be very 
informative in determining the residues important in CXCRl and CXCRl oligomerisation 
and could potentially highlight a therapeutic target for oligomers. Hernanz-Falcon et al. 
(2004) also demonstrated that synthetic peptides generated to the residues in TM I and IV 
blocked CCR5 agonist induced signalling both in vitro and in vivo, demonstrating the 
physiological relevance of these residues.
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In conclusion, the identification of CXCRl and CXCRl homo- and hetero-oligomers 
introduces further complexity to the chemokine signalling network.
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Figure 6.1 Potential method of investigating hetero-oligomer pharmacology
A combination of ER retention/masking sequences derived from the GABAb receptors 
has been suggested to permit characterisation of cell surface hetero-oligomer function. 
Receptors would be modified by the introduction of either the C-terminal region of 
GABAbRl containing the retention sequence or GABAbRl containing the masking 
sequence. Hetero-oligomers would possess the coirect orientation of retention/masking 
sequences fused to the C terminal of the receptors to permit export from the ER to the 
cell surface (a) while homo-oligomers would be retained in the ER as the retention 
sequence would not be masked (b).
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